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Type 2 Diabetes arises from the inability of pancreatic β-cells to compensate for insulin 
resistance induced by environmental factors in genetically predisposed individuals. Goals in 
diabetic research are to restore the functionality of damaged β-cells or to replace them, and 
accomplishing this requires better understanding of the essential determinants of the β-cell 
phenotype. Pdx1, NeuroD1 and MafA are transcription factors critical in maintaining mature 
β-cell function. Epigenetic changes to the chromosome architecture in β-cells are associated 
with the loss of glucose sensitivity and insulin production.  
 
My hypotheses are (1) The transcriptional regulation mediated by Pdx1, NeuroD1 and MafA 
are key determinants of β-cell function; (2) As β-cell dysfunction develops, chromatin 
remodeling adversely affects the function of important β-cell transcriptional regulators. To 
test these hypotheses, I have defined the Pdx1, NeuroD1 and MafA transcriptional regulatory 
network operative in β-cells, and established the epigenetic profile of normal β-cells and 
dysfunctional β-cells with impaired glucose-stimulated insulin secretion (GSIS).  
 
Pdx1 binds more independently, and NeuroD1 and MafA have very similar binding profiles. 
Genes regulated by these transcription factors are over-represented in metabolic, 
developmental and cellular processes. Combinatorial depletion coupled with combinatorial 
co-occupancy of these transcription factors shows that genes with Pdx1 binding sites have the 
most effect on genes that are regulated. When two or three transcription factors are bound, 
they have the most effect on their target genes. Pdx1, NeuroD1 and MafA regulates genes 
involved in GSIS: They repress Itgb1bp2 and Cplx2 to enhance GSIS, and activate Tspyl1, 
F13a1 and Septin7 to dampen the GSIS response, emphasizing the exquisite level of 
regulation required for the appropriate response of β-cells to a glucose stimulus.   
 
viii 
In order to investigate differential epigenetic states in normal and dysfunctional β-cells, I 
profiled marks of active and repressive chromatin in both cellular states. There is a global 
increase of open chromatin in dysfunctional β-cells, indicated by the increase in numbers of 
FAIRE and H3K4me3 peaks and a decrease in H3K27me3 peaks in dysfunctional β-cells. 
Motif analysis of FAIRE peaks in dysfunctional β-cells show a bias for general transcription 
factors, while motifs in normal β-cells show enrichments for tissue-specific transcription 
factors. Genes bound by Pdx1, NeuroD1 and MafA are associated with H3K4me3 in normal 
β-cells. In dysfunctional β-cells however, there is an increase in the association of these 
transcription factors and their target genes with the repressive H3K27me3 mark. Bivalent 
domains marked by both H3K4me3 and H3K27me3 in normal β-cells are enriched for 
developmental processes and cell regulatory processes. Bivalent chromatin states are modified 
to different extents in dysfunctional β-cells and lead to expression changes in genes involved 
in pancreatic development/ function (e.g. MafB, Oxr1, Camk2b, miR-9, Sox17), genes 
involved in neuronal development/ function (e.g. Sema3d, Celsr1), Fox transcription factors 
(e.g. Foxf2, Foxq1), and the potassium channels Kcnc1 and Kcnq1.  
 
Little is known about the transcriptional and epigenetic network governing β-cell function and 
dysfunction. My thesis therefore provides original insight into the Pdx1-, NeuroD1- and 
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1.1.  DIABETES  
 
We are in the midst of a worldwide epidemic of Type 2 Diabetes (T2DM), obesity, and 
metabolic syndrome, each created by complex interactions between ones genes and the 
environment in which one lives. Despite advances in treatment, diabetes is the leading cause 
of chronic renal failure, adult blindness, and limb amputation, and a major risk factor for heart 
disease, stroke, and birth defects
1
. As a result, the cost of diabetes care in the U.S. currently 
exceeds $200 billion annually. The immense human and economic costs will increase further 




The World Health Organization’s definition of diabetes is for a single raised glucose reading 
with symptoms, otherwise raised values on two occasions, of either a) fasting plasma glucose 
concentration ≥ 7.0 mmol/l (126 mg/dl) or b) a glucose tolerance test, two hours after the oral 
dose, with a plasma glucose concentration ≥ 11.1 mmol/l (200 mg/dl)3. Diabetes is a group of 
metabolic diseases in which a person has high blood sugar, because the body does not produce 
enough insulin, and the body’s cells do not respond to the insulin that is produced. This high 
blood sugar produces the classical symptoms of polyuria (frequent urination), 
polydipsia (increased thirst) and polyphagia (increased hunger). 
 
1.1.1.  TYPE 1  D IABETES  MELLITUS (T1DM) 
 
Type 1 Diabetes (T1DM), formally known as insulin-dependent diabetes mellitus (IDDM) or 
juvenile diabetes, affects an estimated 1 million Americans
4
. It is thought to result primarily 
from the destruction of pancreatic β cells in the islets of Langerhans by autologous cytotoxic 
T cells, and leads to insulin deficiency and hyperglycemia (high blood glucose levels). 
Though it may not be its primary cause, auto-immunity is the predominant effector 
mechanism of T1DM. T1DM is exercabated in genetically susceptible individuals
5
, and the 
effect of the environment on an individual is also an important one. Epidemiological studies 
 
3 
also suggest a triggering role for enteroviruses, while other micro-organisms might have a 
protective effect. Therefore prevention of T1DM requires detection at the earliest possible 
point.  
 
1.1.2.  TYPE 2  D IABETES  (T2DM) 
 
Unlike T1DM, which is caused by the lack of insulin, T2DM arises from the diminished 
ability to respond to a given concentration of insulin. This is compounded with the abnormal 
response of pancreatic β-cells to respond to glucose. Numerous studies show that insulin 
resistance precedes the development of hyperglycemia in subjects that eventually develop 
T2DM
6
. However, it is increasingly clear that T2DM only develops in insulin-resistant 
subjects with the onset of β-cell dysfunction7. Both insulin resistance and pancreatic β-cell 
failure are thought to result from the complex interplay of many different pathways under the 




The role of genetics in T2DM is indicated by the familial clustering of insulin sensitivity and 
insulin secretion, the higher concordance rate of T2DM in monozygotic vs. dizygotic twins, 
and the high prevalence of T2DM in some ethnic groups like the Mexican Americans and 
Pima Indians
9
. Patterns of inheritance suggest that this is a polygenic and heterogeneous 
disease, involving multiple genes with different combinations of genes playing a role in 
different subset of individuals. It is still uncertain exactly how many genes and what the 
relative contribution of each gene is, and because T2DM is closely linked to other metabolic 
phenotypes and has a progressive pathogenesis (starting with insulin resistance and β-cell 
dysfunction, leading to clinical hyperglycemia), elements of complexity are inevitably added 
to the interpretation of results from genome-wide association studies (GWAS).   
 
Lifestyle factors are also important in the development of T2DM. Non-smokers with high 
levels of physical activity, a healthy diet (high in fiber, with a high polyunsaturated:saturated 
 
4 
fat) with normal body weight and moderate alcohol consumption, had a 89% lower rate of 
diabetes
10
. Some other factors that exacerbate the development of T2DM include obesity, 
hypertension, elevated cholesterol (combined hyperlipidemia), and metabolic syndrome
3
 (the 
group of risk factors that occur together and increase the risk for coronary artery disease, 
stroke, and T2DM). Other causes include acromegaly, Cushing’s syndrome, chronic 
pancreatitis, cancer, and drugs. Obesity has been found to contribute to approximately 55% of 
cases of T2DM
11
 and is the most potent risk factor for T2DM, possibly by increasing the risk 
of developing insulin resistance, and decreasing consumption of saturated fats and trans-fatty 
acids while replacing them with unsaturated fats may decrease the risk
12
. Adipose tissue in the 
obese releases more of free fatty acids (FFAs), glycerol, hormones, pro-inflammatory 
cytokines and other factors, that strongly influence insulin resistance and T2DM. Non-
essential fatty acids induce insulin resistance and impair ß-cell function, which further impair 
the capacity to compensate for decreased insulin sensitivity. The normal pancreatic β-cell 
response to chronic fuel surfeit and obesity-associated insulin resistance is compensatory 
insulin hyper-secretion to maintain normoglycemia. T2DM only develops in subjects that are 
unable to sustain the β-cell compensatory response. 
 
While adipose tissue was considered to be the body’s fuel depot storing energy in the form of 
triglycerides, growing evidence suggests that the endocrine function of these tissues in fuel 
homeostasis can no longer be neglected. The discovery of the adipocyte-secreted peptide 
hormone leptin led to a paradigm shift favoring this notion
13
. Adipose tissue is known to 
secrete other molecules like Tumor necrosis factor (TNF)-α, Interleukin (IL)-6, Transforming 
growth factor (TGF)-β, angiotensinogen, adiponectin, with some of these having been 
implicated as potential regulators of glucose homeostasis
14
. However, their exact role in 
contributing to T2DM remains to be explored. Environmental toxins may also contribute to 
recent increases in the development of T2DM; a weak positive correlation has been found 






Given the considerable time and resources it takes to translate basic biomedical discoveries 
into clinical tools, any current assessment of the clinical value of recent advances in the 
genetic and biological basis of T2DM is an underestimate. Nevertheless, an improved 
understanding of fundamental disease mechanisms is already emerging; this will aid in 





Figure 1. Genetic and environmental factors may influence the risk of diabetes through the 
pathways illustrated in the figure or through as-yet-unidentified mechanisms affecting insulin 





1.2.  THERAPY AND TREATMENT IN DIABETES  
 
1.2.1.  TREATMENT IN D IABETES  
 
The discovery of insulin in the 1920’s was a breakthrough in T1DM treatment, freeing 
patients from starvation diets that were the mainstream methods of therapy then, prolonging 
survival for a few weeks, months or in rare cases, a few years
4
. Insulin therapy thus changed 
diabetes from a rapidly fatal disease to a chronic one associated with significant secondary 
complications like renal failure, retinopathy, cardiovascular diseases and neuropathy. While 
aggressive insulin therapy that seeks to maintain glucose homeostasis is the golden aim of 
diabetes therapy, patients often find it difficult to achieve such fine control and suffer an 
increased risk of hypoglycaemia
16
. To date, serum biomarkers such as auto-antibodies have 
been widely used to detect T1DM, and improvements in technologies that rely on 
metabolomic studies and development of T-cell readouts might enhance diagnostic 
capabilities.  Current clinical trials focus on identifying environmental triggers while 
therapeutic trials test the efficacy of antigen-specific and antigen-nonspecific immune 
intervention therapies.  
 
Onset of T2DM can be delayed or prevented through proper nutrition and regular 
exercise.  Intensive lifestyle intervention measures may reduce the risk by over 
half
17
. Evidence for the benefit of dietary changes alone, however, is limited. In patients 
with impaired glucose tolerance, diet and exercise and/or metformin (an anti-diabetic drug 
that reduces hyperglycemia by suppressing glucose production in the liver and increasing 
sensitivity to insulin)
18
 or acarbose may decrease the risk of developing diabetes
17
. Lifestyle 
interventions are more effective than metformin. Insulin injections may be added to oral 
medication or used alone. Other classes of medications commonly used to treat T2DM are 
sulfonylureas and non-sulfonylurea secretagogues (triggers insulin release by inhibiting the 
KATP channel in β-cells), alpha-glucosidase inhibitors (to prevent the digestion of 
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carbohydrates), and thiazolidinediones (to decrease triglycerides and increase high-density 




The way T2DM is managed may change with age. Insulin production decreases because of 
age-related impairment of pancreatic β-cells and insulin resistance increases because of the 
loss of lean tissue and the accumulation of fat (especially intra-abdominal fat) and the 
decreased tissue sensitivity to insulin. Glucose tolerance progressively declines with age, and 
age-related glucose intolerance is often accompanied by insulin resistance, but circulating 
insulin levels are similar to those of younger people
19
. Treatment goals for older patients with 
diabetes vary with the individual, and take into account health status, as well as life 
expectancy, level of dependence, and willingness to adhere to a treatment regimen. 
 
1.2.2.  TRANSPLANTATION THERAPY  
 
While whole pancreas transplantation has demonstrated promising results in the treatment of 
T1DM, with patients having a >85% likelihood that they will enjoy insulin-independent 
euglycemia a year later, and about 50% maintaining that favorable metabolic outcome 5 years 
post-transplantation
4
,  clinicians are also working to develop isolated islet transplantation 
techniques as this does not require major surgery. The Edmonton protocol
20
 developed in 
2000 involves a steroid-free immune-suppressive regimen and high-quality islet cells derived 
from 2 or more recently deceased donors, and this resulted in a significantly improved graft 
function. However, an international multi-center trial tested whether the Edmonton protocol 
could be generalized, and it was found that only 14% of subjects remained insulin-
independent 2 years after receiving an islet transplant, and there was a heightened risk of 
infection, β-cell toxicity and nephropathy21. While islet transplantation has the potential to 
treat diabetic patients, the rate-limiting factor is the availability of islets from organ donors
22
. 
Therefore, there remains a clear need for an alternative source of cells capable of 
physiologically regulating insulin secretion.  
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1.2.3.  ALTERNATIVE SOURCES OF BETA ISLETS  
 
Transplantation of mature, physiologically-responsive β-cells generated from stem cells is a 
potential alternative source of islets, and so are xenogenic islets from pigs. The question of 
whether adult β progenitor cells exist has been a controversial issue for decades, and genetic 
lineage tracing provided evidence that pre-existing β-cells, rather than stem/progenitor cells, 
were the major source of new β-cells in adult mice23. However, later experiments showed that 
there exists in the ductal lining, a population of β-cell progenitors that can be activated in the 
injured adult mouse, and differentiation in situ and in explants of these progenitors give rise to 
all islet cell types, including β-cells24. More recently, rare pancreas-derived multi-potent 
precursor cells were isolated from adult human islet tissue that were capable of extensive 
proliferation, self-renewal, and they were capable of generating multiple differentiated 
pancreatic and neural cell types. These cells also ameliorated diabetes in transplanted mice, 





Another alternative source of β-cells would be directed differentiation of embryonic stem cells 
(ESCs) towards the β-cell lineage. Many attempts have been made to achieve this with various 
degrees of success, with most studies being only able to generate highly heterogeneous 
populations of immature β-cells that are not able to respond to environmental stimuli26. Recent 
advances in the field have led to the derivation of pancreatic endoderm from human ESCs
27
. 
Upon glucose stimulation, these differentiated cells were able to secrete human insulin and c-
peptide at levels similar to those of mice that had undergone islet transplantations. They also 
expressed critical β-cell transcription factors, appropriate processing of proinsulin and the 
presence of mature endocrine secretory granules, and demonstrated protection against 
streptozotocin-induced hyperglycemia. The over-expression of three critical pancreatic 
transcription factors were also able to reprogram adult exocrine cells to β-cells28. Porcine islet 
transplantation is another alternative source of β-cells but it requires major immune-





While all these potential therapies are promising, at this point none of them are widely 
practiced. It is therefore imperative to understand in greater detail how the mature β-cell 
phenotype is regulated, and to understand the regulatory mechanisms responsible for glucose-
stimulated β-cell insulin secretion, in order to aid our attempts at duplicating its function in 






1.3.  THE PANCREAS  
 
The adult mammalian pancreas is a heterogeneous organ composed of three major cell types: 
exocrine acinar cells, ductal cells and endocrine cells
30
. Exocrine cells produce digestive 
enzymes like trypsiongen, chymotrypsinogen, amylase, lipase that are shunted into the gut via 
duct cells. The exocrine tissue, organized into dense epithelial acini, makes up >95% of the 
pancreatic mass. Digestive enzymes are secreted into the acinar lumens which drain into small 
ducts, and these merge and feed into progressively larger structures, eventually joining the 
common bile duct. Embedded within the pancreatic exocrine tissue are islets of Langerhans, 
the endocrine component of the pancreas. The islets of Langerhans are highly-vascularized 
micro-organs which consists of several endocrine cell types that function together to maintain 
glucose homeostasis. Histologically, the islets resemble colonies of endocrine tissue 
suspended within the acinar matrix, as if derived from single progenitor cells; however, 




1.3.1.  INTER-SPECIES ISLET COMPARISON  
 
Murine islets are the most well studied and are often described as having a highly ordered 
structure that is 60-80% composed β-cells clustered in a central core, surrounded by 15-20% 
α-cells,  with δ-cells, pancreatic polypeptide (Ppy) cells and ε-cells in the periphery32. Human 
islets tend to contain fewer β-cells and more α-cells compared to rodent islets. The endocrine 
cells in human islets also do not have a distinct distribution (when compared to rat islets) with 
α-, β- and δ-cells randomly distributed throughout the islet33,34, with 50% β-cells, 40% α-cells, 
10% δ-cells and few PPY-cells. Small islets appear to be composed of mainly β-cells, whereas 
large islets have intermingled α- and β-cells34. Islet composition varies not only between 
species, but also within species
34
. Murine islets display a wide array of morphologies under 
various physiological conditions, including pregnancy, obesity and diabetes. In db/db mice, 
which have a mutation in the leptin receptor and are obese and diabetic, islet architecture and 
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cellular composition resemble that of humans, suggesting a high degree of plasticity in islet 




1.3.2.  THE UNIQUE BETA CELL FUNCTION  
 
Pancreatic β-cells are able to greatly expand their function and mass in both physiologic and 
pathologic states of nutrient excess and increased insulin demand, by hypertrophy and 
proliferation of existing β-cells, increased insulin production and secretion, and formation of 
new β-cells from progenitor cells35.  The unique differentiation of the mature β-cell phenotype 
is responsible for the extraordinary efficiency of these specialized cells in storing and 
secreting insulin to regulate metabolism in such an exquisite fashion. With successful 
compensation for insulin resistance, little change in secretory machinery is needed as the 
distinctive specialization of the β-cell is sufficient for optimal glucose-stimulated insulin 
secretion (GSIS); the large acute insulin responses to glucose challenge (observed in obese 
patients) strongly suggest the β-cell phenotype is mostly maintained. The glucose transporter 
(Glut)-2 allows rapid equilibration between extra- and intra-cellular glucose levels. Glucose is 
phosphorylated by Glucokinase (Gk) with a Km of ~8mmol/l, allowing it to function 
efficiently within the normal range of plasma glucose concentrations
36
. Glucose metabolism 
occurs primarily by glycolysis, with pyruvate directed to mitochondria for oxidation and little 
gluconeogenesis
37
 or lactate production
38
 occurs; all these contribute to maximizing the 
efficiency of aerobic glycolysis. The specialized mitochondrial shuttles in the β-cell help to 
contribute to ATP formation (via the glycerol phosphate shuttle that allows reduced 
nicotinamide dinucleotide (NADH) to be oxidized by the mitochondria, enhancing glycolytic 
flux)
39





To maintain this degree of specialization, the genes that are highly expressed in β-cell include 
those of the secretory products (insulin and islet amyloid polypeptide ((IAPP)), essential 
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genes for glucose metabolism (Glut2 and Gk), key enzymes for the mitochondrial shuttles 
(glycerol phosphate dehydrogenase (mGPDH)) and pyruvate carboxylase, and critical 
transcription factors (Chapter 1.3.6.). At the same time, enzymes that participate in 
superfluous pathways such as gluconeogenesis and lactate production would be thought to be 
preferentially suppressed by phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-
phosphatase, fructose-1,6-bisphosphatase, lactate dehydrogenase and hexokinase. This is not 
an exhaustive list of proteins that would have to be expressed and repressed in an active and 
dynamic manner, in response to the changing environmental milieu.   
 
1.3.3.  SYNTHESIS  AND PROCES SING OF INSULIN  
 
The liver maintains the baseline level of glucose but β-cells can respond quickly to spikes in 
blood glucose by releasing stored insulin, while simultaneously producing more. Insulin is 
initially synthesized as a single-chain 86 amino acid precursor polypeptide, preproinsulin. 
Subsequent proteolytic processing removes the amino terminal signal peptide, giving rise to 
proinsulin. Proinsulin is structurally related to insulin-like growth factors (IGF)-I and II, 
which bind weakly to the insulin receptor. Cleavage of an internal 31-residue fragment from 
proinsulin generates C-peptide and the A (21 amino acids) and B (30 amino acids) chains of 
insulin, which are connected by disulfide bonds. β-cells release C-peptide into the 
bloodstream in equimolar quantities and measuring the levels of C-peptide can give medical 
practitioners an idea of the viable β-cell mass41, as it is cleared more slowly than insulin and is 
a useful marker of insulin secretion, allowing discrimination of endogenous and exogenous 
sources of insulin in the evaluation of hypoglycemia. C-peptide also helps provide neuropathy 
and other symptoms of diabetes related to vascular degeneration
42
. β-cells also produce a 37 
amino acid peptide called amylin (IAPP) in a 1:100 amylin:insulin ratio. It is the major 
component of the amyloid fibrils found in the islets of patients with T2DM, and is thought to 
contribute to glycemic control by inhibiting the appearance of nutrients (especially glucose) 
into the plasma
43
.   
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1.3.4.  GLUCOSE-STIMULATED INSULIN SECRETION (GSIS)  
 
Glucose is the main regulator of insulin secretion by the pancreatic β-cell, although amino 
acids, ketones, various nutrients, gastrointestinal peptides, and neurotransmitters also 
influence insulin secretion. Glucose levels > 3.9 mmol/L (70 mg/dL) stimulate insulin 
synthesis, primarily by enhancing protein translation and processing
44
. Insulin is released in 
two phases, the first phase release is rapidly triggered in response to increased blood glucose 
levels, and the second phase release is a sustained, slow release of newly formed vesicles 
independent of sugar. The first phase of glucose-stimulated insulin secretion begins with its 
transport into β-cells by Glut2 (Figure 2). The rate-limiting step in GSIS is glucose 
phosphorylation by Gk to form glucose-6-phosphate, which generates ATP via glycolysis and 
inhibits the activity of an ATP-sensitive K
+
 channel. This channel consists of two separate 
proteins: one is the binding site for some oral hypoglycemics (e.g. sulfonylureas, 
meglitinides); the other is Kir6.2, an inwardly rectifying K
+
 channel protein. Inhibition of 
Kir6.2 induces β-cell membrane depolarization, opening voltage-dependent calcium channels 
that lead to an influx of calcium. This results in activation of phospholipase C, which cleaves 
the membrane phospholipid phosphatidyl inositol 4,5-bisphosphate into inositol 1,2,4-
triphosphate (IP3) and diacylglycerol. IP3 binds to receptor proteins in the endoplasmic 
reticulum (ER) membrane and allows the release of calcium from ER via IP3-gated channels, 
further increasing the intracellular concentration of calcium that triggers the exocytosis of 
insulin-laden vesicles and subsequent insulin secretion.  
 
Insulin exocytosis begins with the synthesis of preproinsulin in the endoplasmic reticulum, 
followed by budding of immature insulin granules from the trans-Golgi network, insulin 
granule maturation, and fusion of release-competent dense-core insulin granules with the 
plasma membrane (Figure 3). A large number of proteins control this secretory pathway but 
the key molecules controlling membrane fusion are the soluble N-ethylmaleimide-sensitive 
factor attachment protein receptor (SNARE) proteins. Like in other secretory cells, the fusion 
of the dense-core insulin granules with the plasma membrane involves the assembly of a 
 
15 
complex between the granule membrane Vesicle-associated membrane protein (Vamp)-2 and 
the integral plasma membrane Syntaxin (Stx)-1a, as well as the membrane-associated 
Synaptosomal-associated protein (Snap)-25. A large number of accessory factors interact with 
SNAREs and influence the assembly of the core complex. Insulin secretory profiles reveal a 
pulsatile pattern of hormone release, with small secretory bursts occurring about every 10 






Figure 2. GSIS in the pancreatic β-cell. Glucose is transported into the β-cell by facilitated 
diffusion through Glut2, which leads to membrane depolarization and an influx of 








Figure 3. Cellular events involved in GSIS. Reactions to the right (electrical activity) are 
synonymous with the triggering pathway in β-cell stimulus secretion coupling. Reactions to the left 
(exocytosis) have the capacity to modify the β-cell secretory response. Some of these reactions are 






1.3.5.  BETA-CELL DYSFUNCTION IN T2DM 
 
Glucotoxicity, lipotoxicity, and glucolipotoxicity are secondary phenomena that are proposed 
to play a role in T2DM. The underlying concept is that once the primary pathogenesis of 
diabetes is established (usually involving both genetic and environmental forces), 
hyperglycemia and hyperlipidemia ensue, exerting additional damaging or toxic effects on the 
β-cell. In addition to their contribution to the deterioration of function after the onset of the 
disease, elevations of plasma fatty acid levels that often accompany insulin resistance may, as 
glucose levels begin to rise beyond the acceptable range, also play a pathogenic role in the 
early stages of the disease
45
. The word glucolipotoxicity is almost paradoxical, because 
physiological levels of glucose and lipids are essential for normal β-cell function. Therefore, 
there exists a spectrum going from normoglycemic and normolipidemic conditions, to that of 
excess. Glucolipotoxicity states that the alternations in intracellular lipid partitioning 
underlying the mechanisms of lipotoxicity are dependent upon elevated glucose levels.  
 
In initial stages of insulin resistance due to obesity, β-cell compensation occurs to increase the 
amount of insulin secreted (Figure 4). Much of this is due to an increase in β-cell mass, 
probably by β-cell replication and islet neogenesis35 and enhanced β-cell function46. Increased 
β-cell function has been attributed to increased islet glucose metabolism, FFA signaling (in 
the form of lipid signaling, lipolysis and triglyceride/ FFA cycling) and sensitivity to incretins 
like Glucagon-like peptide (Glp)-1. Increased parasympathetic nervous system activity in 
islets leads to increased insulin secretion
47
, and the up-regulation of Insulin gene expression 
(that is linked to the complex interaction between second messenger signals derived from 
nutrient metabolism, hormonal stimuli, transcription factors and post-translational processing, 
is implicated in β-cell compensation mechanisms48. 
 
The loss of GSIS observed in the diabetic state is accompanied by important changes in β-cell 
phenotype, demonstrated by changes in gene and protein expression in islets from diabetic 
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Zucker Diabetic Fatty (ZDF) rats
49
, and rats following partial pancreatectomy
50
. The 
alterations in β-cell phenotype has been postulated to be due to dedifferentiation (loss of 
phenotype), in that the highly expressed genes in β-cells (mentioned above) are down-
regulated while those that are normally suppressed are up-regulated in their expression
51
. 
These cells are also highly stressed, with antioxidant, apoptotic, and pro-apoptotic genes being 
activated
52
, with a concommitant increase in c-myc expression and nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB) activation. These changes are consistent with the 
activation of the pro-inflammatory molecule IL1 in conditions of high glucose
53
. There is also 
β-cell hypertrophy, which may be a growth process driven by glucose that stops short of cell 
replication
50
. The loss of the β-cell’s ability to respond to glucose might not only be due to an 
altered phenotype, there could also be important changes in signal transduction pathways that 
might be unrelated to changes in protein levels.  
 
Insufficient insulin secretion from de-compensated β-cells causes increasingly higher blood 
glucose levels that continually surround the pancreatic islets, leading to glucose 
desensitization, β-cell exhaustion and eventually glucose toxicity. Desensitization is a cellular 
response that protects β-cells from excessive stimulation; repeated challenges by high glucose 
concentrations rapidly lead to diminished insulin secretory responses to glucose, but not to 
other agents. On cessation of glucose stimulation, this refractoriness to glucose stimulation 
eventually recovers and the β-cell once again responds normally to glucose54. However, 
repeated and sustained exposure to high glucose concentrations leads to β-cell exhaustion, as 
available insulin granules in the exocytotic vesicles have been depleted due to prolonged 
stimulation of insulin secretion without a sufficient compensatory increase in insulin 
synthesis. This condition can be “rescued” by allowing the β-cells to rest under conditions of 
normal glucose levels for a period of time
55. If the β-cells have been stressed with high levels 
of glucose for too long a period of time, glucose toxicity occurs
56
. In this state, important 
mechanisms such as glucose regulation of the Insulin promoter and insulin synthesis are 
unhinged and the β-cell nearly shuts down. Insulin secretion is greatly affected, especially 
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post-prandially, and the β-cell might even become incapable of producing Insulin mRNA57 
due to the loss of Pancreatic duodenal homeobox (Pdx)-1
58
 and v-maf musculoaponeurotic 




As nutrient excess persists, hyperglycemia and elevated FFAs negatively impact β-cell 
function by generating reactive oxygen species, causing alterations in metabolic pathways and 
increases in intracellular calcium and the activation of endoplasmic reticulum stress. These 
processes adversely affect β-cells by impairing insulin secretion, decreasing Insulin gene 






Figure 4. β-cell failure and the natural history of T2D48. T2D develops in response to over-nutriton 
and lack of physical activity in subjects that have underlying genetic and acquired predispositions to 
both insulin resistance (and/or hyperinsulinemia) and β-cell dysfunction. Over time, islet β-cell 
compensation for the insulin resistance fails, resulting in a progressive decline in β- cell function. As a 
consequence, subjects progress from normal glucose tolerance (NGT) to IGT and finally to established 
T2D. Even after diagnosis of T2D, β-cell function continues to worsen such that subjects progress from 
needing changes in diet/exercise only to requiring oral hypoglycemic agents and eventually insulin for 




1.3.6.  TRANSCRIPTION FACTORS IN PANCREAS DEVELOPMENT AND 
FUNCTION  
 
Transcription factors orchestrate intricate pathways of cellular growth and differentiation by 
regulating the rate of transcription of an array of genes in order to maintain cellular 
homeostasis. Genetic and biochemical studies have begun to unravel the complex cascade of 
factors that control the proliferation and differentiation of cells in the developing pancreas. 
The pancreatic β-cell is solely responsible for the transcription of the Insulin gene and the 
subsequent processing and secretion of insulin in response to increases in extracellular glucose 
concentrations. The absolute or relative dysfunction of β-cell can have profound metabolic 
consequences, leading to the development of hyperglycemia and ultimately, diabetes. 
Therefore, it is imperative to understand the essential determinants of the β-cell phenotype at 
the physiological and molecular level, and much effort has been put into elucidating the 
mechanisms that direct the formation of β-cells in the developing embryo and those 
responsible for the transcription of genes encoding β-cell proteins. Several transcription 
factors have been identified as being crucial to both of these processes (Table 1). These 
nuclear regulatory proteins function by binding to characteristic DNA sequences in the 
upstream regulatory elements of specific genes, and subsequently regulating the rate of 
transcription of those genes. Transcriptional regulation of genes in the β-cell is manifested by 
the morphological and phenotypical changes that occur during development, in addition to the 
synthesis of specific proteins in the mature β-cell, such as Insulin, Glut2, Gk, Neurogenic 










Pancreatic cell type  Function  
FoxA2 Embryonic endoderm and 
all islet cell types 
Necessary for proper endoderm formation and 
expression of Pdx1
61
. Also required for regulated 
insulin secretion in mature β-cells62. 




HNF1α β-cells Activation of insulin and Pdx164. Heterozygous 
mutations cause MODY in humans
65
. 
HNF4α β-cells Activation of Hnf1 α, insulin and Glut266. 
Heterozygous mutations cause MODY in humans
67
.  
Islet1  Pancreatic progenitors, islet-
restricted in the adult  
Early endocrine cell differentiation.
68
 
MafA  Pancreatic progenitors, β-
cell-restricted in the adult  
Controls insulin gene expression in terminally 
differentiated  β-cells69. 
MafB Pancreatic progenitors, α-
cell-restricted in the adult 
Formation of α- and β-cells70. 
NeuroD1  Pancreatic progenitors, islet-
restricted in the adult  
Islet growth and differentiation. Important for Ins 
activation in the mature β-cell71. Heterozygous 
mutations cause MODY in humans.  




Nkx2.2  Pancreatic progenitors, islet-
restricted in the adult  




Nkx6.1  Pancreatic progenitors, β-
cell-restricted in the adult  
Final differentiation of β-cells75.  




Pax6  Pancreatic progenitors, islet-
restricted in the adult  




Pdx1 Pancreatic progenitors, β-
cell-restricted in the adult 
Formation of β- and δ-cells and exocrine tissue78. 
Absence results in lack of pancreas formation
79
. 
Important activator of Ins
80
. Heterozygous 





1.3.7.  TRANSCRIPTION FACTORS IN PANCREATIC DEVELOPMENT  
 
The earliest stages of pancreas organogenesis depend on signaling interactions with 
surrounding tissues, and the local environment in which the pancreas develops is extremely 
dynamic regarding the spatial and temporal positioning of the different tissues. Initially, the 
pancreas primordia are relatively simple structures containing the common pancreatic 
progenitor cells, but with the appearance of numerous differentiated cell types, gut rotation, 
and branching morphogenesis, complexity of the organ increases. Before pancreas 
specification, the formation of definitive endoderm during the gastrulation process is 
controlled by multiple signaling factors and morphogens where the TGF-β family member 




In rodents, the first signs of pancreas organogenesis are the formation, at mid-gestation 
(embryonic day (E) 9–9.5), of two pancreatic buds, first the dorsal then the ventral, in the 
region of the posterior foregut endoderm (Figure 5A)
83
. The specification, differentiation and 
growth of the two pancreatic buds are controlled by various signals originating from the 
adjacent mesodermal tissues, such as retinoic acid (RA) and the inhibition of sonic hedgehog 
(Shh) signaling
84
. Dorsally, the pancreatic bud is sequentially exposed in a spatial and 
temporal fashion to signals from the notochord, dorsal aorta and pancreatic mesenchyme. 
Ventrally, both the cardiac mesoderm and vitellin veins control pancreas development. The 
two buds later fuse and the pancreatic epithelium branches and differentiates within the 
surrounding mesenchyme which further supports pancreatic growth
83
. At the same time, the 
different pancreatic cell types (α, β, δ, ε and PP) differentiates from immature pancreatic 
progenitor cells. During their differentiation endocrine precursors delaminate from the 
epithelium, migrate and aggregate in clusters called islets of Langerhans. 
 
The first indication of pancreas morphogenesis is the up-regulation of the Pdx1 gene encoding 
a transcription factor that is essential for development of this organ. Pdx1-null mice fail to 
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develop a pancreas and dies shortly after birth
81
. Pdx1 mRNA expression is initially detected 
on embryonic E8.5 in the part of the gut epithelium that later develops into pancreas, and is 
crucial for the development of endocrine and exocrine cell types. NeuroD1 is detected as early 
as E9.5 in the pancreatic primordia, indicating that NeuroD1 is present in early precursor 
cells. Pdx1 is also present in the dorsal and ventral buds as they form around E9.5 and is then 
expressed throughout the expanding ductal tree up to E13.5, where the basic helix-loop-helix 
(bHLH) transcription factor Neurogenin (Ngn)-3, determines which of the uncommitted 
pancreatic progenitor cells are to adopt an endocrine, exocrine or ductal fate (Figure 5B)
85
. 
Pdx1 levels decrease at this stage and only reappear in endocrine cells that are destined to 
become β-cells. At E17.5, NeuroD1 is mainly expressed in small clusters of endocrine cells. 
In the adult pancreas, Pdx1 is expressed mainly in β-cells and is essential in regulating genes 
involved in maintaining its glucose-responsive phenotype
86
. Other transcription factors like 
NK homeobox (Nkx)-2.2, Nkx6.1, Paired box (Pax)-4, Pax6, and MafA also contribute to β-
cell development
85
. For example, islet progenitor cells can either become precursors of β/δ 
cells or α-cells, and these alternative fates are promoted by Pax4 and Aristaless-related 
homeobox (Arx) respectively 
87
. Pax6 could act in parallel with Pdx1, Nkx2.2 and Nkx6.1 in 
some of the β-cells in the late stages of pancreatic development88.  MafA has been 
hypothesized to be important for differentiation of β-cells, with Nkx6.1 occuring upstream to 












Figure 5. Pancreatic lineages and genes
89
.  (A) Lineage tracing indicates that all mature pancreatic 
cell types derive from progenitors that express Pdx1 and/or Ptf1a, and that a subset of these progenitors 
go on to express Ngn3 and differentiate into islet cells. (B) Pathways of islet-subtype specification. A 
hypothetical lineage diagram for Ngn3+ endocrine precursors, which give rise to all islet cell types 
(here, a single Ngn3+ cell is depicted giving rise to each subtype, whereas, in reality, the potential of a 
given Ngn3+ cell may be more restricted). 
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In addition to the distinct role of transcription factors in the developing pancreas, many of the 
aforementioned factors also play a major role in the mature adult β-cell. This is evidenced 
clinically by the Maturity Onset Diabetes of the Young (MODY) syndromes, in which 
heterozygous mutations in Hepatocyte nuclear factor (HNF)-4α, HNF1α, Pdx1, HNF1β and 
NeuroD1 cause progressive impairments in insulin secretion and the eventual development of 
T2DM
90
. These transcription factors, along with others, often interact together to mediate 
proper β-cell function that ultimately activates a set of unique β-cell genes, e.g. Ins, Glut2, 
Iapp or Gck).  
 
The usage of Cre–Lox technology in mice has enabled deletions of transcription factors 
specifically in β-cells, thereby enabling evaluation of their cell-specific roles independently of 
their roles in development. The β-cell-specific deletion of Forkhead box (Fox)-a2 leads to the 
attenuation of the genes encoding Pdx1 and ATP-sensitive Kþ channel
61
, thus establishing 
Foxa2 as an important upstream regulator of these two proteins. Similarly, the β-cell-specific 
deletion of Pdx1 in mice results in the attenuation of the genes encoding Insulin, Iapp and 
Glut2
81
. However, although expression of the target genes in both of these β-cell-specific 
deletions is clearly diminished, it is not abolished. Therefore, redundancy must exist in the 





Figure 6. Model for the network of transcription factors that direct β-cell function85. The major β-
cell transcription factors (e.g. Pdx1) are shown as controlling the expression of the genes for other 
factors or for functionally important proteins within the β-cell (e.g. Glut2). The figure also highlights 
the redundancy within the network, so that mutation of any one factor (e.g. Hnf4α) serves only to 




1.3.9.  PDX1 
 
Although no single transcription factor can be considered to be the sole determinant of β-cell 
function, the homeodomain (HD) Pdx1 is the most crucial, with deficits in expression levels 
resulting in reduced insulin secretion, accelerated β-cell apoptosis, and insulin-deficient 
diabetes in mice
81
. PDX1 is also clinically important in humans, as different mutations 
increase susceptibility to the development of hyperglycemia, with a range of phenotypes that 
include MODY4, T2DM, and gestational diabetes
85
. Pdx1 mediates the adaptive 
responsiveness of β-cells to changes in extra-cellular glucose concentrations through the 





, and through the activation of glucose responsive enhancers within the Insulin promoter, 
in conjunction with other transcriptional regulators
93





, and also functions downstream of the insulin 
signaling pathway in the regulation of β-cell mass85. However, the number of target genes is 
certainly much greater, as Pdx1
-/-
 mice display pleiotropic phenotypes
95
. Pdx1 directly 
regulates Insulin transcription through formation of a complex with transcriptional co-
activators on the proximal Insulin promoter
96
, leading to enhancement of elongation by basal 
transcriptional machinery. The co-activator p300 interacts with Pdx1 and enhances Insulin 
transcriptional activity through multiple mechanisms, including the recruitment and activation 
of components of the basal transcriptional machinery and histone/protein acetylation
80,97,98
. 
Two highly conserved sequences in the 50-flanking region of the Pdx1 gene (PH1/area1 and 
PH2/area2) confer β-cell specific transcriptional activity on a heterologous promoter99,100. 
Pdx1 itself binds to the PH1/area1 element and co-operates with Hnf3β to activate 
transcription
100
. Pdx1 may be directly activated by the transcription factors NeuroD1
101
, 
Hnf1α and Hnf3β102. In T2DM islets, Pdx1 mRNA expression was increased, despite 






1.3.10.  NEUROD1 
 
NeuroD1 (a.k.a. β2) is a bHLH transcription factor that plays an important role in pancreas 
development, and restoration of wild-type gene expression in diabetic mouse models can 
induce islet neogenesis and reverse the diabetic phenotype
104
. bHLH proteins are transcription 
factors involved in the determination of cell type and differentiation during development
105
, 





 mice are hyperglycemic and exhibit ketonuria, dying 
within 5 days of birth
71
. These mice have severe diabetes, brought about by the significant 
reduction in the number of islet cells, because of a failure of endocrine cells to aggregate into 
mature islets. Mutations in NEUROD1 are linked to MODY6 in humans
1
, e.g. a missense 
mutation of Arg 111 within the DNA-binding domain diminishes the ability of NeuroD1 to 
bind to DNA and is associated with T2DM in the heterozygous state
1
. Another mutation 
causes C-terminal truncation of NeuroD1 and leads to a more severe clinical phenotype of 
T2DM
1
. It functions in a complex with the ubiquitously expressed E47 protein
107
 and the 





 gene transcription. Over-expressing E47 inhibits Gcg gene expression, but 
activates Insulin gene transcription, suggesting that the NeuroD1/E47 ratio may be critical for 
the regulation of both Insulin and Gcg expression
108
. NeuroD1/E47 also binds to and activates 
the upstream Gk promoter in the islet
109
 and Islet-specific glucose-6-phophatase catalytic-
subunit-related protein
110
. NeuroD1 may be controlled at the transcriptional and post-




, and the main role of 
NeuroD1 in the mature β-cell may be to actively repress the Somatostatin (Sst) promoter in 
order to maintain Insulin expression
112
. NeuroD1 is also implicated in the regulation of insulin 





, which is an ion channel transporter, and Sulfonylurea receptor (Sur)-1, 
which forms potassium channels with Kir6.2
111
. The mis-expression of NeuroD1 in a human 
fetal epithelial cell line induced the expression of several genes required for vesicular 
trafficking and exocytosis, including Sec24D, Snap25, Stx1 and Munc18
114
. This finding 
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suggests that NeuroD1 may regulate insulin exocytosis in pancreatic β-cells by directly 
inducing the expression of genes involved in exocytosis.  
 
1.3.11.  MAFA 
 
The C1/RIPE3b element in the Insulin gene promoter plays a critical role in β-cell-specific 
and glucose-regulated expression of Insulin
115
, and a β-cell-restricted C1-binding factor that 
appeared in response to glucose in pancreatic β-cell nuclear extracts was originally detected 
by gel mobility shift analysis and subsequently purified biochemically and identified as 
MafA
116
. MafA is a basic leucine-leucine zipper (bLZ) transcription factor that is only found 
in the β-cells of the pancreas and plays an important role in maintenance of β-cell function117. 
Although v-Maf was identified as a retroviral transforming protein
118
, it is now widely 
accepted that Maf family proteins are regulators of a wide variety of cell- and tissue-specific 
gene expression, and also play a role in cell differentiation during development, e.g. gain- or 
loss-of-function experiments in the developing chick embryo revealed that L-Maf is a key 
regulator of lens development
119
. Glucose and oxidative stress regulate MafA expression at the 
transcriptional level through FoxO1, a forkhead transcription factor involved in oxidative 
stress responses and metabolism
120
. Pdx1, FoxA2 and Nkx2.2 were found to bind to a cis-
regulatory region of MafA approximately 8 kb upstream of the transcription start site, 
regulating its β-cell-specific expression121. In contrast to Pdx1 and NeuroD1, β-cell 
development does not appear to be affected in MafA-deficient mice, although adult mutant 
animals are glucose intolerant due to diminished Insulin transcription and impaired glucose-
stimulated insulin secretion, decreased β-cell number and altered islet architecture43. The 
relative unimportance of MafA in β-cell development is surprising, because MafA is produced 
only in insulin-producing cells of the second and principal phase of β-cell production during 
mice embryogenesis
42
. The phenotype of MafA knockout animals are not as severe as Pdx1 or 
NeuroD1 animals, perhaps because MafA is restricted to β-cells of the pancreas, or because 
other Maf family members (MafB or C) may compensate for the loss of MafA
32
. MafA 





, pyruvate carboxylase, prohormone convertase 1/3, but it is not known if 




1.3.12.  SYNERGISTIC ACTIVITY OF TRANSCRIPTION FACTORS  
 
Pdx1/VP16 expression, together with NeuroD1 or Ngn3 markedly induced Insulin gene 
transcription, ameliorated glucose tolerance, and substantially induced insulin biosynthesis 
and various β-cell factors necessary for its function, viz., Gk, Sur1, and Kir6.2 in the liver123. 
This triple expression was more effective than when the genes were ectopically over-
expressed on their own, possibly due to marked induction of the Insulin mRNA expression to 
increase Insulin promoter activity by an auto-regulatory loop
124
. Another possibility is that the 
transcription factors are recruited to the Insulin promoter region by MafA, and together with 
Pdx-1 and NeuroD1, this enables these transcription factors to exert strong synergistic effects 
and to markedly induce Insulin gene expression
124
. Pdx1, E47 and NeuroD1 interacts 
synergistically to stimulate Insulin promoter activity
107
. Pdx1, MafA, and NeuroD1/E47 acting 
through the Insulin promoter proximal A1, C1, and E1 sites respectively, play an important 
role in maintaining basal promoter activity of the human INS gene, with evidence of the 
transcription factors having a synergistic effect on the human INS promoter
125
. Pdx1 had the 
strongest stimulatory effect on the Insulin promoter, relative to the weaker effects of MafA, 
NeuroD1, and E47. When the human INS promoter was modified to resemble the rat Insulin1 
promoter, there was more synergistic activation generated
100
, emphasizing the differences in 
regulation of the human promoter and the well-characterized rodent Insulin promoter. Pdx1, 
Pax6, NeuroD1, and Nkx 2.2 regulate the Insulin gene by binding regulatory control regions 
of other genes selectively transcribed in islet cells
126
.  MafA functionally interacts with Pdx1 
and NeuroD1 to promote synergistic activation of the Insulin enhancer-driven reporter cell 
line in non β-cells127, and MafA, NeuroD1/E47, and Pdx1 cyclically bind to the mouse 
Insulin2 promoter
128
. Pdx1 and NeuroD1 co-occupy the promoters of not just the Insulin gene, 
but many other genes involved in secretion, transporters, transcription and microRNAs 
(miRNAs) involved in maintaining β-cell function86, suggesting that Pdx1 and NeuroD1 co-
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regulate a significant number of genes. Ngn3, Pdx1 and MafA were able to reprogram 
differentiated pancreatic exocrine cells in adult mice to cells very similar to β-cells, these β-
cells were indistinguishable from endogenous islet β-cells in size, shape and ultrastructure, 
expressing genes essential for β-cell function could ameliorate hyperglycaemia by 





1.4.  EPIGENETIC REGULATION IN PANCREATIC BETA-CELLS  
 
Although obesity, reduced physical activity, and aging increase susceptibility to T2DM, many 
people exposed to these risk factors do not develop the disease. Recent genome-wide 
association studies have identified a number of genetic variants that explain some of the inter-
individual variation in diabetes susceptibility
129
. There is also increasing evidence suggesting 
a role for epigenetic factors in the intricate interplay between genes and the environment, 
especially in complex diseases like T2DM
130
. Epigenetics is defined as heritable changes in 
gene function that occur without a change in the nucleotide sequence, and these modifications 
of the genome provide a mechanism that allows the stable propagation of gene activity states 
from one generation of cells to the next
131
. Epigenetic states can be modified by 
environmental factors, which may contribute to the development of abnormal phenotypes. In 
plants, it is well established that epigenetic modifications can be inherited from one generation 
to the next132. There are at least two main classes of epigenetic information that can be 
inherited with chromosomes: one involving changes in chromatin proteins (usually involving 
modification of histone tails), and the other involving changes in DNA methylation.  
 
In eukryotes, DNA is assembled with histones to form the nucleosome, in which 147 base 
pairs of DNA is wrapped approximately two turns around an octameric complex composed of 
two molecules of each of the four histones H2A, H2B, H3, and H4. The core histones are 
densely packed but their NH2-terminal tails can be modified by acetylation, methylation, 
glycosylation, sumoylation, phosphorylation, and ADP ribosylation
133
. These modifications 
are important for determining the accessibility of the DNA to the transcription machinery as 
well as for DNA replication, recombination, and higher-order chromosomal organization. The 
most common moditications involve acetylation and methylation of lysine residues in the H3 
and H4 amino termini. Histone deacetylases (HDACs) remove and histone acetyl transferases 
(HATs) add acetyl groups to lysine residues on histone tails
133
. HAT activity and increased 
histone acetylation usually correlate with increases in gene transcription; an initial explanation 
for how that happened was that histone acetylation removed the positive charges of the native 
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lysine residues on histone tails, abolishing the binding of negatively charged DNA, resulting 
in a relaxed chromatin state that facilitated access to transcriptional machinery, allowing 
transcription
133
. Histone acetylation may also recruit bromodomain proteins that can act as 
transcriptional activators
134
. However, recent work has led to the proposal of different models, 
for example the histone code hypothesis which suggests that multiple histone modifications 
act in combination to regulate transcription
135
. H2A.Z associates with functional regulatory 




1.4.1.  H ISTONE METHYLATION  
 
Histone methylation is associated with both transcriptional repression and activation, 
depending on the degree of methylation and the specific lysine and/or arginine residue 
modified, and lysine residues can be mono-, di-, or tri-methylated in vivo, providing an added 
complexity of transcriptional regulation
134
. The mono-methylations of H3K27, H3K9, H4K20, 
H3K79, and H2BK5 are all linked to gene activation, while tri-methylations of H3K27, 
H3K9, and H3K79 are linked to repression
136
. High levels of H3K4me1, H3K4me2, and 
H3K4me3 are detected surrounding transcription start sites (TSSs), while H3K36me3 peaks 
are near the 3’ end of genes. The apparently opposite modifications H3K4me3 and 
H3K27me3 have been found to co-localize in ‘‘bivalent domains’’ in ESCs137, and these have 
been suggested to function in the differentiation of these cells, as these “bivalent domains” 
have been found in developmental regulators. Recent evidence has confirmed the presence of 
these domains in mouse embryonic fibroblasts (MEFs), neural progenitors
138
 and human T 
cells
139
, proving that these “bivalent domains” are not an ESC-specific phenomenon. A 
comparison of H3K4me3 and H3K27me3 in islets show that these “bivalent domains” are 
usually mutually exclusive or absent, but there are few genes that had high levels of both 
marks, e.g. the Homeobox (Hox) gene clusters and neuronal transcription factors, perhaps 
indicating a retention of “memory” of earlier transcription or the re-activation of these genes 





1.4.2.  DNA  METHYLATION  
 
The second major class of epigenetic regulation is DNA methylation, where a cytosine base is 
modified by DNA methyltransferase (DNMT) at the C5 position of cytosine. Approximately 
70% of CpG dinucleotides in human DNA are constitutively methylated, while most of the 
unmethylated CpGs are located in CpG islands, which are CG-rich sequences located near 
coding sequences that act as promoters for the genes that are associated with them. 
Approximately half of mammalian genes have CpG islands. Methylation of CpG sites is 
maintained by DNMTs: DNMT1 maintains DNA methylation during replication
141
 while 
DNMT3a and b are involved in de novo DNA methylation
142
. DNA methylation is commonly 
associated with gene silencing and is achieved by modifying the binding affinity of 
transcription factors that are essential for activating gene transcription, or by recruiting 
proteins that bind specifically to methylated CGs (methyl-CG-binding proteins e.g. MeCP2). 
These in turn further recruit HDACs and co-repressors like Sin3A
143
. This silencing effect 
contributes to X-chromosomal inactivation, genomic imprinting, and transcriptional regulation 
of tissue-specific genes during development and differentiation
131
.  Most CpG islands remain 
unmethylated in normal cells, but in certain conditions e.g. cancer
144
 and oxidative stress, 
previously unmethylated CpG sites can become de novo methylated. This anomalous 
methylation is accompanied by local changes in histone modification and chromatin 
organization, resulting in the CpG island and its associated promoter taking on a repressed 
conformation which is incompatible with gene transcription. It is not known what makes 
particular CpG islands susceptible to aberrant methylation. A “sequence signature associated 
with aberrant methylation” is proposed to exist145, where Pdx1 was identified as being 1 of 15 
CpG genes (a total of 1749 genes with CpG islands were examined) that was methylation-





Although DNA methylation and histone modification are carried out by different chemical 
reactions and require different sets of enzymes, there seems to be a biological relationship 
between the two systems that plays a part in modulating gene repression programs in 
mammalians. It appears that this relationship can work in both directions: Histone methylation 
can direct DNA methylation patterns, and DNA methylation can simultaneously serve as a 
template for some histone modifications after DNA replication (Figure 7)
146
. At the molecular 
level, these connections might be accomplished through direct interactions between histone  
methyltransferases (HMTs) and DNMTs. For example, methylation of lysine 9 on H3 
promotes DNA methylation, while CpG methylation stimulates methylation of lysine 9 on 
H3
147
. Therefore chromatin modifications induced by adverse stimuli are self-reinforcing and 






Figure 7. The link between DNA methylation, histone modification and chromatin 
remodelling
148
. In mammalian cells, both DNA methylation and histone modification are involved in 
chromatin silencing. DNA methylation and histone modification are believed to be interdependent 
processes. Three possible models of how they might influence each other are shown. (A) A model of 
DNA methylation directing histone methylation. DNA methylation patterns are established through de 
novo methylation by DMT3A and DNMT3B, and are maintained by DNMT1. Methyl-CpG-binding 
proteins (MBD) and HDAC complexes, such as the MECP2–Sin3a–HDAC complex, are believed to 
then be recruited to the methylated region to induce histone deacetylation and silencing. The chromatin 
then attracts HMTs such as Suv39h or G9a, which methylate the lysine 9 residue on histone H3 (H3K9) 
and stabilize the inactive state of the chromatin. (B) A model of histone methylation directing DNA 
methylation. Methyl H3K9 acts as a signal for inactive chromatin by recruiting HP1 to methylated 
histones, which might in turn recruit DNMTs directly or indirectly (through an unknown factor, factor 
X) to the silent chromatin to maintain DNA methylation and stabilize the inactive chromatin. (C) A 
model of chromatin remodelling driving DNA methylation. The ATP-dependent chromatin-remodelling 
and DNA-helicase activities of proteins, such as ATRX and Lsh, might facilitate DNA methylation and 
histone modification by unwinding nucleosomal DNA to increase its accessibility to DNMTs, HDACs 
and HMTs. The disrupted function of these proteins impairs both DNA methylation and histone 




1.4.3.  EPIGENETICS ,  THE ENVIRONMENT &  T2DM 
 
Initial observations suggesting a role for environmental cues in establishing an epigenetic 
mark came from studies of the agouti mouse model, where a retrotransposon element 
containing a strong promoter is inserted close to the promoter of the gene encoding the Agouti 
protein. If the retrotransposon promoter sequence is methylated, the offspring are wild-type 
agouti because it cannot override the agouti promoter, and vice versa. Interestingly, yellow 
mothers produce more offspring than agouti mothers, but their offspring suffer from obesity, 
hyperinsulinaemia and diabetes
149
. Maternal diet alters the phenotype of these mice: when 
pregnant females are fed a methyl-donor-rich diet, a larger proportion of offspring have a 
wild-type coat color (indicating that methylation has silenced the offspring’s retrotransposon, 
allowing the wild type agouti promoter to be expressed) in comparison to mothers fed a 
standard diet, showing that maternal nutrition can change the stable expression of genes in 




In the context of T2DM, pregnant women exposed to famine conditions during their late stage 
pregnancy in 1944/5 gave birth to smaller babies with an increased risk of developing insulin 
resistance
151
, and these observations have been repeated in rodent models of intrauterine 
growth retardation (IUGR). The effects of neonatal leptin (a hormone that regulates energy 
intake and expenditure) on hepatic gene expression and epigenetic status in adulthood were 
found to be directionally dependent on the animal's nutritional status in utero. This showed 
that during mammalian development, the direction of the response to one cue can be 
determined by previous exposure to another, suggesting the potential for a discontinuous 




One of the key environmental perturbations associated with T2DM is exposure to an adverse 
intrauterine milieu, such as IUGR which induces mitochondrial dysfunction in the β-cell, 





Uteroplacental insufficiency (the most common cause of IUGR in the developed world) 
induces epigenetic modifications in offspring: pups are born spontaneously with decreased 
levels of glucose, insulin, Igf1 and amino acids
154
. Diabetes develops in these animals at 15–
26 weeks of age with underlying β-cell secretory defects and insulin resistance, epigenetic 
modifications affecting processes important to glucose regulation and insulin secretion have 
been described in the IUGR liver, pancreatic β-cells and muscle154.  
 
The 6q21 region / HDAC2 gene is significantly associated with diabetes
155
. Another locus 
identified in a genome wide scan of type 2 diabetes lies on chromosome 19q13 and the HDAC 
SIRT2 maps there
156
. In mice heterozygous for the HAT cyclic adenosine monophosphate 
(cAMP)-response element (Cre)-binding protein (CBP) demonstrate increased insulin 
sensitivity and glucose tolerance even while demonstrating a marked lipodystrophy of white 
adipose tissue
157
. Exposure to oxidative stress can directly mediate both DNA methylation and 
remodelling of chromatin in multiple disease models, perhaps explaining how aberrant 
epigenetic programming leads to T2DM
158
. Random DNA methylation changes that occur 
during aging in several tissue types are also associated with increased oxidative stress, 
affecting the expression of multiple genes
158
. Because of their abundant lysine residues, 
histones are susceptible to oxidative stress
159
. The discovery of histone demethylases (e.g. the 
Jumonji C family) link epigenetic processes to oxygen gradients during development
160
. This 
is particularly relevant to T2DM as there are now substantial data showing that oxidative 
stress plays a significant role in β-cell deterioration. 
 
Therefore, the molecular defects leading to obesity & diabetes may be via several hierarchical 
genetic or epigenetic levels of control (Figure 8): (1) Abnormal acetylation/deacetylation of 
transcription factors resulting in anomalous gene expression (2) Mutation of transcription 
factors leading to aberrant gene expression (c) Atypical expression of transcription factors 




Figure 8. Schematic of how histone acetyltransferases and histone deacetylases may modulate the 
chromatin surrounding important diabetes genes either through direct interactions with specific 
transcription factors, or via specific complexes
104
.   
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1.4.4.  EPIGENETICS AND THE MATURE BETA-CELL  
 
Pdx1 does not appear to have the intrinsic ability to either modify histones or directly alter 
chromatin structure, but once its transcriptional co-activators are recruited, they serve as a 
physical or functional bridge that allows Pdx1 to communicate with components of the basal 
transcriptional machinery, leading to either activation or repression of downstream target 
genes. For example, Pdx1 associates with HDAC1 and -2 under low glucose conditions (1-
3mM) to repress Insulin gene expression, and recruits the transcriptional co-activator and 
HAT p300 to the Insulin promoter only in high glucose conditions (10-30mM)
161
. The HMT 
Set7/9 is recruited by Pdx1 to the Insulin and Glut2 genes, leading to H3K4me2 and 
recruitment of RNA polymerase II
162
. Pdx1 modulates histone H4 acetylation to directly 
activate Insulin gene expression in β-cells163; exogeneous Pdx1 expression in α-cells also 




MODY is a monogenic autosomal form of T2DM, and 6 genes (HNF4α, GK, HNF1α, PDX1, 
HNF1α, and NEUROD1) that associate with HATs and HDACs have each been found to 
cause this disease.  Mutations in PDX1 lead to MODY4, and as mentioned above, Pdx1 has a 
functional interaction with p300 that is required for Insulin gene transcription. Pdx1 also 
regulates its own transcription through histone H3 and H4 acetylation
165
. A mutant form of 
PDX1 in humans has an increased affinity for p300, but a lower DNA binding capability, 
suggesting that Pdx1 sequestration of HAT activity and its resultant chromatin remodeling 




In IUGR rodents, mSin3A/HDAC is first recruited to the Pdx1 promoter
167
; histone tails are 
deacetylated and Pdx1 transcription repressed (Figure 9). At the neonatal stage, this epigenetic 
process is reversible and might define an important developmental window for therapeutic 
approaches. As dimethylated H3K9 accumulates, DNMT3A is recruited to the Pdx1 promoter 
and initiates de novo DNA methylation, which locks in the Pdx1-silenced state in the IUGR 
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adult pancreas, resulting in diabetes
167
. Pdx1 and MafA expression and activity are decreased 
in diet-induced obese (DIO) animals
168
 and in cell culture conditions mimicking diabetes
169
, 
leading to a decrease in insulin biosynthesis and secretion. A mutation in p300 abolishes 
binding to NeuroD1 and destroys the ability of p300 to activate Insulin E-box directed 
transcription in β-cells, leading to MODY6, thus showing the importance of p300 interactions 
with E-box activators in Insulin gene transcription
166
. Co-immunoprecipitation studies show 
that insulinoma-associated (IA)-1, cyclin D1, and HDACs functionally interact to regulate 
NeuroD1
170
. Small heterodimer partner (SHP) is one of the unique members of the orphan 
nuclear receptor superfamily that lacks a conventional DNA-binding domain
171
. SHP directly 
regulates the transcriptional activity of Hnf4α172 and acts as a co-regulator of NeuroD1 via 




Therefore, the association of many β-cell transcriptional regulators with HATs, HMTs and 







Figure 9. Epigenetic changes at Pdx1 in IUGR rats during the development of T2DM
167. (A) In 
pancreatic β-cells, the Pdx1 proximal promoter is normally found in an unmethylated (white circles) 
open chromatin state allowing access to transcription factors such as Usf1 and is associated with 
nucleosomes characterized by acetylated (Ac, blue octagons) histones H3 and H4 and with 
trimethylated H3K4 (Me, green hexagons). (B) In IUGR fetal and (C) 2 week-old islets, histone 
acetylation is progressively lost through association with a mSin3A–HDAC1–DNMT1 repressor 
complex, with trimethylated H3K4 disappearing and dimethylated H3K9 (Me, red triangles) appearing 
after birth. (D) IUGR adult islets are characterized by inactive chromatin with dimethylated H3K9 and 




1.4.5.  GLOBAL EPIGENETIC PROFILING OF THE PANCREAS  
 
Genes that have similar and/or co-ordinated expression patterns in specific tissues or at 
specific developmental stages are often clustered, like the Hox and β-globin loci174. The 
regulation of such gene clusters is often co-ordinated by shared common cis-regulatory 
elements, which activate expression through mechanisms that typically result in histone 
modifications associated with transcriptionally active chromatin. For example, genes in the β-
globin cluster are activated by a shared locus control region, which, through chromatin loop 
formation, makes physical contact with individual promoters of the cluster in a developmental 
stage-specific manner
175
. The human INSULIN gene has recently been found to be part of a 
large open chromatin domain specific in islets which is marked by histone acetylation and 
H3K4 di-methylation marks distributed over the entire coding region and an 80-kb region 
around it
176
. This region also contains the {tyrosine hydroxylase (TH)-(INS)-insulin-like 
growth factor 2 antisense (IGF2AS)-insulin-like growth factor 2 (IGF2)} gene cluster
176
 and 
their islet specific co-ordinate gene expression, suggesting their possible function in the 
maintenance of this unusually large region of open chromatin.  
 
In another recent study that looked at open regions of chromatin in human pancreatic islets
177
, 
the authors identified islet-specific clusters of open chromatin sites (termed COREs (clusters 
of open regulatory elements)), of which many genes encoding proteins with known function in 
islets (such as PDX1, PAX6, GLP1R, SLC30A8 and CPE), belong. They overlapped these 
CORE regions with 20 loci that have previously been associated with either T2DM or fasting 
glycemia, and found that 38 single nucleotide polymorphisms (SNPs) at 10 loci overlapped 
with islet-specific regions of open chromatin. This included the T2DM-associated SNP 
rs7903146 in the transcription factor 7–like 2 (TCF7L2) gene, which encodes a transcription 
factor involved in Wnt signaling and is a well-established risk locus for T2DM
178
. They 
detected an allelic imbalance in open chromatin signal in nine islet samples obtained from 
individuals who were heterozygous for the T-risk allele of rs7903146, indicating that the T 
allele is located in more open chromatin than is the non-risk C allele (Figure 10). This 
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suggests that the T allele may exert its effect on T2DM risk by altering the accessibility of the 
TCF7L2 DNA, and they showed in luciferase assays that the T allele had greater enhancer 




In another new study, open chromatin regions, CCCTC-binding factor (CTCF)-binding sites, 
H3K4me3, H3K4me1, and H3K79me2 were profiled across the entire genome in human 
islets
179
. Integrated analysis of these large-scale data sets identified 18 000 putative TSSs, 
30% of which were previously unannotated by RefSeq and at least several hundred of these 
are islet-active TSSs, including those for major islet miRNAs previously implicated in the 
control of glucose homeostasis
180
. Interestingly, active chromatin marks (H3K4me3 and 
H3K79me2) were absent from a subset of highly islet-expressed genes, including those 
encoding islet-specific hormones (INS, GCG, SST, IAPP, PPY, and Transthyretin (TTR). 
This observation suggests that some genes critical for islet function could have an 
unconventional promoter chromatin signature, indicative of a unique transcriptional control 
mechanism, and a similar proposal was also put forth by the group that found that the Insulin 
gene was part of a large open chromatin domain
176
. Fifty SNPs associated with islet-related 
diseases and traits were also found to map to within 500bp of a candidate non-promoter 
regulatory element, and 4 of the 12 elements that function as enhancers in vitro: FTO, 
Potassium voltage-gated channel, KQT-like subfamily, member (KCNQ)-1, TCF7L2, and 
Wolfram syndrome (WFS)-1 harbor T2D-associated SNPs, including two (TCF7L2 and 
WFS1) that exhibit significant allele-specific differences in activity
179
. These results suggest 
that altered enhancer activity plays a role in the molecular mechanism underlying at least a 
subset of T2D genetic association signals. 
 
In summary, there is a growing body of current literature suggesting a role for epigenetic 
interactions in the complex interplay between gene regulation and the environment. 
Nevertheless, our knowledge about the molecular mechanisms linking environmental factors 





Figure 10. Model for the chromatin state and mechanism for the TCF7L2 association in Type 2 
Diabetes
181
. (A) The T risk allele of the T2D-associated variant in the TCF7L2 gene (SNP rs7903146) 
is associated with open chromatin, which may facilitate protein-DNA binding and associate with 
increased levels of transcription relative to the non-risk allele. (B) The non-risk C allele is associated 
with closed chromatin, which may reduce access for protein binding. 
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1.5.  EXPERIMENTAL HYPOTHESES AND APPROACH  
 
Type 2 Diabetes arises from the inability of pancreatic β-cells to compensate for insulin 







, or a combination of both
184
, have been proposed to 
contribute to β-cell failure. Major goals in diabetic research are to restore the functionality of 
damaged β-cells or to replace them. Although insulin replacement remains the mainstay of 
treatment in T2DM, considerable effort has been devoted to developing approaches for cell-
based therapy. Through these efforts, it may become possible to introduce cells into diabetic 
patients that not only produce insulin, but also respond appropriately to metabolic signals that 
regulate insulin production, processing, and secretion. Accomplishing this goal requires a 
better understanding of the essential determinants of the β-cell phenotype at the physiological 
and molecular level. Pdx1, NeuroD1 and MafA are transcription factors necessary for 
maintaining mature β-cell function and critical for pancreas development85. Epigenetic 
changes to the chromosome architecture in β-cells have been associated with the loss of both 
glucose sensitivity and insulin production
130
. The use of genome-wide technologies to study 
gene expression and regulation in patients or animal models with T2DM has increased rapidly 
over recent years, generating long lists of new T2DM candidate genes. However, the use of 
global techniques to study epigenetic modifications in these systems has been limited, and 
epigenetic changes associated with T2DM are therefore still poorly understood. Therefore, 
understanding how these transcription factors regulate mature β-cell function, and the role of 
epigenetic changes associated with these transcription factors may provide useful knowledge 
in deriving β-cells from ESCs, in differentiating reprogrammed ESCs from diabetic patients, 





I have taken a two-pronged approach in my PhD dissertation, where my main hypotheses are: 
 
1. The molecular mechanisms governing the dynamic regulation and/or co-regulation of Pdx1, 
NeuroD1 and MafA are key determinants of β-cell function. 
2. As β-cell dysfunction develops, modulation of the chromatin environment adversely affects 
expression and activity of Pdx1, MafA, NeuroD1, and possibly other key β-cell transcriptional 
regulators. 
 
To test these hypotheses, the aims are to: 
1. Define the Pdx1, NeuroD1, and MafA transcriptional regulatory network operative in β-
cells. 
2. Establish the epigenetic profile of β-cells in order to investigate the role of chromatin 
remodeling in β-cell dysfunction. 
 
For these purposes, I have used a combination of genome-wide sequencing technologies 
combined with gene expression analyses to profile the global transcriptional occupancy of 
Pdx1, NeuroD1 and MafA, thus correlating transcriptional occupancy with gene regulation. I 
have also functionalized some of these target genes in order to gain deeper insight into the 
Pdx1, NeuroD1 and MafA-regulated processes. I have profiled global epigenomic changes in 
pancreatic β-cells with an impaired GSIS response. By investigating the molecular 
mechanisms of β-cell regulation and dysregulation, it will provide new insights on (1) How 
these important transcription factors work to regulate mature β-cell function, (2) How the 
epigenome is linked to pancreatic transcription factor-mediated activity in GSIS and the 
epigenetic mechanisms associated with β-cell dysfunction, and (3) Provide clues as to how the 
chromatin environment may be modified as a potential therapeutic avenue in treatment of 
diabetes. In addition, this information will be useful in developing in vitro ESC differentiation 
protocols to produce functional glucose-responsive β-cells. 
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1.6.  SIGNIFICANCE OF WORK  
 
Some other pertinent questions are whether the epigenetic changes induced by today’s 
sedentary lifestyle can be inherited by coming generations, and whether these changes are 
reversible. Clinical trials with HDAC inhibitors have repeatedly demonstrated low toxicity 
despite the expectation that they may cause global gene dysregulation, and preliminary studies 
indicate that they may prove useful in treating diabetes
185
. It is desirable that the balance of 
genes whose regulation would be altered with by epigenetic modifiers would tip the balance 
from unfavorable diabetogenes to those with enhanced benefits. With the insights gained from 
these experiments, it is hoped that eventually, genome-wide transcriptional and epigenetic 
characterization will lead to patient-specific therapies that also allow monitoring of genome-

























2.1.  CELL CULTURE  
 
2.1.1.  NIT-1  CELLS  
 
NIT-1 mouse insulinoma cells (ATCC) were grown in Kaighn’s modification of Ham’s F12 
media (F12K) (Life Technologies), with 1.5g/l sodium bicarbonate, supplemented with 10% 
dialyzed fetal bovine serum (Life Technologies). They were grown in a monolayer with a 
change of media every 2-3 days, and passaged at a 1:2-3 ratio when the dish was ~70% 
confluent, with the following procedure: Each dish was rinsed twice with 1xPBS solution 
(Gibco) and incubated in 3ml 0.05% Trypsin (Gibco) for 3 minutes at 37°C to allow 
detachment of cells from the culture surface. The trypsin-treated cells were diluted with 7ml 
NIT-1 culture media, pelleted in a centrifuge for 5 min/500rpm, and re-suspended in 5ml fresh 
NIT-1 media. The cells were titrated to achieve a single cell suspension and seeded. 
 
2.1.2.  MOUSE EMBRYONIC STEM CELLS  (ESCS)  
 
Feeder-free E14 mouse ES cells (ESCs) were maintained on 0.1% gelatin coated dishes in 
E14 proliferative medium containing DMEM/15% ES FBS (Gibco), 0.1mM MEM non-
essential amino acids (Gibco), 2mM L-glutamine (Gibco), 0.1mM β-mercaptoethanol (Gibco), 
and CHO- Leukemia inhibitory factor (LIF) (1,000 U/ml). The cells were passaged every 2 
days in a similar fashion as the NIT-1 cells, and seeded on gelatin-coated plates at a density of 
4x10
6
 cells per 10cm
2
 dish. Mouse ES cells cultured on mouse embryonic fibroblast (MEF) 
feeder layers were maintained in the proliferative medium described above, with the exception 
of CHO-LIF.  
 
2.1.3.  D IRECTED ESC  D IFFERENTIATION TOWARDS THE PANCREATIC L INEAGE  
 
In stage 1, ESC differentiation was initiated by generating embryoid bodies, to allow cells to 
form a three-dimensional structure that allows intra-cellular signaling. LIF was withdrawn to 
promote spontaneous differentiation. In Stage 2, serum was withdrawn and Nodal signaling 
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was promoted with the addition of Activin A (R&D Biosystems) added to potentiate 
endoderm formation, FGF4 (R&D Biosystems) was added to induce anterior gut fate. In stage 
3, Activin A and FGF4 were maintained in the culture medium and bone morphogenic protein 
(BMP) 4 (R&D Biosystems) 4 and FGF10 (R&D Biosystems) were added to expand the 
population of putative pancreatic progenitors. Pancreas specification depends on addition of 
RA and suppression of SHH by cyclopamine (Sigma), which represses the mesodermal 
markers Gsc, Bra. Low glucose was used in stages 4 and 5 because glucose restriction may 
initiate generation of insulin producing cells. Nicotinamide (Sigma), a SIRT-specific inhibitor, 
is commonly used as part of the differentiation cocktail to drive ESCs towards the β-cell 
lineage
186
. β-cellulin (R&D Biosystems), a glycoprotein highly expressed in the pancreas, was 
added to promote the differentiation, regeneration and proliferation of pancreatic β-cells. 
 
2.1.4.  CRYOPRESERVATION OF CELL L INES  
 
Confluent cell cultures were trypsinised as described above and centrifuged for 5 minutes at 
500rpm. The cells were re-suspended in freezing media (70% DMEM with 20% FBS and 
10% dimethyl sulphoxide) and transferred into Nunc cryotubes at 1ml per vial. The cryotubes 
were placed at -80°C overnight in Mr Frosty containers buffered with isopropyl alcohol and 
then transferred to a liquid nitrogen tank the following day for long-term storage. 
 
2.1.5.  THAWING OF CELL L INES  
 
Frozen cryotubes were retrieved from liquid nitrogen tanks and placed immediately into a 
37°C water bath. The cells were rapidly thawed and then transferred into 10ml of pre-warmed 
culture media. The cell suspension was pelleted for 5 minutes at 500rpm, then gently 
resuspended in culture media and plated in 10 cm
2 
tissue culture dishes to allow for overnight 





2.2.  CELL-BASED ASSAYS  
 
2.2.1.  RNA  INTERFERENCE (RNA I)  ON NIT-1  CELLS  
 
RNA interference (RNAi) experiments were performed with Dharmacon siGENOME 
SMARTpool reagents or Ambion Silencer siRNAs against mouse genes (Appendix 1).The 
Dharmacon siCONTROL nontargeting siRNA pool or the Ambion siNTC was used as a 
negative control. NIT-1 cells were transfected according to manufacturer’s instructions in 12-
well plates at a density of 2.5 x 10
5





2.2.2.  GSIS 
 
NIT-1 cells were seeded in 12-well plates at a density of 4 x 10
5
 cells and left to grow till 70% 
confluency before the experiment. The cells were rinsed 2X with PBS and starved for 2 hours 
at 37°C with RPMI (Life Technologies) before washing 3x with 1xKRH (10xKRH 
formulation: 15.194g NaCl, 700.8mg KCl, 326.6mg KH2PO4, 288.96mg MgSO4, to a 
volume of 200ml H2O. 100ml 1xKRH: 10ml 10x KRH, 2ml 1M HEPES, 1% BSA, 256µl 
CaCl2, pH 7.38-7.42). The cells were incubated in 500µl 1xKRH for 1 hour and the media 
removed and stored on ice (basal secretion). 500ul 1xKRH with 20mM glucose was then 
added and incubated for 1 hour and the media removed and stored on ice (stimulated 
secretion). The media from the basal and stimulated cells were spun at 500rcf for 5 minutes 
and the supernatant used for subsequent ELISAs.  
 
2.2.3.  GLUCOLIPOTOXICITY TREATMENT OF NIT-1  CELLS  
 
150,000 cells/well were seeded in triplicate wells/ condition in a 12-well plate and grown to 
60-70% confluence. Varying concentrations of 150mM palmitic acid (Sigma) and glucose 
(Sigma) was added to RPMI for 2 days.  
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 2.2.4.  ESTABLISHMENT OF THE PDX1-CLONAL MOUSE ESC  L INE  
 
The Ainv18 cell line (gift of George Daley, Harvard Medical School, Boston, MA) is an E14 
mouse ES line modified for targeted gene insertion downstream of a doxycycline-responsive 
promoter 183. The Pdx1 transgene was PCR-amplified from a mouse cDNA library and 
subcloned into the KpnI/XbaI sites of the pLox-N-tag-HA vector (George Daley, Harvard 
Medical School, Boston, MA) with the following primers, restriction sites indicated in 
uppercase: Forward 5’-ATTACTCTCGAGTAACAGTGAGGAGCAGTA -3’ and Reverse 
5’-CGTACGGTCGACTCA CCG GGG TTC CTG CGG -3’. An additional nucleotide was 
inserted in the forward primer to allow in-frame processing of the Pdx1 insert with the N-
terminal HA tags. For targeted insertion at the HPRT locus, 20µg each of pLox-N-tag-HA-
Pdx1 and pSALK-Cre were transfected with Lipofectamine 2000 (Life Technologies) into 
6x10
5
 AINV18 cells seeded in 10cm
2
 dishes. For derivation of Ainv18-Pdx1 clonal lines, 
mouse ESC medium was supplemented with 350µg/ml G418 solution (Life Technologies) 24 
hours after transfection and maintained for 14 days. Colonies arising from G418 selection 
were individually picked and expanded on neomycin-resistant MEFs. Site-specific integration 
was confirmed by PCR analysis with the following primers: LoxinF 5'-cta-gat-ctc-gaa-gga-tct-
gga-g-3' and LoxinR 5'–ata-ctt-tct-cgg-cag-gag-ca-3'. To induce over-expression, AINV18-
Pdx1 cells were treated with 1μg/mL doxycycline in mouse ESC medium. Protein was 
harvested to test and confirm the efficacy of regulation by doxycycline. 
 
2.3.  MOLECULAR BIOLOGY TECHNIQUES  
 
2.3.1.  CLONING  
 
The sub-cloning of DNA fragments into vectors was achieved by restriction enzyme 
digestion, gel purification of digested DNA, and T4 ligase treatment to yield the final 
construct. Restriction digests were preformed overnight at 37
oC according to manufacturers’ 
instructions (New England Biolabs). The following day, digested DNA was resolved on 1-
1.5% agarose gels in TAE buffer, and the desired fragments were visualized under UV 
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lighting and excised from the gel. The DNA fragments were released from agarose matrix 
using the Qiagen gel extraction kit according to manufacturer’s instructions. The 
concentration of the recovered DNA was quantified by UV absorbance using the nanodrop 
instrument, and ligations were performed at 5:1 (insert:vector) molar ratio in 20µl reactions 




2.3.2.  TRANSFORMATION OF CHEMICALLY  COMPETENT CELLS  
 
For transformation of ligated plasmids, a 50μl aliquot of One-Shot Top10 chemically 
competent E.coli cells (Invitrogen) was thawed on ice. Approximately 10ng of ligation 
reaction was added to the thawed cells and gently mixed followed by incubation on ice for 30 
minutes. Transformation was induced by heat-shock treatment at 42ºC for 1 minute. The cells 
were cooled on ice for 2 minutes, and 200µl of nutrient-rich LB-SOC was then added to the 
tube for incubation at 37ºC for 1 hour in a bacterial shaker. Following incubation, 50-300ul of 
the culture was plated on LB-agar plates containing the appropriate antibiotic selection, and 
the plates were placed in an incubator at 37ºC overnight to allow growth of bacterial colonies. 
 
2.3.3.  ISOLATION OF PLAS MID DNA  FROM BACTERIA  
 
Bacterial colonies containing positive ligation events were expanded as follows: 5ml LB 
medium with appropriate antibiotic selection was inoculated for overnight culture at 37ºC. 
The overnight cell suspensions were centrifuged at max speed for 15 minutes to pellet 
bacteria. The bacterial cells were then lysed and plasmid DNA purified using the Qiagen 
miniprep kit according to manufacturer’s instructions. The DNA was eluted in 50µl dH2O and 





2.3.4.  PREPARATION OF BACTERIAL STOCKS  
 
Bacterial stocks of successful transformation events were prepared in 33.3% sterile glycerol. 
The LB-glycerol suspension was vortexed to ensure thorough mixing, cooled on ice for 1 
hour, and then placed at -80
o
C for long term storage. 
 
2.4.  GENE EXPRESSION ANALYSIS  
 
2.4.1.  RNA  EXTRACTION  
 
RNA was extracted from mammalian cells with TriZol reagent (Invitrogen) and then further 
purified with the RNeasy minikit (Qiagen) according to manufacturer’s instructions. RNA 
samples were treated with DNase for removal of genomic DNA contamination. This was 
performed in 100 µl reactions containing 5 µg RNA, 0.2 U/µl RNAse inhibitor, and 0.15 U/µl 
RNase-free DNase (ProMega). Samples were incubated at 37
o
C for 30 minutes, followed by 
heat-inactivation of enzymes at 65
o
C for 15 minutes. The RNA samples were then purified 
using two phenol extractions and one chloroform extraction, and back extractions were 
performed with each step using equal volumes of sterile dH20 to minimize loss of RNA. Total 
RNA was precipitated, washed with 70% ethanol and finally re-suspended in 30µl of sterile 
nuclease-free dH20. 
 
2.4.2.  CDNA  SYNTHESIS  
 
cDNA was synthesized with 100ng - 1 µg total RNA using the High Capacity cDNA Archive 
kit (Applied Biosystems) as per manufacturer’s instructions. Briefly, cDNA synthesis was 
performed in 20µl reactions consisting of RNA diluted in 10 µl nuclease-free dH20, and 
cDNA Archive kit components: 1xReverse Transcriptase buffer, 5.5mM MgCl2, 500µM 
dNTP mix, 2.5µM random primers, 0.25U/µl MultiScribe Reverse Transcriptase. Synthesis 
reactions were incubated in a PCR thermocycler at 25
o
C for 10 minutes followed by 37
o
C for 
2 hours. The cDNA samples were stored at -20
o
C following synthesis. 
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2.4.3.  QUANTITATIVE REAL-T IME PCR 
 
Quantitative PCR assays were performed as follows: Reversed transcribed cDNA samples 
were diluted 10x in nuclease-free water, and added to 5µl TaqMan® Universal PCR Master 
Mix reagent (Applied Biosystems) containing 0.5µl of a single TaqMan probe (20xTaqMan® 
Gene Expression Assay reagents; Applied Biosystems). The list of TaqMan probes are 
provided in Appendix 2. Reactions were conducted in duplicate within 384-well reaction 
plates (ABI) at a final volume of 10µl on the ABI Prism 7900 machine. For SYBR Green 
reactions, primers against the gene of interest were designed with the following criteria: 
spanning at least one intron, 15-25 bp in length with a 40-60% GC content, and a melting 
temperature™ of 57-63oC. 
 
2.4.4.  ILLUMINA MOUSE ARRAYS  
 
 
The whole-genome Illumina Mouse Ref-8 v2.1 beadchips were used for microarray analysis 
of RNAi-treated samples. These Illumina beadchips allow interrogation of approximately 
25,600 well annotated mouse Refseq transcripts. For the microarray analyses, mRNA was 
harvested from 3 or 4 biological replicates per experiment. These samples were reverse-
transcribed, Cy3-labeled, and hybridized to Illumina MouseRef-8 v2.1 Expression Beadchips 
according to the manufacturer’s protocol (Illumina Inc.). Following the wash of Illumina 
chips, microarray signals were scanned with an Illumina BeadStation array reader, and the 
data were background-normalized and assessed for quality with cluster dendrograms and 








2.4.5.  STATISTICAL  ANALYSIS  OF M ICROARRAY DATA  
 
The microarray data were processed with Genespring GX v10.2 (Agilent Technologies). The 
unpaired Student's t test was used to determine statistical significance with Benjamini and 
Hochberg multiple-testing correction (FDR<0.05), and genes demonstrating ≥ 1.5-fold change 
were reported as statistically significant. For statistical analysis of overlapping genes between 
RNAi samples, computer simulations were conducted as follows: a number of genes 
corresponding to the actual number of genes within each list were randomly sampled from the 
Illumina mouse Ref-8 v2.1 Beadchip. The random gene lists were overlapped to derive a 
percentage, and this process was repeated 100 times to yield an average percentage overlap by 
chance. Finally, p-values were computed by comparing the 100 simulated overlaps to the 
actual overlap percentage using one-sample t-tests. 
 
2.4.6.  FUNCTIONAL ANNOTATIONS USING THE PANTHER DATABASE  
 
The microarray gene lists were uploaded to the Panther database for functional annotations 
(http://www.pantherdb.org). In this analysis, the Panther Gene Expression tool set was used to 
classify differentially-regulated genes under biological process groups using the “Compare 
Gene List” function, relative to the 25,600 Illumina mouse Ref-8 v2.1 transcripts, and the 
binomial test was used to identify statistically significant over- or under-represented 
functional categories within the RNAi or over-expression gene lists. 
 
2.4.7.  FUNCTIONAL ANNOTATIONS USING INGENUITY PATHWAY ANALYSIS  
 
The RefSeq list of genes was uploaded into IPA (Ingenuity® Systems)
187
 and identified the 
top biological networks and pathways associated with the transcription factor binding sites for 
Pdx1, NeuroD1 and MafA. The same procedure was performed with the peaks from the 
H3K4me3, H3K27me3 and FAIRE libraries. Each identifier was mapped to its corresponding 
object in the Ingenuity® Knowledge Base and termed network eligible molecules. These were 
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then overlaid onto a global molecular network developed from information contained in the 
Ingenuity Knowledge Base, and networks were then algorithmically generated based on their 
connectivity. The functional analysis identified the biological functions and/or diseases that 
were most significantly enriched to the data set.  
 
2.5.  PROTEIN EXPRESSION ANALYSIS  
 
2.5.1.  CELL LYSIS  AND PROTEIN QUANTITATION  
 
Confluent cell cultures were harvested by scraping and washing with 1xPBS solution. The 
cells were centrifuged for 5 minutes at 500rpm, and then re-suspended in cell lysis buffer 
comprising 50mM Tris pH 7.4, 150mM NaCl, 2mM EDTA, 1% NP-40, 0.1% SDS, and 
1xEDTA-free Protease inhibitor (Roche). The cell lysate was incubated with rotation for 10 
minutes at 4
o
C and was cleared by centrifugation at 12,000 rpm for 30 minutes at 4
o
C. The 
supernatant was transferred to a fresh tube and protein was quantitated using the Bradford 
assay (Bio-Rad Laboratories). Six bovine serum albumin (BSA) protein standards were used 
at 0µg, 50µg, 100µg, 200µg, 300µg and 400µg for the Bradford assay. Protein samples and 
standards were diluted in 0.15M NaCl prior to triplicate loadings onto a 96-well ELISA plate. 
Absorbance values were measured on a Sunrise Tecan Microplate Reader at A595 nm. 
 
2.5.2.  SDS-PAGE 
 
Denaturing polyacrylamide gel electrophoresis was conducted to resolve proteins by size. 
Thirty micrograms of protein was added to 6x SDS loading buffer (250mM Tris/HCl pH6.8, 
30% glycerol, 10% SDS, 5% β-mercaptoethanol, and 0.02% bromophenol blue), followed by 
incubation at 95
o
C for 5 minutes. Protein samples were loaded onto a 10% or 12% acrylamide 
gel for electrophoresis at 100V for 1.5 hours. The resolved protein samples were then 
electroblotted onto Hybond C extra nitrocellulose membrane (Amersham) for 1 hour in 
Western Transfer Buffer (20% Ethanol, 70% dH20, and 1xWestern Transfer Buffer stock 
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containing 14.5g Glycine and 3.0g Tris base). Consistency of protein loading and quality of 
Western blot transfer was assessed by Ponceau S staining (0.5% Ponceau S, 1% glacial acetic 
acid). In this protocol, the electro-blotted membrane was rinsed once in Tris-buffered saline 
containing Tween-20 (TBS-T; 10mM Tris/HCl pH 8.0, 150mM NaCl, 0.5% Tween-20; pH 
8.). Ponceau S was then applied for 30 seconds to enable visualization of proteins on the 
membrane, following which the membrane was rinsed twice in dH20 and then thrice in TBS-
T. The nitrocellulose membranes were immediately probed for protein or stored at 4
o
C in air-
tight boxes containing TBS-T. 
 
2.5.3.  PROTEIN DETECTION AND CHEMILUMINES CENCE DETECTION  
 
Immunodetection of proteins was carried out as follows: Nitrocellulose membranes were 
blocked for 1 hour at room temperature in 5% (w/v) skimmed milk powder and 1% BSA. 
Protein detection was performed with rabbit-anti-Pdx1 antibody (1:500; Upstate) or rabbit-
anti-MafA (1:500, Abcam), or goat-anti-NeuroD1, sc:590, Santa Cruz Biotechnology), 
followed by HRP-conjugated donkey-anti-mouse or donkey-anti-rabbit secondary antibodies 
(Santa Cruz Biotechnology) at a dilution of 1:5000. Loading consistency was determined with 
mouse-anti-β-actin or donkey anti-GAPDH (1:1000; Invitrogen) and goat-anti-donkey HRP 
secondary antibodies (1:5000; Santa Cruz Biotechnology). The primary antibodies were 
incubated overnight at 4
o
C and the secondary antibodies were incubated for 1 hour at room 
temperature, with 3xTBS-T rinses for 15 minutes performed in between incubations. 
Chemiluminescence detection was carried out with the Enhanced-Chemiluminescence (ECL) 
Western blotting kit (Amersham) according to manufacturer’s instructions. 
 
2.5.4.  ENZYME-L INKED IMMUNOSORBENT ASSAY (ELISA) 
 
The amount of insulin was measured quantitatively using the Mouse Insulin ELISA 
(Mercodia) per manufacturer’s instructions. Briefly, the samples were diluted 20x and 10µl of 





C, 900rpm for 2 hours, then washed 6x with wash buffer. 200µl of TMB was 
added to the wells and incubated for 15 min and the reaction was stopped with 50µl stop 
solution. Insulin in the sample binds with (HRP)-conjugated anti-insulin antibody as well as 
an anti-insulin antibody is bound to the wells of a 96-well plate, and the bound HRP complex 
is detected by a reaction with TMB and the output measured with the Sunrise Tecan 
Microplate Reader at wavelength 450nm. The standards were averaged and a scatter plot point 
to point graph was plotted. The OD of the samples was averaged. Depending on the OD of the 
samples, the appropriate formula was used to calculate the insulin concentration. The secreted 
insulin concentration (S) is divided by the basal insulin concentration (B), to obtain the 
percentage increase of secreted insulin; % increase==S/B*100%. The triplicate % increase 
was averaged. The standard deviation and error bars were calculated with the triplicate % 
increases. 
 
2.5.5.  CHROMATIN IMMUNOPRECIPITATION (CHIP) 
 
NIT-1 cells were cultured to a density of 1x10
8
 cells for each IP. Two biological ChIP 
replicates were performed per experiment. Cells were cross-linked for 10 minutes at room 
temperature with 1% (w/v) formaldehyde and the reaction was subsequently quenched with 
125mM glycine. Nuclear fractions were isolated with a 3-step protocol that involved washing 
with increasing concentrations of SDS and high-speed centrifugation, and the cross-linked 
DNA was sheared to lengths of 200-500 bp with a Branson water sonicator. Chromatin was 
pre-cleared with thrice-washed Dynabeads for an hour at 4
o
C, and 6µg of ChIP antibody 
(Pdx1 (Upstate), NeuroD1 (Santa Cruz), MafA (Abcam), H3K4me3, H3K27me3) was 
incubated with the pre-cleared chromatin overnight. Dynabeads (Life Technologies) were 
added to the antibody-chromatin complexes the next day and incubated for 3 hours at 4
o
C. 
Following incubation, the antibody-bead-chromatin complexes were rinsed and pelleted, and 
re-suspended in fresh 0.1% ChIP buffer (50mM HEPES, 150mM NaCl, 2mM EDTA, 1% 
Triton x-100, 0.1% NaDOC, 0.1% SDS), and washed 2 times. The antibody-bead-chromatin 





C, 1400rpm for 40 minutes. Cross-links were reversed and protein removed by 
incubating the chromatin at 42
o
C for 2 hours with Pronase (0.2mg/ml) and an overnight 
incubation at 68
o
C. Finally, the samples were treated twice with phenol/chloroform/Isoamyl 
alcohol (25:24:1), then precipitated and rinsed once in 70% ethanol before re-suspension in 
10-50µl of nuclease-free water. 
 
2.5.6.  QUANTITATIVE PCR  FOR CHIP  ENRICHMENT  
 
Quantitative PCR (qPCR) for ChIP enrichment was performed on the ABI PRISM 7900 
machine with 1xSYBR Green PCR mastermix (Applied Biosystems), under the following 
conditions: 50
o
C for 2 minutes, 95
o
C for 10 minutes, and 40 cycles of 95
o
C for 15s and 60
o
C 
for 1 minute. Fluorescence from the amplified products was measured by laser spectral 
analyses on the ABI Prism 7900 machine, and the data were processed and displayed in the 
form of real-time amplification plots generated by the SDS software (v2.2; Applied 
Biosystems). ChIP fold-enrichment was determined by normalizing Threshold cycle (Ct) 
values of ChIP samples against sonicated whole cell DNA extract, and then subsequently to a 
non-enriched ChIP control region set at a value of 1. Details of primers are provided in 
Appendix 3. All PCR primers gave a single product as confirmed by heat dissociation analysis 
on the ABI Prism 7900 (Applied Biosystems), under the following conditions: 95
o
C for 15s, 
60
o




C for 15s. The data from this analysis were 
compiled by the SDS software (v2.2; Applied Biosystems) and displayed as melting curve 
graphs. The graphs were checked for specificity of PCR amplified product as indicated by a 
single, well-defined melting curve peak. 
 
2.5.7.  FORMALDEHYDE-ASSOCIATED IS OLATION OF REGULATORY ELEMENTS 
(FAIRE) 
 
NIT-1 cells were harvested for Formaldehyde-Assisted Isolation of Regulatory Elements 
(FAIRE) 
188
. Briefly, the cells were washed 2x with PBS and 1% formaldehyde was added to 
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~70% confluent 10-cm dishes of NIT-1 cells for 10 minutes - this was the FAIRE sample. The 
cross-linked chromatin was sheared to a range of 100-500bp and cross-links were reversed by 
incubating an overnight incubation at 65
o
C. The DNA was extracted in a double 
phenol/chloroform/Isoamyl alcohol (25:24:1) step, then precipitated and rinsed once in 70% 
ethanol before resuspension in 10-50µl of nuclease-free water. The FAIRE reference library 
was prepared in a similar fashion, except the cells were not fixed with formaldehyde.  
 
2.6.  BIOINFORMATICS ANALYSIS OF CHIP  AND FAIRE  LIBRARIES  
 
2.6.1.  CHIP-  AND FAIRE-SEQUENCING L IBRARY GENERATION AND 
IDENTIFICATION OF ENRICHED REGIONS  
 
10ng of purified ChIP or FAIRE sample (determined by Picogreen) was prepared for deep 
sequencing according to manufacturer’s protocols (Illumina, Inc). Briefly, the DNA was end-
repaired and blunt ended fragments generated. “A” bases were added to the 3’ end of the 
DNA fragments, leaving a 3’-dA overhang. Adapters were ligated to these overhangs and 
PCR enrichment of adapter-modified DNA fragments was performed. The samples were run 
on an agarose gel and 200-300bp fragments excised and purified.  The amplified library was 
assayed for quantity and quality with the Agilent Bioanalyzer 2000, and 5nM submitted for 
sequencing.  
 
ChIP and FAIRE libraries were prepared in biological replicates and the raw reads from each 
biological replicate was pooled together and combined unique reads were filtered and used for 
subsequent analyses. HOMER
189
 and MACS algorithms were used to perform peak calling, 
binding peaks were defined as those above the FDR (False Discovery rate) cutoff of 0.001 and 
poisson p-value ~ 2.7
-07
. Transcription factor MACS or HOMER peaks were overlapped to the 
University of California, Santa Cruz (UCSC) genome data browser, using the Feburary 2006 




In the epigenetic analysis, the raw mapped reads (in BED format) for H3K4me3 and 
H3K27me3 were used for peak calling by HOMER
189
. Control samples (genome sequencing 
without antibodies for H3K4me and H3K27me) were used as the background input. Two-fold 
enrichment relative to the background and an FDR of 0.001 were used as the thresholds. For 
the FAIRE experiments, F-Seq
190
 was used for peak identification based on the raw mapped 
reads. The sequencing output of DNA without formaldehyde fixation was used for control. 
The identified peaks from the control sequencing were subtracted from those from the FAIRE 
sequencing. The standard deviation of 6.0 was used for the threshold. The gene-wise 
distribution of the peaks was examined by means of the ‘annotatePeaks’ command of 
HOMER. The closest transcription start site from each peak was identified for gene 
annotation.  For motif finding, the motif lengths of 8, 10, and 12bp were searched against the 
repeat-masked mouse genome (mm8). Position-specific weight matrices were based on the 
HOMER’s database. 
 
2.6.2.  ASSOCIATION OF TRANS CRIPTION FACTOR ENRICHED REGIONS IN GENES  
 
Enriched regions were associated with genes by idenfiying the closest annotated RefSeq gene 
within 10kb. Enriched regions >10 kb from any annotated RefSeq gene were not associated 
with any gene. Enriched regions were associated with only the closest gene. While some 
binding sites may regulate several neighboring genes, this is likely not the general case, and, 
while the approach described would miss such interactions, it eliminates a large number of 
incorrect associations. Sites were considered to be in promoter regions if they fell within 3 kb 
of a RefSeq TSS, within a enhancer if they fell between 2 kb and 50 kb from a RefSeq TSS, 
and distal if they were >50 kb from a RefSeq TSS. To identify overlapping and co-occupied 
sites, locations of sites of maximal enrichment were compared for Pdx1, NeuroD1 and MafA 





2.6.3.  DE NOVO MOTIF ANALYSIS  
 
To identify motifs associated with the ChIP-Seq libraries, a de novo motif discovery strategy 
was employed. ChIP-Seq peaks of Pdx1, NeuroD1 and MafA were input into HOMER, which 
extracted peak sequences with less than 70% repeats and accounted for GC biases by using 
randomly selected background sequences matching GC characteristics of input sequences 
 
2.6.4.  OVERLAPPING OF H ISTONE MARKS WITH TRANSCRIPTION FACTOR 
B INDING S ITES (TFBS) 
 
Transcription-factor binding sites (TFBSs) were defined as the above-identified peaks for 
each TF. The surrounding regions (5kb upstream and downstream) of each TFBS were 
examined for the tag distribution of H3K4me3 and H3K27me3. As for the co-occupancy of 
the TFs, the TFBSs that overlapped within 50bp were merged into a single peak. The numbers 
of H3K4me3 and H3K27me3 tags were counted according to the distance from the center of 
the TFBS and then log10 transformed for modification level. The minimum modification level 
for H3K4me3 and H3K27me3 among the three TFBSs and co-occupied sites was taken and 
used for the basal level. Each modification level was normalized based on the basal level of 
H3K4me3 and H3K27me3 respectively. Associated genes were identified based on the 
location of the TFBS. The expression level of the genes that contain a TFBS with the 
H3K27me3 level increased by 1.5-fold in the dysfunctional cells was compared between the 
























3.1.  INTRODUCTION  
 
The highly specialized function of pancreatic β-cells is dependent upon sustained expression 
of important transcriptional regulators. To expand our knowledge of the β-cell transcriptional 
regulatory network and to explore what other genes are important in pancreatic β-cell 
function, I have chosen to work on Pdx1, NeuroD1 and MafA and their possible co-regulatory 
roles in modulating pancreatic β-cell function. These core transcription factors contribute to 
the hallmark characteristics of pancreatic β-cells by: (1) Activation of target genes that encode 
Insulin and other important β-cell transcriptional regulators, and (2) Recruiting co-activators 
that are necessary to mediate the above-mentioned regulation. In pancreatic β-cells, Pdx1, 
NeuroD1 and MafA have been shown to respectively occupy the A3, E1 and C1 elements 
within a 340-bp region upstream of the transcriptional start site of the Ins gene
191
. The Ins 
promoter is organized in a complex arrangement of discrete cis-acting sequence motifs, which 
serve as binding sites for ubiquitous and β-cell-specific transcription factors192.  The co-
ordinated interaction between these cis-sequence elements and trans-acting transcription 
factors at the promoter contributes to the β-cell-specific expression of the Insulin gene, and 
the exquisitely-controlled regulation of its expression in response to nutrients (e.g. glucose, 




Pdx1, a member of the large family of HD-containing proteins, is expressed in precursors of 
the endocrine and exocrine compartments of the pancreas and is essential for pancreas 
development, β-cell differentiation and maintenance of the mature β-cell85. In mature β-cells, 
Pdx1 transactivates the gene encoding Insulin and other genes involved in glucose sensing and 




 mice are glucose intolerant, with increased islet 
apoptosis, decreased islet mass, and abnormal islet architecture, indicating that proper gene 
dosage of Pdx1 is crucial for normal glucose homeostasis
194
. These findings are consistent 
with the report that humans heterozygous for an inactivating mutation of Pdx1 suffer from 
MODY4
195
. The 283 amino acid long Pdx1 protein is very homologous among different 
species. The N-terminus contains the transactivation domain. The middle region contains a 
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homeodomain, which is responsible for DNA binding and protein-protein interactions as a 




Over-expression and targeted disruption studies have established a crucial role for NeuroD1 in 
regulating brain and pancreatic islet development
197
. NeuroD1 is expressed in pancreatic and 
intestinal endocrine cells and neural tissues and the NeuroD1-null mouse exhibits a mild 
reduction of δ-cells, a moderate loss of α-cells, and a severe reduction of β-cells71. This 
profound effect on β-cell number signiﬁes a critical role for NeuroD1 in addition to Insulin 
gene transactivation in the β-cell, because insulin is not required for the β-cell formation or 
maintenance.  NeuroD1 does not bind directly to DNA but binds as a heterodimer with Class 




The bLZ transcription factor MafA binds to the C1 element of the Insulin promoter in β-
cells
199
. During pancreas development, MafA is first detected at the beginning of the principal 
phase of insulin-producing cell production, comparatively later than Pdx1 and NeuroD, which 
are expressed from the early stage of pancreas development. In addition, while both Pdx1 and 
NeuroD1 are expressed in various cell types in the pancreas, MafA is expressed only in β-
cells. Therefore, it is likely that MafA is the principal factor required for β-cell formation and 
function. MafA
-/-
 mice display glucose intolerance and developed T2DM, with age-dependent 
pancreatic islet abnormalities
69
. Expression of Insulin1, Insulin2, Pdx1, NeuroD1, Glut2 is 
decreased, and glucose-, arginine-, and KCl-stimulated insulin secretion was severely 
impaired in these animals. 
 
An earlier chromatin immunoprecipitation-chip (ChIP-chip) study has shown that Pdx1 and 
NeuroD1 co-occupy 440 genomic loci
86
, suggesting that a significant fraction of Pdx1 and 
NeuroD1 binding sites exist within regulatory modules, where they may control gene 
expression in a synergistic manner. However, it remains unclear whether MafA interacts at 
similar loci to co-regulate genes important for β-cell function, as no genome-wide binding 
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studies have been performed for MafA. It is also unclear what the downstream effectors of 
these transcription factors are, and how they contribute to maintaining the glucose-responsive 
state of β-cells. It is therefore important to elucidate the transcriptional networks regulated by 
Pdx1, NeuroD1 and MafA, where detailed knowledge of these pathways remain key to 
understanding mature β-cell function. 
 
Hypothesis: The molecular mechanisms governing the dynamic and/or co-regulation of 
Pdx1, NeuroD1 and MafA are key determinants of β-cell function.  
 
Questions I will address in this chapter are: 
 
1) Where on the genome do Pdx1, NeuroD1 and MafA bind in β-cells? Is there evidence for 
co-regulation of these transcription factors at other genomic loci, apart from the Insulin gene? 
2) Which genes are affected upon depletion of these transcription factors, and what biological 
network are they significantly involved in regulating? 
3) How does transcription factor occupancy correlate with gene regulation in a genome-wide 
manner?  
  
Currently, there are no suitable human β-cell lines available, as most of the β-cell lines 
derived are difficult to be propagated in vitro, and such lines gradually lose their differentiated 
function over the time in vitro
200
. Among all of the engineered human β-cell lines, only two 
cell lines β-lox5201 and NAKT-15202 continue to possess the normal β-cell characteristics and 
function to at least some degree, and only a few articles have been published using them. It is 
exceedingly difficult to immortalize human β-cells because of their short half-life (50 days). 
Their tendency to undergo apoptosis after islet isolation, combined with the loss of cell-to-
matrix interaction and the stress induced by tissue culturing procedures renders the β-cells to 
become un-differentiated and undergo further apoptosis
203
. Due to the lack of availability of a 
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human β-cell line, despite the differences in the physiological and metabolic regulation of 
rodents and humans, I elected a rodent model for the basis for my experiments, because they 





There are several commonly studied mouse and rat β-cell lines, such as MIN-6 and NIT-1 
(mouse), and INS-1 (rat). Although INS-1 cells are responsive to glucose within the 
physiological range, they require β-mercaptoethanol in the culture medium, which is toxic to 
the cells and irreversibly denatures their proteins
205
. Moreover, the genomic (databases, 
annotations and other scientists experimental data) and molecular biological tools and 
reagents (antibodies, siRNAs, etcetera) available for mouse are more readily available, so I 
elected to use a mouse β-cell line. MIN-6 cells express Glut2 and Gk and respond to glucose 
within the physiological range of glucose in the presence of nicotinamide
206
, but oftentimes a 
sudden loss of GSIS from MIN-6 cells during the course of the passages is noticed, possibly 
due to an outgrowth of cells with a poor response to glucose or a reduced expression of the 
genes responsible for GSIS
207
. NIT-1 cells have high levels of Insulin mRNA with less than 
5% containing glucagon, and none contain PP or Sst
208
. They robustly secrete insulin in 
response to glucose stimulation, though not at physiological levels of glucose. Since the aims 
of my thesis focus mainly on understanding the transcriptional and epigenetic regulatory 
network in pancreatic β-cells and do not include studying the effect of anti-diabetic drugs on 
the cells or involve β-cell transplantation into diabetic animals, I elected to use NIT-1 cells in 
my experiments. 
 
I addressed my experimental questions using ChIP coupled with high-throughput sequencing 
(ChIP-Seq) technologies to map the Pdx1, NeuroD1 and MafA binding sites in a mouse 
insulinoma β-cell line NIT-1, and siRNA-depleted these transcription factors in order to look 




3.2.  RESULTS  
 
3.2.1.  CHIP  OF PDX1,  NEUROD1  AND MAFA  IN NIT-1  CELLS  
 
 
To test my hypothesis that Pdx1, NeuroD1 and MafA were bound at similar and dissimilar 
sites, I performed ChIP with chromatin isolated from the β-cell line NIT-1, with Pdx1, 
NeuroD1 and MafA antibodies, with rabbit and goat IgG antibodies as a control for non-
specific protein-DNA interactions. Input DNA (sheared chromatin not used in any antibody 
pull-down) served as a control to measure genomic background, cell line variation and PCR-
amplification bias. Chromatin was purified and sheared by sonication to obtain DNA 
fragments within a 100-500bp range (Figure 11A). To test the quality of the ChIP for Pdx1, 
NeuroD1 and MafA, I measured the signal obtained on the best characterized co-regulated 
gene, Insulin. Figure 11B shows the specificity of the Pdx1 antibody, as there was a 17-fold 
enrichment for the Insulin promoter using the antibody, versus a 1.2-fold enrichment with the 
non-specific rabbit IgG antiserum. Fold enrichment represents the abundance of enriched 
DNA fragments over a control region not bound by the antibody of interest, and many factors 
can affect it, including binding affinity of antibody, accessibility of target region, quality of 
the antibody-antigen interaction, the concentration of antibody, and the fold enrichment 
depends on both the absolute IP efficiency and on the background
209
. Pdx1 also bound to 
another region on the Insulin gene promoter (27-fold enrichment), and Mtmr7 and Pde43. 
NeuroD1 and MafA were also bound to the same regions as Pdx1 (Figure 11C, D) with 
slightly different binding affinities (50-70 fold enrichment for NeuroD1 for the Insulin gene 
vs. 20-50 fold enrichment for MafA). 
 
As mentioned earlier, a ChIP-chip paper had identified 440 sites in which Pdx1, NeuroD1 and 
MafA were found to co-occupy. I asked whether these sites were similarly occupied in my 
cells, and whether MafA was also occupying those sites. I selected 19 sites positively 
identified to be bound by Pdx1 and NeuroD1 and verified that they were bound in my cells, 
and also interrogated the same sites to see if they were occupied by MafA (Figure 12), with 
Insulin as a positive control. MafA bound to almost all the same sites as Pdx1 and NeuroD1, 
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with a lesser fold enrichment for all of them, save one. This showed support for the hypothesis 
that these three transcription factors work together to co-regulate multiple genes, not just at 
the Insulin promoter. Pdx1, NeuroD1 and MafA all bound strongly to the Il1-R1 gene, which 
is the signal transducing receptor for IL-1 (a principal proinflammatory cytokine), and it has 
been identified in genetic studies to be highly associated with T1DM
210
. 10 of 19 genes are 
unannotated transcripts but they showed strong binding of all three transcription factors. A 
few of them (e.g. M12C1, chr4:5499) were highly conserved across vertebrates, perhaps 
indicative of the presence of enhancers or previously uncharacterized regulatory regions 




(A)   (B) 






   
 
Figure 11. Specific ChIP of Pdx-1, NeuroD1 and MafA anti-serum. (A) NIT-1 chromatin sheared to 
a 100-500bp range of DNA fragments. ChIP from NIT-1 cells was performed using antibodies against 
(B) Pdx1, (C) NeuroD1 and (D) MafA, with rabbit or goat IgG antibodies as a non-specific antibody 
control. Fold enrichment represents the abundance of enriched DNA fragments over a control region 
(Utf1) shown to not be bound by Pdx1 and NeuroD1. Each ChIP experiment was performed with three 
technical replicates for each RT-PCR, and the average of the normalized ratio to the target gene/Utf1 
was calculated and presented. This data is representative of ChIP experiments performed in three 







































































Figure 12. Pdx1, NeuroD1 and MafA binds to sites previously identified as Pdx1 and NeuroD1 
targets
86
. ChIP from NIT-1 cells was performed using antibodies against Pdx1, NeuroD1 and MafA, in 
the same manner as Figure 11. Each ChIP experiment was performed with three technical replicates for 
each RT-PCR, and the average of the normalized ratio to the target gene/Utf1 was calculated and 
presented.  








Figure 13. Regions of the mouse genome identified to be bound by Pdx1, NeuroD1 and MafA are 





3.2.2.  GLOBAL TRANSCRIPTIONAL B INDING LANDSCAPE OF PDX1,  NEUROD1  
AND MAFA 
 
I extended the search for Pdx1, NeuroD1 and MafA target genes to a genome-wide level by 
performing ChIP-Seq on NIT-1 cells with specific antibodies. I performed the ChIPs in 
biological duplicates (i.e. chromatin was harvested from two separate batches of cells and 
ChIPs performed on different days) and validated the quality of the ChIPs in the same fashion 
as Figure 11 before preparing the sample for sequencing. Input DNA was sequenced as a 
control for background noise, and subsequent reads mapped against that. The number of 
mapped reads per 10bp window (genome-wide) of each biological replicate was counted, and 
the correlation between each transcription factor ChIP-Seq library was calculated. Pdx1, 
NeuroD1 and MafA ChIP-Seq biological replicates show 0.99, 0.97 and 0.97 correlation with 
one another respectively (Figure 14).  
 
As the biological replicates were highly correlated with one another, the raw reads from each 
biological replicate were pooled together and these combined reads were used for subsequent 
analyses (Table 2). HOMER was used to perform peak calling, binding peaks were defined as 
those above the FDR (False Discovery rate) cutoff of 0.001 and Poisson p-value ~ 2.7
-07
. 
23132 peak regions were identified to be Pdx1-bound, 31031 peak regions NeuroD1-bound 
and 24108 peak regions MafA-bound. The unique reads were also put through MACS and 
similar numbers of peaks were identified (Pdx1:26153, NeuroD1:34507, MafA:26234). Pdx1, 
NeuroD1 and MafA were shown to bind to one another’s promoters, and the Insulin promoter 
was also bound by all three transcription factors (Figure 15). To validate some of the binding 
sites, 10 peaks with a significant p-value were selected from all the binding sites identified to 
be bound by each of the three transcription factors, and another 10 binding sites were 
randomly selected to be bound by each of the three transcription factors. I designed primers 
against these regions (20 for each transcription factor) and new ChIPs were prepared and 
ChIP-qPCRs were run. The positive enrichments overall (Figure 16) shows that the ChIP-Seq 
libraries generated were generally reliable and had identified bona fide binding sites.  
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Transcription factor MACS peaks were overlapped to the University of California, Santa Cruz 
(UCSC) genome data browser, using the Feburary 2006 (NCBI36/mm8) Mus musculus 
reference assembly. The peaks regions were visualized (Figure 17) and are found to be evenly 
distributed across the genome, with no preference for particular chromosomes. The peaks 
were next annotated based on the genomic region that they overlapped to:  Promoter, intron, 
exon, intergenic, 5'UTR and 3'UTR. The relative enrichments of ChIP regions of Pdx1, 
NeuroD1 and MafA (Figure 18) are displayed in important genomic features, such as 
promoters, immediate downstream of genes, and gene bodies, with respect to the genome 
background. Pdx1 shows very high relative enrichment in promoters, with 15% of ChIP 
regions enriched at the promoter compared to 2.7% of the genome background but very low 
enrichment in bidirectional ones, with only 1.7% of ChIP regions found within 3 kb upstream 
of TSS (Figure 18A). NeuroD1 and MafA had 6.4% and 5.7% of their peaks in the promoters 
(Figure 18B). A different representation of the genome-wide peak annotation is displayed in 
Figure 19, where transcription factor peak calling with the HOMER algorithm was used. A 
similar result was obtained, with 17% of peaks for Pdx1 found in the promoter, compared to 
6% of peaks in NeuroD1 and 6% of peaks in MafA. 
 
The average binding sites of Pdx1, NeuroD1 and MafA were mapped around the promoter 
regions (±6kb from the TSS), and a peak of enrichment was observed around the promoter for 
all the transcription factors, indicating they bound together at the promoter (Figure 20). Pdx1, 
NeuroD1 and MafA peaks were over-lapped with Pdx1, NeuroD1 and MafA peak centers. 
There was enrichment around all the three peak centers, suggesting that they associate 




 Pdx1 NeuroD1 MafA 
Replicate 1 9062661 12537461 27396468 
Replicate 2 12260471 17092581 18295806 
Total 21323132 29630042 27396468 
HOMER 23132 31031 24108 




Total peaks 3’ UTR Promoter TSS Exon Intron Intergenic 5’ UTR 
Pdx1 26153 87 4013 239 533 8598 9561 101 
NeuroD1 34507 137 2009 287 676 13759 14106 57 
MafA 26234 110 1378 228 567 10783 10991 51 
 
Table 2. Mapping and peak calling of Pdx1, NeuroD1 and MafA ChIP-Seq libraries.       
Pdx1, NeuroD1 and MafA ChIP-Seq was performed in NIT-1 cells and the reads were mapped to the 
mm8 genome with ELAND. Using HOMER, there were 23132 Pdx1 peaks, 34507 NeuroD1 peaks and 












Figure 14. Biological replicates of Pdx1, NeuroD1 and MafA ChIP-Seq libraries are highly 
correlated with one another. The number of mapped reads per 10bp window (genome-wide) were 
counted, and the correlation between replicates was calculated. (A) Pdx1, (B) NeuroD1 and (C) MafA 
ChIP-Seq biological replicates show 0.99, 0.97 and 0.97 correlation with one another respectively. 
































Figure 15. Pdx1, NeuroD1 and MafA binding at the Pdx1, NeuroD1, MafA and Ins1 gene. Pdx1, 
NeuroD1 and MafA ChIP-Seq was performed in NIT-1 cells and the binding of all three transcription 
factors at the (A) Pdx1, (B) NeuroD1, (C) MafA and (D) Insulin1 promoter was visualized with the 
Integrated Genomics Viewer (IVG)
211
 software. The input library was included as a control for 















Figure 16. Confirmation of Pdx1, NeuroD1 and MafA ChIP-Seq bound genes by ChIP-qPCR. 
ChIP from NIT-1 cells was performed using antibodies against (A) Pdx1, (B) NeuroD1 and (C) MafA,  
in the same manner as Figure 11. Genes 1-10 have a highly significant p-value and genes 11-20 were 
randomly picked from all the regions identified to be bound by each transcription factor. Each ChIP 
experiment was performed with three technical replicates for each RT-PCR, and the average of the 































































































































































































































































Figure 17. Distribution of ChIP regions of Pdx1, NeuroD1 and MafA over the genome along with 
their scores or peak heights. The line graph illustrates the distribution of (A) Pdx1, (B) NeuroD1 and 
(C) MafA peak heights (or scores). The red bars in the main plot represent ChIP regions. The x-axis of 
the main plot represents the actual chromosome sizes (in base pairs) and the y-axis represents 









Figure 18. Relative enrichments of ChIP regions of Pdx1, NeuroD1 and MafA in important 
genomic features, such as promoters, immediate downstream of genes, and gene bodies, with respect 
to the genome background. The blue bars represent the percentages of the tiled or mappable regions 
that are located in such genomic regions (genome background) and the red bars the percentages of ChIP 
regions. (A) Pdx1 shows very high relative enrichment in promoters (15% of ChIP regions compared to 
2.7 % of the genome background) but very low enrichment in bidirectional ones (only 1.7 % of ChIP 
regions within 3 kb up stream of TSS). (B) NeuroD1 shows 6.1% enrichment in promoters. (C) MafA 





Figure 19. Relative enrichments of ChIP regions of Pdx1, NeuroD1 and MafA in important 
genomic features. ChIP-Seq peaks were uploaded to UCSC mm8 refGene and annotated based on the 
genomic location (promoter, intron, exon, intergenic, 5'UTR and 3'UTR) they overlapped to. 17% of 
peaks in Pdx1 are localized to the promoter in contrast to 6% in NeuroD1 and MafA. (Gireesh Bogu 






Figure 20. Pdx1, NeuroD1 and MafA are enriched around the TSS. Average binding sites of Pdx1 
(blue), Neurod1 (red) and MafA (green) were mapped around the promoters (±6 kb) and a peak for all 
three transcription factors was observed at the promoter, indicating they are bound there. (Gireesh Bogu 










Figure 21. Spatial distribution of the distance (in base pairs) of Pdx1, NeuroD1 and MafA. Pdx1 
peaks, NeuroD1 and MafA peaks are overlapped with (A) Pdx1, (B) NeuroD1 and (C) MafA peak 
centers. The Pdx1, NeuroD1, MafA enrichment around all 3 peak centers suggest they associate with 
strongly with each other. (Gireesh Bogu performed the analysis.) 
 
89 
To identify the DNA binding sequences associated with each transcription factor, a de novo 
motif discovery strategy was employed. ChIP-Seq peaks of Pdx1, NeuroD1 and MafA were 
input into HOMER, which extracted peak sequences with less than 70% repeats and 
accounted for GC biases by using randomly selected background sequences matching GC 
characteristics of input sequences. De novo motifs for Pdx1, NeuroD1 and MafA were thus 
identified (Figure 22). The top motif for Pdx1 had a p value of 1E-523, and the motifs for 
NeuroD1 and MafA were almost identical, with p values of 1E-3395 and 1E-3104 
respectively. The motifs were also checked against the TRANSFEC database to see if they 
matched known motifs. The previously identified Pdx1 motif was among the top three motifs, 
with a p value of 1E-260. The motifs for NeuroD1 and MafA have not been described, and the 
motif for the transcription factor Atoh1 came up on top (p value 1E-3395). Interestingly, the 
motif for the general transcription factor E2A was among the top five motifs for both 
NeuroD1 and MafA, with p values of 1E-554 and 1E-547 respectively. A full list of identified 
motifs is available in Supplementary Table 1. 
 
I next wanted to ask if these transcription factors bound alone or together across the genome. 
To this end, Pdx1, NeuroD1 and MafA ChIP-Seq peaks were resized to ± 65 bp from the peak 
center and overlapped by a single base pair. There were 12780 Pdx1-only peaks, 8828 
NeuroD1-only and 3473 MafA-only peaks (Figure 23A). There were 657 peaks common to 
both Pdx1 and MafA, 2225 to Pdx1 and NeuroD1, and very strikingly, 12508 peaks were 
bound by both MafA and NeuroD1. There were 7470 common peak regions bound by all 
three transcription factors. The same analysis was also performed at the promoters of genes 
(±2kb from transcription start site). Figure 23B shows that the same trend was seen, with a 
larger number of Pdx1 only peaks than NeuroD1 or MafA only (3094 vs 682 and 299 
respectively). There was also the same striking number of peaks co-occupied by both 
NeuroD1 and MafA (798), though the number of peaks co-occupied by Pdx1 and NeuroD1 













Figure 22. DNA binding motifs discovered for Pdx1, NeuroD1 and MafA. Fixed-width peaks from 
(A) Pdx1, (B) NeuroD1 and (C) MafA ChIP-Seq peaks (±50bp from peak center) were input into 
HOMER for de novo motif discovery. The Pdx1 top motif had a p-value 1e
-523
, the top motif of 
NeuroD1 had a p-value 1e
-3395
, and the top motif for Mafa had a p-value of 1e
-3104
. (Gireesh Bogu 









Figure 23. Co-occupancy of Pdx1, NeuroD1 and MafA. Genomic regions bound by Pdx1, NeuroD1 
and MafA either individually or together were identified by resizing peaks to ±65bp from peak center, 
with an overlap by a single base pair. (A) Co-occupancy of Pdx1, NeuroD1 and MafA binding sites 
with all ChIP-Seq peaks, and (B) shows co-occupancy at promoters of genes (±2kb from transcription 
start site). Pdx1 has more independent sites, while there is a big overlap of NeuroD1 and MafA binding 





3.2.3.  PDX1,  NEUROD1  &  MAFA  ARE BOUND TO GENES INVOLVED IN S IMILAR 
B IOLOGICAL PROCESSES  
 
To shed light onto biological relevance of the network of genes bound by Pdx1, NeuroD1 and 
MafA, I uploaded the RefSeq list of nearest bound genes by each transcription factor into 
Ingenuity Pathway Analysis (IPA, Ingenuity® Systems)
187
 and identified the top biological 
networks and pathways associated with the transcription factor binding sites for Pdx1 (Table 
3), NeuroD1  (Table 4) and MafA (Table 5). Each identifier was mapped to its corresponding 
object in the Ingenuity® Knowledge Base and termed network eligible molecules. These were 
then overlaid onto a global molecular network developed from information contained in the 
Ingenuity Knowledge Base, and networks were then algorithmically generated based on their 
connectivity. The functional analysis identified the biological functions and/or diseases that 
were most significantly enriched in the data set.  
 












) (Table 3).  Pdx1 binding sites are also highly enriched in 
cellular regulatory activities, e.g. cell death (p < 2.65
-32





), and it is involved in embryonic (p<9.2
-12
) and organ development 
(p<2.05
-13
), nervous system development and function (p<1.45
-12
). A full list of genes 
involved in those pathways is listed in Supplementary Table 2A. 
 
NeuroD1-bound genes are associated with lipid and amino acid metabolism, endocrine system 
development and function, and general cellular functions (Table 4). Disease networks 





), gastrointestinal disease (p<3.5
-64
), and metabolic disease (p<7.06
-56
). Like 
Pdx1, NeuroD1-bound genes appear to be involved in general cellular regulatory activities, 
e.g. cell death (p<5.32
-31
), cellular growth and proliferation (p<1.45
-26
) and cellular 
development (p<5.17
-16





), nervous system and development (p<9.08
-16
) and tissue development 
(p<4.01
-15
). A full list of genes involved in those pathways is listed in Supplementary Table 
2B. 
 
Genes bound by MafA are associated with infectious diseases, lipid metabolism, and general 
cellular processes and maintenance (Table 5). MafA disease-related networks are similar to 
that of Pdx1 and NeuroD1, comprising of genetic disorders (p<2.22
-107
), neurological diseases 
(p<7.43
-83
), gastrointestinal disease (p<8.19
-67
), and metabolic disease (p<4.96
-62
). Similarly, 
MafA-bound genes also appeared to be involved in general cellular regulatory activities, e.g. 
cell death (p<4.18
-33
), cellular growth and proliferation (p<2.47
-25
) and cellular development 
(p<7.43
-21
).  Genes bound by MafA also are linked to in organ development (p<5.63
-19
), 
nervous system and development (p<4.39
-17
) and organismal survival (p<4.51
-16
). A full list of 
genes involved in those pathways is listed in Supplementary Table 2C. 
 
The similarities in the biological networks and pathways identified suggests that Pdx1, 
NeuroD1 and MafA share common regulatory roles in maintaining the β-cell phenotype, by 




Associated Network Functions Network Score 
 Gene Expression, Cellular Assembly and Organization, Cellular 
Compromise 
20 
 RNA Post-Transcriptional Modification, Protein Synthesis, Cellular 
Assembly and Organization 
20 
 Dermatological Diseases and Conditions, Genetic Disorder, Hair and 
Skin Development and Function 
20 
  RNA Post-Transcriptional Modification, Gene Expression, Protein 
Synthesis  
20 
 Developmental Disorder, Genetic Disorder, Neurological Disease 20 
 
   Diseases and Disorders p-value # Molecules 
Genetic Disorder 4.04E-75 4095 
Neurological Disease 1.85E-57 2466 
Metabolic Disease  6.39E-46 1766 
Gastrointestinal Disease 2.39E-43 2450 
Endocrine System Disorders 1.75E-39 1559 
   Molecular and Cellular Functions p-value # Molecules 
Cell Death 2.65E-32 1812 
Gene Expression 5.76E-30 1313 
Cell Cycle 4.31E-29 897 
Cellular Growth and Proliferation  2.65E-20 1826 
Cellular Development 9.39E-18 1576 
   Physiological System Development and Function p-value # Molecules 
Organismal Survival 1.17E-16 596 
Organismal Development 3.80E-15 746 
Organ Development 2.05E-13 617 
Nervous System Development and Function 1.45E-12 1028 
Embryonic Development 9.20E-12 473 
 
Table 3. Top biological networks and pathways associated with Pdx1 target genes.   
Pdx1 ChIP-Seq peaks were identified with MACS and IPA was used to generate this list of networks 
associated with its biological, molecular and cellular function, physiological system development and 
function. The score is a numerical value used to rank networks according to their degree of relevance to 




Associated Network Functions  Network Score 
 Lipid Metabolism, Small Molecule Biochemistry, Vitamin and Mineral 
Metabolism 
20 
 Amino Acid Metabolism, Post-Translational Modification, Small 
Molecule Biochemistry 
20 
 Endocrine System Development and Function, Tissue Morphology, 
Cellular Growth and Proliferation 
20 
 Cellular Assembly and Organization, Cell Cycle, DNA Replication, 
Recombination, and Repair 
20 




   Diseases and Disorders p-value # Molecules 
Genetic Disorder 3.87E-104 4267 
Neurological Disease 2.81E-77 2580 
Gastrointestinal Disease 3.50E-64 2455 
Cardiovascular Disease 1.59E-60 1656 
Metabolic Disease 7.06E-56 1842 
   Molecular and Cellular Functions p-value # Molecules 
Cell Death 5.32E-31 1845 
Cellular Growth and Proliferation 1.45E-26 1901 
Gene Expression 8.58E-26 1264 
Cell Cycle 1.16E-18 866 
Cellular Development 5.17E-16 1638 
   Physiological System Development and Function p-value # Molecules 
Organ Development 1.66E-16 653 
Nervous System Development and Function 9.08E-16 1116 
Tissue Development 4.02E-15 1025 
Organismal Development 1.95E-14 969 
Organismal Survival 7.18E-14 594 
 
Table 4. Top biological networks and pathways associated with NeuroD1 target genes. 
NeuroD1 ChIP-Seq peaks were identified with MACS and IPA was used to generate this list of 
networks associated with its biological, molecular and cellular function, physiological system 
development and function. The score is a numerical value used to rank networks according to their 




Associated Network Function Network Score  
Infection Mechanism, Infectious Disease, Antigen Presentation 22  
RNA Post-Transcriptional Modification, Skeletal and Muscular System 
Development and Function, Tissue Development 
22  
Cell-To-Cell Signaling and Interaction, Cellular Assembly and 
Organization, Cellular Function and Maintenance 
22  
Lipid Metabolism, Small Molecule Biochemistry, Cellular Development 22  
Cell Morphology, Cellular Function and Maintenance, DNA 




Diseases and Disorders p-value # Molecules 
Genetic Disorder 2.22E-107 3841 
Neurological Disease 7.43E-83 2350 
Gastrointestinal Disease 8.19E-67 2224 
Cardiovascular Disease 2.24E-65 1522 
Metabolic Disease 4.96E-62 1689 
 
  
Molecular and Cellular Functions p-value # Molecules 
Cell Death 4.18E-33 1662 
Cellular Growth and Proliferation 2.47E-25 1727 
Gene Expression 2.12E-24 1129 
Cell Cycle 5.60E-21 792 
Cellular Development 7.43E-21 1498 
 
  
Physiological System Development and Function p-value # Molecules 
Tissue Development 2.17E-20 900 
Organ Development 5.63E-19 615 
Organismal Development 2.30E-18 806 
Nervous System Development and Function 4.39E-17 1035 
Organismal Survival 4.51E-16 549 
 
Table 5. Top biological networks and pathways associated with MafA target genes. 
MafA ChIP-Seq peaks were identified with MACS and IPA was used to generate this list of networks 
associated with its biological, molecular and cellular function, physiological system development and 
function. The score is a numerical value used to rank networks according to their degree of relevance to 




3.2.4.  PDX1,  NEUROD1  AND MAFA  REGULATE A COMMON SET OF GENES  
 
I hypothesized that, as these transcription factors had commonalities in the function of the 
genes they bound to, similarities would also exist in the genes regulated by them. To test this 
hypothesis, RNA interference (RNAi) was performed for Pdx1, NeuroD1 and MafA in 
biological quadruplicate to identify genes regulated upon each transcription factor 
knockdown. After 48 hours of RNAi, the expression of Pdx1, NeuroD1 and MafA was 
decreased to 30%, 25%, and 5% respectively (Figure 24A). Corresponding decreases in the 
protein levels were also observed (Figure 24B).  
 
In order to assess global gene expression changes in the RNAi samples, Illumina bead chip 
arrays were used. In response to the depletion of endogenous Pdx1, 570 genes were 
significantly regulated, of which 403 were up- and 167 down-regulated (±1.5 fold, p<0.05). In 
response to the depletion of NeuroD1, 1550 genes were significantly regulated, of which 946 
were up- and 604 down-regulated (±1.5 fold, p<0.05). When MafA protein levels were 
reduced, 552 genes were significantly regulated, of which 341 were up- and 212 down-
regulated (±1.5 fold, p<0.05). A complete list of genes in each of the microarray datasets is 
available in Supplementary Table 3.  
 
To look at how Pdx1, NeuroD1 and MafA genes were co-regulated, genes that changed upon 
each transcription factor knockdown were overlapped (Figure 25) and compared. Strikingly, 
834 genes were regulated by NeuroD1 only, in comparison to the 175 and 151 regulated by 
Pdx1 and MafA respectively. There was also a lesser number of genes found to be regulated 
by both Pdx1 and MafA (39), when compared to Pdx1 and NeuroD1 (84) and MafA and 
NeuroD1 (86).  
 
The comparatively large number of NeuroD1-only genes suggested that NeuroD1 had more 
indirect targets, which led me to ask whether the target genes of NeuroD1 consisted of more 
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transcription factors, when compared to Pdx1 and MafA regulated genes. To address this, the 
genes identified to be regulated by Pdx1, NeuroD1 and MafA in the RNAi-depleted genes 
were overlapped with a list of 1700 known transcription factors (courtesy of Dr Shaym 
Pyrakar, Genome Institute of Singapore). 12.5% of NeuroD1 target genes were identified as 
transcription factors, compared to 8.5% in Pdx1 and MafA target genes (Table 6).   
 
To gain insight into the biological processes regulated by Pdx1, NeuroD1 and MafA, the list 
of genes identified in the microarrays was uploaded into the PANTHER database
212
. In this 
analysis, the genes were clustered into functional themes and compared to the Mus musculus 
reference list to look for statistically over (+) and under (-) represented pathways.  Out of all 
the pathways enriched, there were three broad categories: metabolic processes, developmental 
processes and cellular processes. Supplementary Table 4 provides the full lists of genes that 
are involved in each pathway. These annonations suggest that Pdx1, NeuroD1 and MafA 
interact in a similar fashion to co-regulate pathways involved in metabolic processes (e.g. 
protein metabolism, nucleoside metabolism, lipid metabolism), developmental processes (e.g. 
response to pheromones, system development), and cellular processes (e.g. signal 








   
 
Figure 24. siRNA depletion of endogenous Pdx1, NeuroD1 and MafA mRNA and protein levels. 
(A) Pdx1, NeuroD1 and MafA levels were depleted by RNA interference using siRNA against each 
transcription factor in NIT-1 cells. RNA was harvested between 24hrs and 48hrs post-transfection and 
transcript levels assayed by RT-PCR. Mean values ± S.E. are plotted as percentages relative to the non-
targeting control (NTC) (100%).  The siRNA experiments were performed in quadruplicate and 
normalized to endogenous β-actin. (B) Corresponding decrease in protein levels following Pdx1, 








































Figure 25. Significant overlap of Pdx1, NeuroD1 and MafA regulated genes. Pdx1, NeuroD1 and 
MafA RNAi genes regulated ±1.5 fold show statistically significant overlap. NeuroD1-only regulated 












Table 6. NeuroD1 targets more transcription factors than Pdx1 and MafA.  
The genes identified to be regulated by Pdx1, NeuroD1 and MafA in the RNAi-depleted genes were 
overlapped with a list containing 1700 known transcription factors (Dr Shaym Pyrakar). 12.5% of 















































































































































































































































































































































































3.2.5.  COMBINATORIAL REGULATION OF PDX1,  NEUROD1  AND MAFA 
 
As the binding sites of the three transcription factors and their downstream target genes could 
be categorized into similar regulatory networks, and Pdx1, NeuroD1 and MafA are found to 
synergistically bind to and regulate the Insulin promoter
124
, I hypothesized that these three 
transcriptional factors would combinatorially regulate other genes in the genome. As shown in 
Figure 23, Pdx1 and MafA had 657 peaks common only to them, Pdx1 and NeuroD1 had 
2225 common only to them, and strikingly, there were 12508 peaks commonly bound by only 
NeuroD1 and MafA. There were 7470 peaks with all three transcription factors bound. Again, 
this suggests NeuroD1 and MafA have very similar binding patterns, as evidenced by their 
similarities in their identified motifs (Figure 22). 
 
To look at genes that were dually or triply regulated by the transcription factors, I performed 
RNAi of combinations of transcription factors, i.e. Pdx1 and NeuroD1, Pdx1 and MafA, 
NeuroD1 and MafA, and Pdx1 NeuroD1 and MafA in biological quadruplicates. After 48 
hours of RNAi, the expression of Pdx1 and NeuroD1 decreased to 30 and 43% respectively, 
the expression of Pdx1 and MafA decreased to 40% and 20% respectively, and NeuroD1 and 
MafA levels decreased to 40% and 15% respectively (Figure 26). The knockdown efficiency 
was reduced in the triple transfection efficiency despite optimization (data not shown), with 
Pdx1, NeuroD1 and MafA mRNA levels remaining at 40-55% after 48 hours of RNAi. In 
order to assess global gene expression changes in the RNAi samples, Illumina bead chip 
arrays were used. In response to the depletion of endogenous Pdx1 and NeuroD1, 1167 genes 
were significantly regulated ±1.5 fold, p<0.05. In response to the depletion of Pdx1 and MafA, 
2339 genes were significantly regulated ±1.5 fold, p<0.05. When NeuroD1 and MafA mRNA 
levels were reduced, 1424 genes were significantly regulated ±1.5 fold, p<0.05. A complete 




To look at how Pdx1, NeuroD1 and MafA genes were co-regulated, genes that were changing 
upon each combination of transcription factor knockdown were overlapped (Figure 27) and 
compared. Strikingly, 1427 genes were regulated by the Pdx1-MafA only combination, in 
comparison to the 242 genes and 499 genes regulated by the Pdx1-NeuroD1 and NeuroD1-










Figure 26. siRNA depletion of endogenous Pdx1, NeuroD1 and MafA mRNA in combination with 
one another. (A) Pdx1, NeuroD1 and MafA levels were depleted by RNA interference using siRNA 
against eqimolar concentrations of Pdx1 and NeuroD1 siRNA, Pdx1 and MafA siRNA, and NeuroD1 
and MafA siRNA in NIT-1 cells. RNA was harvested 48hrs post-transfection and transcript levels 
assayed by RT-PCR. Mean values ± S.E. are plotted as percentages relative to NTC (100%).  The 
siRNA experiments were performed in quadruplicate and normalized to endogenous β-actin. (B) Pdx1, 
NeuroD1 and MafA were simultaneously depleted in equimolar concentrations by RNA interference. 
RNA was harvested 24 and 48hrs post-transfection and transcript levels assayed by RT-PCR. Mean 
values ± S.E. are plotted as percentages relative to NTC (100%).  The siRNA experiments were 








































































Figure 27. Overlap of Pdx1-MafA, Pdx1-NeuroD1 and NeuroD1-MafA regulated genes. Pdx1, 
NeuroD1 and MafA RNAi genes regulated ±1.5 fold show significant overlap. (Gireesh Bogu 






For ease of explanation in this manuscript, I use the term “regulated” for genes that changed 
expression (up- or down-regulated) in response to a transcription factor knockdown, while 
genes that show the binding of a transcription factor are termed as “bound”. To explore how 
combinatorial transcription factor binding correlated with changes in gene expression upon 
combinatorial transcription factor knockdown, the number of regulated genes (i.e. genes that 
change in response to single or double or triple knockdown of the transcription factors) were 
overlapped with genes that show transcription factor binding (i.e. the gene may be bound by 
one, two or all three transcription factors).  
 
To achieve that, transcription factor ChIP-Seq peaks were resized to 65bp from peak center 
and peaks that were within ±2kb distance from a TSS were selected for this analysis.  Genes 
with a Pdx1 binding site (00P) show the most change in expression in the single transcription 
factor knockdown experiments, be it Pdx1-depleted cells or NeuroD1-depleted cells or MafA-
depleted cells (Figure 28A). There are also more genes going up upon each transcription 
factor knockdown, regardless of the transcription factor that is depleted. This suggests that in 
general, the three transcription factors are acting as repressors, rather than activators. A 
similar trend is seen with genes that have a NeuroD1 binding site (00N), but the number of 
genes changing expression in this group is less than those with a Pdx1 binding site. When 
there are NeuroD1 and MafA binding sites present (0MN), there are more genes changing in 
the NeuroD1-knockdown experiment. The presence of MafA alone (00M) appears to affect 
the regulation of genes to a smaller extent.   
 
The same gene sets showing combinations of transcription factor binding sites as in Figure 
28A were overlapped with genes found to be regulated by the double transcription factor 
knockdowns (Figure 28B). Similar to what was seen in Figure 28A, there are the most number 
of genes changing in all the double transcription factor knockdown experiments, be it Pdx1-
NeuroD1-depletion or Pdx1-MafA-depletion or NeuroD1-MafA-depletion, as long as there is 
a Pdx1-binding site present (00P). Again, there are more genes are up-regulated instead of 
 
108 
down-regulated. There are also more number of genes changing in the double transcription 
factor knockdown that have a Pdx1 binding site (100 - 250) as compared to 50 – 170 in the 
single transcription factor knockdown. Genes with both NeuroD1 and MafA binding sites 
(0MN) and those with just NeuroD1 binding sites (00N) also showed an increase in the 
number of genes that they were regulating (50-100), when compared to 0MN and 00N in the 
single transcription factor knockdown (10-50 genes). The similarties in behavior of 00N and 
0MN could be partly due to the similarities in the binding sites of NeuroD1 and MafA, as 
previously identified (Figure 22). 
 
When genes bound by transcription factor binding sites were overlapped with genes regulated 
by the triple transcription factor knockdown (Figure 28C), genes with a Pdx1 binding site 
(00P) showed the most number of genes changing, as observed previously. The number of 
genes that changed were fewer than that observed in the double knockdown (130 up- and 
down-regulated, compared to 100 – 250 up- and down-regulated), perhaps due to the lesser 
degree of efficiency in the knockdown levels of Pdx1, NeuroD1 and MafA in the triple 
knockdown experiment (Figure 28B).   
 
Taken together, Figure 28 shows that genes containing Pdx1 binding sites in their promoters 
display maximal differential expression in the single, double or triple knockdown 
experiments. There are also more genes going up upon each transcription factor knockdown, 
regardless of the transcription factor that is depleted, suggesting that these transcription 
factors act more as repressors than activators. 
 
To tease apart the relationship between genes that are bound and regulated by the transcription 
factor combinations, the fraction of bound genes [termed B, i.e. genes that show transcription 
factor binding in the gene promoter (± 2kb from TSS)] that are regulated [i.e. genes that are 
bound by a transcription factor and show differential expression upon transcription factor 
knockdown (termed BR)] was expressed as a percentage (i.e. BR*100/B), and plotted as a 
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heatmap (Figure 29). This was to gain insight into the genes that are most responsive to 
transcription factor binding. The x-axis indicates the number of genes regulated, as identified 
in the microarray data from siRNA-depleted transcription factors. The y-axis indicates 
transcription factor binding sites (TFBS) in various combinations. The colors indicate 
percentage of genes that are bound and regulated (BR), as a fraction of the total number of 
bound genes (BR/B), with red being the most (10%), yellow being in the middle (6-8%) and 
blue being the least (<4%). There were three distinct clusters of genes: the Pdx1-MafA, Pdx1-
NeuroD1, and NeuroD1-MafA cluster (red), the NeuroD1 and Pdx1-NeuroD1-MafA 
regulated gene cluster (yellow), and the Pdx1 and MafA alone regulated gene cluster (blue). 
Genes that are triply and doubly bound have the highest percentage of genes that are regulated 
by the double transcription factor knockdown (red cluster), while a lesser percentage of genes 
are regulated by NeuroD1 or all three transcription factors (yellow cluster). The Pdx1 and 
MafA single transcription factor knockdowns have the lowest percentage of BR genes (blue 
cluster). This indicates that the triply bound genes have the highest effect on regulated genes, 
compared to the doubly and singly bound genes. 
 
The highest percentage of genes regulated is those in the double knockdown, irrespective of 
whether the gene is bound by single, double or all three transcription factors. The fact that the 
doubly and triply bound genes show a high BR/B value is not merely an artifact of the lesser 
number of doubly and triply bound genes (i.e. lesser number of genes in the denominator (B) 
would inflate the value of BR/B). If that were the case, only the triply bound genes would 
show the highest percentage of BR/B, because the number of genes triply bound is the fewest 
of all the bound combinations of genes. However, the data shows that a high percentage of BR 
is also observed in double knockdown genes that are doubly and singly bound.  
 
Of the single transcription factor regulated genes, NeuroD1-regulated genes had a higher 
percentage of bound genes (6-8%) compared to Pdx1 and MafA (<4%). This could be due to 
the fact that 12.5% of NeuroD1-regulated genes were transcription factors (Table 6), as 
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compared to 8.5% of Pdx1 and MafA target genes. This higher proportion of transcription 
factors in NeuroD1-regulated genes suggests that NeuroD1 mediates downstream gene 
expression changes via other transcription factors.  The effect of the genes regulated by the 
triple knockdown was less than those regulated by the double knockdown (Figure 29). This is 
perhaps due to the lesser degree of efficiency in the knockdown levels of Pdx1, NeuroD1 and 
MafA in the triple knockdown experiment. 
 
Taken together, this figure shows that triply bound genes have the most effect on gene 
regulation, followed by genes that are doubly bound by transcription factors. Genes bound by 











Figure 28. Genes containing Pdx1 binding sites have the most effect on regulated genes. 
Transcription factor peaks at the nearest gene promoter (±2kb from TSS) were resized to 65bp peaks 
(±65 bp from peak center) and overlapped with genes identified to be regulated in single (A), double 
(B) and triple (C) transcription factor knockdowns. 00P: Pdx1 binding sites, 00M: MafA binding sites, 
00N: NeuroD1 binding sites; 0PM: Pdx1 and MafA binding sites, 0PN: Pdx1 and NeuroD1 binding 
sites, 0MN: MafA and NeuroD1 binding sites; PMN: Pdx1, MafA and NeuroD1 binding sites. y axis = 
number of genes regulated, as identified in the microarray of siRNA-depleted transcription factor, x 
axis = transcription factor binding sites. Genes containing Pdx1 binding sites in their promoters display 
maximal differential expression in the single, double or triple knockdown experiments. There are also 
more genes going up upon each transcription factor knockdown, regardless of the transcription factor 
that is depleted, suggesting that these transcription factors act more as repressors than activators. 






Figure 29. Triply bound genes have the highest effect on regulated genes, compared to the doubly 
and singly bound genes. The fraction of bound genes [termed B, i.e. genes that show transcription 
factor binding in the gene promoter (± 2kb from TSS)] that are regulated [i.e. genes that are bound by a 
transcription factor and show differential expression upon transcription factor knockdown (termed BR)] 
was expressed as a percentage (i.e. BR*100/B), and plotted as a heatmap. The x-axis indicates the 
number of genes regulated, as identified in the microarray of siRNA-depleted transcription factor. The 
y-axis indicates transcription factor binding sites in various combinations. The colors indicate 
percentage of genes that are bound and regulated (BR), as a fraction of the total number of bound genes 
(BR/B), with red being the most (10%), yellow being in the middle (6-8%) and blue being the least 
(<4%). Triply bound genes have the most effect on gene regulation, followed by genes that are doubly 
bound by transcription factors. Genes bound by a single transcription factor have a fewer percentage of 






3.3.  DISCUSSION  
 
3.3.1.  THE PDX1,  NEUROD1  AND MAFA  GENOMIC B INDING LANDS CAPE   
 
Pdx1 and NeuroD1 co-occupy 440 genomic loci
86
, suggesting that a significant fraction of 
Pdx-1 and NeuroD1 binding sites exist within regulatory modules, where they may control 
gene expression in a synergistic manner. However, it was unknown whether MafA interacts at 
similar loci to co-regulate genes important for β-cell function, as no genome-wide binding 
studies have been performed for MafA. Besides, the Pdx1 and NeuroD1 experiments were 
carried out on custom-made promoter arrays which contained promoter elements, enhancers 
and highly conserved regions, genomic elements that represent miRNAs, and putative 
regulatory elements identified through serial analysis of chromatin occupancy (SACO). 
Therefore, there is bias in the data due to the pre-selection of putative binding sites, repeat 
masking of the arrays, and less sensitivity due to a lack in base-pair resolution of binding sites. 
With new generation ChIP-Seq technology, these shortcomings are overcome as sensitivity 
and statistical certainty can be adjusted to detect rare DNA-protein interaction sites. The 
accuracy is also not limited by the spacing of pre-determined probes, and binding affinities of 
a protein to different regions of DNA can be compared
213
.  As such, to address my hypothesis 
that Pdx1, NeuroD1 and MafA were bound at similar and dissimilar sites across the genome, I 
performed ChIP-Seq with chromatin isolated from the β-cell line NIT-1, with Pdx1, NeuroD1 
and MafA antibodies.   
 
23132 peak regions were identified to be Pdx1-bound, 31031 peak regions NeuroD1-bound 
and 24108 peak regions MafA-bound (Table 2). Pdx1 shows very high relative enrichment in 
promoters, with 17.3% of ChIP regions enriched at the promoter compared 6.4% in NeuroD1 
and 5.7% in MafA (Figure 19). MafA regulates the Pdx1 promoter in β-cells122, and it was not 
previously known if other co-regulatory process occur. I have shown that Pdx1, NeuroD1 and 
MafA bound to one another’s promoters, along with the Insulin promoter (Figure 15). The 
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Pdx1, NeuroD1 and MafA peaks are enriched around all three peak centers, suggesting they 
associated strongly with one another (Figure 21).   
 
The transcription factor motifs found to be enriched by HOMER (Figure 22) demonstrated 
that the ChIPs were robust and of good quality. HOMER is a de novo motif discovery 
algorithm that scores motifs by looking for motifs with differential enrichment between two 
sets of sequences, the first being the target sequences of interest (i.e. the ChIP-Seq dataset) 
and the second being a set of background sequences (i.e. whole genome background) 
189
.  De 
novo motif discovery is a more unbiased method of motif discovery than known motif 
scanning, which involves finding all the known motifs in a sequence. The distinction between 
our de novo motif discovery and traditional de novo motif discovery is that in the former, all 
the ChIP-Seq peaks are input into HOMER, and in the latter, the top several hundred ChIP-
Seq peaks with highest p values are used. Therefore, our method of de novo motif discovery is 
a more stringent and robust method of identifying motifs enriched in the dataset. Enrichment 
values reported by HOMER should be extremely significant, << 1
e-50
, and the p values of 
these motifs I identified were far more significant.  
 
The known Pdx1 motif was identified in my Pdx1 ChIP-Seq dataset, with a p value of 1e
-260
. 





 respectively. It is noteworthy that they had such similarities, probably due to 
the large overlaps in the number of binding sites (Figure 23). Interestingly, the motif for the 
transcription factor Atoh1 came up on top (p value 1e
-3395
). Like NeuroD1, Atoh1 is a bHLH 
transcription factor that activates E-box dependent transcription. Apart from its role in 
endodermal development and pancreatic function, Neurod1 is also crucial for mediating the 
differentiation of cerebellar granule cells downstream of Atoh1-mediated proliferation of the 
precursors
214
 and has recently been shown to be a direct target of Atoh1 in the developing 
brain
215
. Another motif that was highly enriched in the NeuroD1 and MafA ChIP-Seq datasets 




 respectively.  The E2A gene encodes transcription 
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factors of the bHLH family which are implicated in cell-specific transcriptional control in 
several cell lineages. The second domain (located between amino acids 369 and 485) 
functions preferentially in pancreatic β-cell lines, showing a pattern of heptad repeats of 
leucine residues characteristic of bLZ transcription factors
216
. Therefore, the selective 
properties of this activation domain may contribute to cell-specific transcription directed by 
the E2A gene. NeuroD1 itself is unable to bind DNA and functions in a
 
complex with the 




, and the presence of 
a tissue-enriched and a ubiquitously
 
distributed bHLH factor in the activator complex is 
characteristic
 
of other tissue-specific members of this family, the best characterized
 
of which 
are involved in myogenic
218
 and neuronal differentiation
219
. These activators bind to the 
consensus
 
sequence CANNTG (E-box), with hetero-dimerization increasing
 
DNA binding and 
activation capacity. NeuroD1-directed transcription of Insulin has been shown to occur via the 
E-box within the Insulin promoter
97,107
. Taken together, these results confirm that majority of 
the binding sequences are relevant for Pdx1, NeuroD1 and MafA. 
 
3.3.2.  PDX1,  NEUROD1  AND MAFA  REGULATE B IOLOGICALLY S IMILAR 
NETWORKS  
 
There were many more Pdx1-only peaks (12780) when compared to NeuroD1 and MafA 
(8828 and 3743) (Figure 23). Strikingly, 12508 peaks were bound by both MafA and 
NeuroD1, compared to 657 peaks common to both Pdx1 and MafA and 2225 to Pdx1 and 
NeuroD1. This suggests that Pdx1 is acting more independently, with MafA and NeuroD1 
having very similar and possibly redundant roles. A more independent role of Pdx1 would 
also concur with the fact that 17% of Pdx1 peaks were found in promoter regions, compared 
to NeuroD1 and MafA.  When Pdx1, NeuroD1 and MafA were depleted, most genes were 
changing upon NeuroD1 depletion (1550), in comparison to Pdx1 (570) and MafA (522). To 
look at how Pdx1, NeuroD1 and MafA genes were co-regulated, genes that were changing 
upon each transcription factor knockdown were overlapped and compared (Figure 25). In line 
with the fact that depletion of NeuroD1 had more effect on target genes, 834 genes were 
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regulated by NeuroD1 only, in comparison to the 175 and 151 regulated by Pdx1 and MafA 
respectively. This suggests that NeuroD1 is acting in an indirect manner. In all three cases, 
there was a greater number of genes being up-regulated upon knock-down, indicating that 
these transcription factors had a generally more repressive role on their target genes, rather 
than activating. 
 
To shed biological insight into the network of genes bound and regulated by Pdx1, NeuroD1 
and MafA, the ChIP-Seq peaks and siRNA-microarray genes were uploaded into IPA and 
PANTHER. Genes targeted by Pdx1, NeuroD1 and MafA were over-represented in highly 
significant pathways including those involved in metabolic processes (e.g. protein 
metabolism, nucleoside metabolism, lipid metabolism), developmental processes (e.g. 
response to pheromones, organ and nervous system development), and cellular processes (e.g. 
signal transduction, vesicle-mediated transport, cell cycle, cell death, cellular growth and 
proliferation) (Tables 3-5). These annonations suggest that Pdx1, NeuroD1 and MafA all 
interact in a similar fashion to common regulatory roles in maintaining the β-cell phenotype, 
by means of regulating metabolic activities, organ development and cell cycle activities. 
 
3.3.3.  COMBINATORIAL B INDING OF PDX1,  NEUROD1  AND MAFA   
 
As the binding sites of Pdx1, NeuroD1 and MafA and the genes they regulated categorized 
into similar regulatory networks, and these three transcription factors synergistically bind to 
and regulate the Insulin promoter
124
, I hypothesized that these three transcriptional factors 
would combinatorially regulate other genes in the genome. To explore how combinatorial 
transcription factor binding correlated with changes in gene expression upon combinatorial 
transcription factor knockdown, the number of regulated genes that had any combination of a 
transcription factor was overlapped with the genes identified to be changing upon each 
combination of transcription factor knockdown. Genes containing Pdx1 binding sites in their 
promoters display maximal differential expression in the single, double or triple knockdown 
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experiments (Figure 28). There are also more genes going up upon each transcription factor 
knockdown, regardless of the transcription factor that is depleted, suggesting that these 
transcription factors act more as repressors than activators. The highest percentage of genes 
regulated is those in the double knockdown, irrespective of whether the gene is bound by 
single, double or all three transcription factors (Figure 29). Of the single transcription factor 
regulated genes, NeuroD1-regulated genes had a higher percentage of bound genes (6-8%) 
compared to Pdx1 and MafA (<4%). This could be due to the fact that 12.5% of NeuroD1-
regulated genes were transcription factors (Table 6), as compared to 8.5% of Pdx1 and MafA 
target genes. This higher proportion of transcription factors in NeuroD1 regulated genes 
suggests that NeuroD1 mediates downstream gene expression changes via other transcription 
factors.  Taken together, these figures show that while Pdx1 on its own had the most effect on 
gene regulation, triply and doubly bound genes have more effect on gene regulation.   
 
3.4.  SUMMARY  
 
There is increasing evidence that transcription factors act synergistically to achieve normal 
pancreatic development and function. Rapid progress has been made to elucidate regulatory 
mechanisms controlled by key β-cell genes. In this chapter, I have looked at the transcription 
network regulated by Pdx1, NeuroD1 and MafA. I have shown that they are involved in 
regulating metabolic processes, developmental processes and cellular processes. Of the three 
transcription factors, Pdx1 appears to be the dominant one, while NeuroD1 has more of an 
indirect role in regulating β-cell genes. When the three transcription factors are bound at the 
same gene, there is most effect on gene regulation. Improving our knowledge of these 
important transcription factors, establishing their hierarchy, identifying and characterizing 
novel transcription factors, and ultimately regulating their expression to ensure glucose 
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4.1.  INTRODUCTION  
 
Transcription factors play an important role in pancreatic β-cell development and function. 
This is manifested clinically by the MODY syndromes, in which heterozygous mutations in 
HNF4α, HNF1α, PDX1, HNF1β and NEUROD1 cause progressive impairments in insulin 
secretion and the eventual development of diabetes mellitus
90
. To understand how β-cell 
transcription factors might regulate β-cell function, it is often useful to think of these factors 
as forming a network that ultimately activates a set of unique β-cell genes (e.g. Ins, Glut2, 
Iapp or Gck). The main function of the mature β-cell is to respond appropriately with the 
secretion of insulin, to the fluctuating levels of blood glucose. This is mediated and controlled 
by many factors, of which Pdx1, NeuroD1 and MafA are a few. 
 
Pdx1 mediates the adaptive responsiveness of β-cells to changes in extra-cellular glucose 





, and through the activation of glucose responsive enhancers within the 
Insulin promoter, in conjunction with other transcriptional functions. It also controls the 




, and also functions downstream of the insulin signaling 
pathway in the regulation of β-cell mass85. However, the number of target genes is certainly 
much greater, as Pdx1
-/-
 mice display pleiotropic phenotypes
95
. NeuroD1 is implicated in the 





 and Sur1, which forms potassium channels with Kir6.2
111
. The mis-
expression of NeuroD1 in a human fetal epithelial cell line induced the expression of several 
genes required for vesicular trafficking and exocytosis, including Sec24D, Snap25, Stx1 and 
Munc18
114
. This finding suggests that NeuroD1 may regulate insulin exocytosis in pancreatic 
β-cells by directly inducing the expression of genes involved in exocytosis. In contrast to 
Pdx1 and NeuroD1, β-cell development does not appear to be affected in MafA deficient 
mice, although adult mutant animals are glucose intolerant due to diminished Insulin 
transcription and impaired GSIS, decreased β-cell number and altered islet architecture43. 
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MafA appears to also play a role in mediating the expression of grauphilin, adiponectin, 
Glut2, Nkx6.1, Pdx1
122




As Pdx1, NeuroD1 and MafA have been shown to co-regulate many genes of similar 
biological functions (Chapter 3), I hypothesized that the genes bound to and regulated by 
all three transcription factors would play an important role in the main function of the 
mature β-cell, which is to secrete insulin in response to glucose. To address this question, I 
decided to study in greater detail 16 genes that were: (1) Bound by all three transcription 
factors and (2) had a change in gene expression upon depletion of each transcription factor. I 
hypothesized that, if these Pdx1 NeuroD1 and MafA target genes were important in 
maintaining the insulin secretory response, depletion of their expression in β-cells would 
result in impaired ability to respond to glucose, as determined by a GSIS assay. I also looked 
at changes in expression of critical genes involved in the GSIS response to better understand 
the molecular mechanisms behind the effects of these genes.   
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4.2.  RESULTS  
 
4.2.1.   PDX1,  NEUROD1  AND MAFA  REGULATE THEIR TARGET GENES  
 
In order to test my hypothesis that downstream target genes of Pdx1, NeuroD1 and MafA are 
of functional importance to the mature β-cell, I sought to test the effects of their depletion on 
NIT-1 cells. I selected 16 genes (Table 8) from an overlap of genes commonly bound by 
Pdx1, NeuroD1 and MafA, that also had expression changes upon each transcription factor 
knockdown in the microarray. Most of these genes had no previous known function or role in 
the pancreatic β-cell, and have not been well characterized in other cell types. They are: 
Extracellular leucine-rich repeat and fibronectin type III domain containing (Elfn)-2, Exocyst 
complex component (Exoc)-4, Integrin β 1 binding protein (melusin) (Itgb1bp)-2, 
Glucosaminyl (N-acetyl) transferase 2 I-branching enzyme (I blood group) (Gcnt)-2, Salt-
inducible kinase (Sik)-2, Protein phosphatase 1 regulatory (inhibitor) subunit (Ppp1r)-3a, 
Septin7, Aldolase B fructose-bisphosphate (Aldob), Histone cluster 1 (Hist1)-H1c, ATPase 
Na+/K+ transporting β1 polypeptide (Atp1b1), Solute carrier family 1 (glial high affinity 
glutamate transporter) member 2 (Slc1a2), Complexin (Cplx)-2, Coagulation factor XIII A1 
polypeptide (F13a1), Src homology 2 domain containing transforming protein (Shc)-3, TSPY-
like (Tspyl)-4, and BEN domain containing (Bend)-7.  
 
I verified they were bound by the transcription factors and had changes in gene expression in 
response to each transcription factor knockdown. Figure 30 and the heatmap in Figure 31, 
shows they were all bound by Pdx1, NeuroD1 and MafA relative to the control input library, 
and all had either increases or decreases in gene expression both on the microarray and by 
qPCR validation. E.g. in Figure 30A, Pdx1, NeuroD1 and MafA have peaks approximately 
1kb upstream of the Elfn2 TSS, with peak heights of 20, 67 and 77 respective to the input 
control library which has non-specific peaks of 11 in that same region. These results together 
confirm that the target regions selected for functional characterization are indeed occupied and 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 30. Pdx1, NeuroD1 and MafA binding at 16 of its target genes. Pdx1, NeuroD1 and MafA 
ChIP-Seq was performed in NIT-1 cells and the binding of all three transcription factors at the (A) 
Elfn2 (B) Exoc4 (C) Itgb1bp2 (D) Gcnt2 (E) Sik2 (F) Ppp1r3a (G) Septin7 (H) Aldob (I) Hist1H1c (J) 
Atp1b1 (K) Slc1a2 (L) Cplx2 (M) F13a1 (N) Shc3 (O) Tspyl4 (P) Bend7 gene promoters is visualized 
with the IVG
211
 software. The input library was included as a control for background signal. Numbers 











Figure 31. mRNA heatmap of qRT-PCR validation of 16 genes identified to be bound and 
regulated by Pdx1, NeuroD1 and MafA. NIT-1 cells were transfected with siRNAs against Pdx1, 
NeuroD1 and MafA and RNA was harvested 48hrs post-transfection and transcript levels assayed by 
RT-PCR. Mean values were plotted relative to NTC (100%) and normalized to β-actin. The results are 
graphically displayed, with the expression levels ranging from 0.1 (white) to 6.7 (gray) and a value of 1 




4.2.2.  TARGET GENES OF PDX1,  NEUROD1  AND MAFA  REGULATE GSIS  IN 
PANCREATIC BETA-CELLS  
 
As the primary function of the mature β-cell is to secrete insulin in response to glucose, I 
hypothesized that target genes of Pdx1, NeuroD1 and MafA would be involved in this 
regulatory process. To address this question, NIT-1 cells were transfected in biological 
duplicate with siRNAs against the aforementioned 16 genes (Section 4.4.1.). RNA was 
harvested 48 hours post-transfection and tested for the efficacy of knockdown. As shown in 
Figure 32, all the target genes showed 50-90% depletion of its gene relative to NTC siRNA. I 
next went on to see if the ability of the cells to secrete insulin when challenged with glucose 
was hampered by the introduction of these 16 siRNAs. To that end, GSIS assays were 
performed on NIT-1 cells transfected with each of the 16 siRNAs in biological triplicates. The 
amount of insulin secreted when the cells were challenged with glucose vs. basal insulin 
secretion was quantified with ELISA. siRNAs against Septin-7, Tspy1, Cplx2 (p≤0.05), 
Itgb1bp2 and F13al (p≤0.1) resulted in a 20-40% increase in GSIS compared with the NTC 
siRNA (Figure 33). 
  
The question that subsequently arose was how these 5 genes were mediating their increase in 
GSIS. To address that, I looked at a panel of β-cell genes involved in various aspects of β-cell 
function (Table 9) to see if the changes in GSIS were due to changes in expression of some of 
these genes. Briefly, these genes are all expressed in the pancreatic β-cell and play a role in 
regulating GSIS. They are Nkx6.1, Aryl-hydrocarbon receptor nuclear translocator (Arnt)-2, 
Proprotein convertase subtilisin/kexin type (Pcsk)-1, Ins2, Glut2, Transmembrane (Tmem)-27, 
Snap25, Vamp2, Stx1a, Calcium channel voltage-dependent P/Q type alpha (Cacna)-1a to c, 
Styl4, Potassium inwardly-rectifying channel subfamily J member 11 (Kirrel6.2), Syt7, 
Stxbp1, Uncoupling protein (Ucp)-2, ATPase Ca
2+
 transporting cardiac muscle fast twitch 1 
(Serca), and Chromogranin (Chg)-b. I also looked at genes involved in cell signaling 
processes: Protein tyrosine phosphatase receptor type N (Ptprn), Kin of IRRE like (Kirrel)-2, 
Glutamate decarboxylase (Gad)-1, and Iapp. I also looked at genes that were involved in 
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protection against apoptosis: Hnf1α, Igf2, Chloride intracellular channel (Clic)-1 and genes 
modulating its response to nutrients: NDRG family member (Ndgr)-2, and Gk.   
 
When Pdx1, NeuroD1 and MafA are depleted from NIT-1 cells, there is an increase in mRNA 
levels of Itgb1bp2 and Cplx2 (Figure 31). Upon knockdown of Itgb1bp2 (Figure 34) and 
Cplx2 (Figure 35), there is a 20% increase (p≤0.1) and 30% increase in GSIS (p≤0.05) 
respectively, with a simultaneous ≥1.5 fold increase in levels of Nkx6.1 and Glut2 relative to 
NTC siRNA. There was also a ≥1.5 fold increase in mRNA levels of genes involved in the 
insulin secretory process upon Itgb1bp2 knockdown, e.g. Snap25, Cacna1b, Kirrel6.2, Syt7, 
Stxbp1, Serca (p≤0.05). On top of those genes that increased in mRNA expression, in samples 
treated with siRNAs against Cplx2, there were more insulin secretory genes that showed a 
≥1.5 fold increase in expression, e.g. Vamp2, Syt1a, Cacna1a and 1c, and Chgb (p≤0.05). 
This suggests that Pdx1, NeuroD1 and MafA bind directly to and repress Itgb1bp2 and Cplx2 
to stimulate the GSIS response in β-cells via increasing the transcription of important β-cell 
genes, including those involved in the GSIS secretory response. There also appears to be a 
slight anti-apoptotic effect mediated by Itgb1bp2 and Cplx2, in that decreasing both of them 





When Pdx1, NeuroD1 and MafA were depleted from cells, there was a decrease in mRNA 
levels of Tspyl1, F13a1 and Septin7 (Figure 31). Upon knockdown of Tspyl1, F13a1 and 
Sept7, there was a 30-40% increase in GSIS (Tspyl1 and Septin7: p≤0.05, F13a1: p≤0.1), with 
a concomitant ≥1.5 fold increase in mRNA levels of IAPP, Ndrg2, Glut2 and Gad1 (p≤0.05) 
(Figures 36–38). There was also a ≥1.5 fold increase in expression of genes involved in the 
insulin secretory response, e.g. Snap25, Vamp2, Cacna1b, Kirrel6.2, Stxbp1, Serca and Chgb 
(p≤0.05). This suggests that Pdx1, NeuroD1 and MafA bind to and increase the expression of 
Tspyl1, F13a1, and Sept7, possibly resulting in an indirect reduction of GSIS as depletion of 





Figure 32. mRNA heatmap of NIT-1 cells transfected with 16 siRNAs. NIT-1 cells were transfected 
in duplicate with 16 siRNAs against genes I identified to be Pdx1, NeuroD1 and MafA targets. RNA 
was harvested 48hrs post-transfection and transcript levels assayed by RT-PCR. Mean values were 
plotted relative to NTC (100%) and normalized to β-actin. The results are graphically displayed, with 








Figure 33. GSIS of NIT-1 cells transfected with siRNAs against 16 genes triply bound and 
regulated by Pdx1, NeuroD1 and MafA. NIT-1 cells were transfected in triplicate with siRNAs 
against 16 genes identified to be Pdx1, NeuroD1 and MafA targets, and GSIS assays were performed. 
The cells were starved for 2 hours at 37°C before incubation with 1xKRH for 1 hour (basal secetion) 
before incubation with 1XKRH with 20mM glucose for 1 hour (stimulated secretion). Released insulin 
in the supernatent was quantified with ELISA in technical triplicates and the values are means ± SE 
(n=3). **p ≤ 0.05, *p ≤ 0.1. siRNAs against Septin7, Cplx2, Tspyl4, Itgb1bp2 and F13a1 resulted in 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 34. Itgb1bp2-depletion in NIT-1 cells leads to an increase in expression of key β-cell genes. 
NIT-1 cells were transfected with siRNAs against Itgb1bp2 and RNA was harvested 48hr post-
transfection. Transcript levels of important β-cell genes were analyzed with qRT-PCR and normalized 
against ß-actin. The transfections were performed in biological duplicates and the RT-PCRs in 
technical duplicates, and the average of the normalized ratio of target gene/ß-actin was calculated and 
presented with standard deviation. **p ≤ 0.05.  






Figure 35. Cplx2-depletion in NIT-1 cells leads to an increase in expression of key β-cell genes.  
NIT-1 cells were transfected with siRNAs against Cplx2 and RNA was harvested 48hr post-
transfection. Transcript levels of important β-cell genes were analyzed with qRT-PCR and normalized 
against ß-actin. The transfections were performed in biological duplicates and the RT-PCRs in 
technical duplicates, and the average of the normalized ratio of target gene/ß-actin was calculated and 







Figure 36. Tspyl1-depletion in NIT-1 cells leads to an increase in expression of key β-cell genes. 
NIT-1 cells were transfected with siRNAs against Tspyl1 and RNA was harvested 48hr post-
transfection. Transcript levels of important β-cell genes were analyzed with qRT-PCR and normalized 
against ß-actin. The transfections were performed in biological duplicates and the RT-PCRs in 
technical duplicates, and the average of the normalized ratio of target gene/ß-actin was calculated and 







Figure 37. F13a1-depletion in NIT-1 cells leads to an increase in expression of key β-cell genes. 
NIT-1 cells were transfected with siRNAs against F13a1 and RNA was harvested 48hr post-
transfection. Transcript levels of important β-cell genes were analyzed with qRT-PCR and normalized 
against ß-actin. The transfections were performed in biological duplicates and the RT-PCRs in 
technical duplicates, and the average of the normalized ratio of target gene/ß-actin was calculated and 







Figure 38. Septin7-depletion in NIT-1 cells leads to an increase in expression of key β-cell genes. 
NIT-1 cells were transfected with siRNAs against Septin7 and RNA was harvested 48hr post-
transfection. Transcript levels of important β-cell genes were analyzed with qRT-PCR and normalized 
against ß-actin. The transfections were performed in biological duplicates and the RT-PCRs in 
technical duplicates, and the average of the normalized ratio of target gene/ß-actin was calculated and 





4.3.  DISCUSSION  
 
Pancreatic β-cells are able to sense glucose and other nutrient secretagogues to regulate 
insulin exocytosis, thereby maintaining glucose homeostasis. This systems biology of insulin 
secretion controls translation of metabolic signals into intracellular messengers recognized by 
the exocytotic machinery. Pdx1, NeuroD1 and MafA are key transcriptional regulators of the 
mature β-cell phenotype, with their target genes having a range of regulatory effects in many 
aspects, such as cellular metabolism, developmental processes, and cellular activities such as 
regulation of cell cycle, cell death and proliferation (Section 3). These genes bound by these 
three transcription factors are also associated with genetic diseases, neurological and 
metabolic disorders and gastrointestinal disease. Because of their importance in regulating the 
mature β-cell phenotype, I hypothesized that the genes bound to and regulated by all three 
transcription factors would play an important role in the main function of the mature β-cell, 
which is to secrete insulin in response to glucose.  
 
4.3.1.  ITGB1BP2  AND CPLX2  POSITIVELY REGULATE GSIS 
 
When Pdx1, NeuroD1 and MafA were depleted from NIT-1 cells, there was an increase in 
mRNA levels of Itgb1bp2 (Figure 31). Upon knockdown of Itg1bp2, there was a 20% increase 
(p≤0.1) in GSIS, with a ≥1.5 fold increase in expression of many key β-cell genes (Figure 34). 
This suggests that Pdx1, NeuroD1 and MafA bind to and repress Itgb1bp2 to increase the 
GSIS response in β-cells via increasing the transcription of important β-cell genes, including 
those involved in the GSIS secretory response. There was also a slight anti-apoptotic effect 
mediated by Itgb1bp2, in that its depletion led to a decrease in expression of Clic1. Clic1 is a 
target gene of NeuroD1 and the increase in Clic1 in hyperglycaemic conditions sensitizes 
mouse β-cells to high glucose stress, which causes ER stress and apoptosis113. The expression 
of Clic1 under high glucose conditions also decreased the expression of Pdx1, Gk and 
Insulin
113
. Therefore, perhaps Pdx1, NeuroD1 and MafA indirectly reduces the expression of 
Clic1 in normal β-cells via Itgb1bp2, to protect the cells from stress and apoptosis. 
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The only known role of Itgb1bp2 is its involvement during maturation and/or organization of 
muscles cells
222
. It interacts with the β-integrin cytoplasmic domain and appears to be 
regulated by intracellular signals affecting Ca
2+
 concentration. The ability of pancreatic β-cells 





release of intracellular Ca
2+
 stores (by the influx of extracellular Ca
2+
 or by other external 
signals) is also thought to be involved in regulating insulin secretion in order to enhance or 
prolong insulin secretion instead of directly triggering it
266
. It is not inconceivable that similar 
mechanisms could be similarly involved here, with Pdx1, NeuroD1 and MafA responding to 
extracellular Ca
2+
 signals via Itgb1bp2, in order to indirectly influence the β-cell’s GSIS 
response.  
 
A 30% increase in the GSIS response (p≤0.05) was seen when Cplx2, another target of Pdx1, 
NeuroD1 and MafA, was depleted from β-cells (Figure 35). This increase in GSIS also 
involved the ≥1.5 fold up-regulation of important β-cell genes, especially those involved in 
mediating the GSIS response. Similar to the effects of Itgb1bp2-depletion, there was also a 
decrease in the anti-apoptotic gene Clic1, suggesting a minor role in Pdx1, NeuroD1 and 
MafA indirectly reducing the expression of Clic1 in normal β-cells via Cplx2 to protect 
against apoptosis. 
 
Cplx is a small protein that binds rapidly with high affinity to the SNARE complex, which is a 
multistage process central to synaptic transmission and hormone release; therefore Cplx has a 
regulatory role in fast exocytosis
267
. There are 4 Cplx isoforms in vertebrates, all of them 
highly enriched in the nervous system, with some present in other tissues. The function of 
Cplxs in regulated exocytosis is controversial, with several early studies suggesting a negative 
role in the release of neurotransmitters
268
 such as acetylcholine
269
, and spontaneous 
neurotransmitter release upon knockout of Cplx was observed
270
. Other studies indicate that 
Cplxs plays a positive role in exocytosis, with adrenal chromaffin cells from Cplx2 knockout 
mice exhibiting markedly diminished releasable vesicle pools
237
, and insulin secretion was 
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diminished in pancreatic β-cells both over- and under-expressing Cplx1271.  Cplx2 is expressed 
at low levels in different tissues, and in neuronal cells has a function similar to Cplx1 in the 
control of SNARE-mediated exocytosis
272
. The mouse MIN6 and rat INS1 β-cell line do not 
expresses Cplx2, but the mouse β–TC6 cell line expresses low levels of Cplx2, unlike all the 
pancreatic β-cell lines which express Cplx1 at high levels271, suggesting that the expression of 
this gene is regulated in a β-cell line-dependent manner (possibly due to clonal selection 
during generation of cell lines). Cplx1 and Cplx2 are encoded by two different genes and are 
probably differentially regulated in β-cells, as demonstrated by the differential expression 
levels and cellular localizations of Cplx1 and Cplx2 in the rat forebrain and hippocampus
273
.    
 
I have shown that Cplx2 is repressed by Pdx1, NeuroD1 and MafA, and upon Cplx2 
knockdown in the NIT-1 β-cell line, there is a 30% increase in GSIS, together with the 
increase in expression of key β-cell genes, including those involved in the insulin secretory 
response (Figure 35). This indicates Cplx2 plays a repressive role in the GSIS response in 
pancreatic β-cells, unlike Cplx1. It also appears it is necessary for Pdx1, NeuroD1 and MafA 
to repress Cplx2 in β-cells in order to maintain a robust GSIS response.  
 
4.3.2.  TSPYL1,  F13A1  AND SEPTIN7  NEGATIVELY REGULATE GSIS 
 
F13a1 has a well-established role in blood clotting, it encodes the coagulation factor XIII A 
subunit, which is the last zymogen to become activated in the blood coagulation cascade
238
. It 
is expressed in the pancreas but has no known function there. Tspyl1 is expressed in the 
pancreas and has no known function at all. Septin7 is an E2F1/2 responsive gene and is 
typically regulated at G2/M in the cell cycle
274
. It is a filament-forming cytoskeletal GTPase 






When Pdx1, NeuroD1 and MafA were depleted from cells, there was a decrease in mRNA 
levels of Tspyl1, F13a1 and Septin7 (Figure 31). Upon knockdown of Tspyl1, F13a1 and 
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Sept7, there was a 30-40% increase in GSIS (Tspyl1 and Septin7: p≤0.05, F13a1: p≤0.1), with 
a concomitant ≥1.5 fold increase in key β-cell genes (Figure 36-38). This suggests that Pdx1, 
NeuroD1 and MafA bind to and increase the expression of Tspyl1, F13a1, and Sept7, possibly 
resulting in an indirect reduction of GSIS as depletion of these genes lead to an increase in 
GSIS. 
 
This is perhaps counter-intuitive to the positive effect on GSIS of Pdx1, NeuroD1 and MafA 
via Itgb1bp2 and Cplx2, as mentioned in Section 4.3.1. However, it is not surprising that there 
are genes negatively involved in regulating GSIS. Activation of the α subunit of the 
heterotrimeric G protein Gαz inhibits GSIS in vitro and in vivo, with increased insulin 
secretion observed in Gαz
-/-
 islets due to the relief of a tonic inhibition of adenylyl cyclase 
(cAMP production was significantly increased in Gαz
-/-
 islets in the absence of exogenous 
stimulation)
275
. Activation of β-cell M3 muscarinic receptors (M3R) enhances GSIS via 
stimulation of G proteins of the Gq family, which are under the inhibitory control of regulators 
of G protein signaling (RGS) proteins. RGS4 was identified as a potent negative regulator of 
M3R function in pancreatic β-cells. The pancreatic β-cell needs to respond in the appropriate 
temporal manner to external signals, it should not be secreting insulin indiscriminately in an 
excessive manner, nor should it be inhibited in its ability to respond, given the proper 
stimulus. Taken together, these results clearly demonstrates the complexity of regulation in 





4.4.  SUMMARY  
 
A fundamental property of pancreatic β-cells is their capacity to regulate the release of insulin 
and other hormones in direct response to changes in extracellular glucose concentration. In 
large part, this ability defines β-cell function since insulin is produced and released in the 
body only from these specialized cells. Insulin is crucial to regulating blood glucose, and 
reduced insulin secretion is a key feature of both T1DM and T2DM, and therefore, GSIS is a 
well-accepted measure of β-cell function. 
 
I have shown that Pdx1, NeuroD1 and MafA repress Itgb1bp2 and Cplx2 in order to achieve 
an enhanced GSIS response. Pdx1, NeuroD1 and MafA activate Tspyl1, F13a1 and Septin7 to 
reduce GSIS (Figure 39). This additional knowledge emphasizes the exquisite level of 







Figure 39. Schematic diagram of how Pdx1, NeuroD1 and MafA interact with their target genes 























5.1.  INTRODU CTION  
 
T2DM develops as a result of insulin resistance coupled with impaired β-cell function, and is 
closely associated with increased plasma FFA concentrations and elevated glucose 
concentrations
169
. Continuous over-stimulation of the β-cell by glucose leads to depletion of 
insulin stores, excessively high levels of ROS, worsening of hyperglycemia, and finally 
deterioration of the β-cell (glucotoxicity)276. FFAs enhance the β-cell response on acute 
application but long-term exposure exerts lipotoxic effects and leads to blunted GSIS and 
decreased cell viability
277
. The combination of FFAs and high glucose has been suggested to 





Pdx1 associates with HDAC1 and -2 in low glucose conditions (1-3mM) to repress INS gene 
expression, and recruits the co-activator HAT p300 to the Insulin promoter only in high 
glucose conditions (10-30mM)
161
. The HMT Set7/9 is recruited by Pdx1 to the Insulin and 
Glut2 genes, leading to H3K4me2 and recruitment of RNA polymerase II
162
. Pdx1 modulates 
histone H4 acetylation to directly activate Insulin gene expression in β-cells; exogenous Pdx1 
expression in α-cells also leads to Insulin expression via H4 acetylation164. Expression of Pdx1 
is permanently reduced in IUGR rats when the Pdx1 gene undergoes epigenetic modifications 
throughout development leading to its silencing
167
. Pdx1 and MafA expression and activity are 
decreased in DIO animals and in cell culture conditions mimicking diabetes, leading to a 
decrease in insulin biosynthesis and secretion
169
. A mutation in p300 removes binding to 
NeuroD1 and destroyed the ability of p300 to activate Insulin E-box directed transcription in 
β-cells, leading to MODY6166. Therefore, the association of many β-cell transcriptional 
regulators with HATs, HMTs and HDACs provide correlative evidence for histone 




The mono-methylations of H3K27, H3K9, H4K20, H3K79, and H2BK5 are linked to gene 
activation, while tri-methylations of H3K27, H3K9, and H3K79 are linked to repression
136
. 
The apparently opposite modifications H3K4me3 and H3K27me3 co-localize in ‘‘bivalent 
domains’’ in embryonic stem cells137, and these have been suggested to function in the 
differentiation of these cells, as these “bivalent domains” have been found in developmental 
regulators. Recent evidence has confirmed the presence of these domains in mouse embryonic 
fibroblasts, neural progenitors
138
 and human T cells
139, proving that these “bivalent domains” 
are not an ESC-specific phenomenon.  
 
The human INS gene has recently been found to be part of a large open chromatin domain 
specific in islets which is marked by histone acetylation and H3K4 di-methylation marks 
distributed over the entire coding region and an 80kb region around it
176
. In another recent 
study that looked at open regions of chromatin in human pancreatic islets
177
, the authors 
identified islet-specific COREs, of which many genes encoding proteins with known function 
in islets (such as PDX1, PAX6, GLP1R, SLC30A8 and CPE), belong
178
. In another new 
study, open chromatin regions, CTCF-binding sites, H3K4me3, H3K4me1, and H3K79me2 
were profiled across the entire genome in human islets
179
. Integrated analysis of these large-
scale data sets identified 18000 putative TSSs, of which 30% were previously unannotated by 
RefSeq and at least several hundred of these are islet-active TSSs, including those for major 
islet miRNAs previously implicated in the control of glucose homeostasis
180
. In summary, 
there is a growing body of current literature suggesting a role for epigenetic interactions in the 
complex interplay between gene regulation and the environment.  
 
Therefore, my hypothesis is that is that as β-cell dysfunction progressively develops, 
modulation of the chromatin environment adversely affects the expression and activity of 





Questions I will address in this chapter are: 
 
1) Where are the regions of active and repressive chromatin in normal and dysfunctional β-
cells?  
2) Are there differences in open and closed regions of chromatin in normal and β-cells, and 
how do these change upon β-cell becoming dysfunction?  
3) How does the global Pdx1, NeuroD1 and MafA occupancy correlate with histone marks in 
normal β-cells, and do these patterns change upon β-cell dysfunction? 
4) Are there bivalent domains in normal β-cells? Do these domains change upon β-cell 
dysfunction?  
 
To answer these questions, I have profiled H3K4me3 (an active mark of chromatin), 
H3K27me3 (a repressive mark of chromatin) in normal β-cells to identify regions of 
chromatin that are actively transcribed and those that are not, and compared that with the same 
histone marks identified in β-cells that have a decrease in GSIS after treatment with high 
glucose and fatty acids, i.e. dysfunctional β-cells. I have also used the FAIRE technique188 to 
identify regions of open and closed chromatin in normal and dysfunctional β-cells. FAIRE 
performed in human cells strongly enriches DNA coincident with the location of DNaseI 




5.2.  RESULTS  
 
5.2.1.  GENERATION OF DYSFUNCTIONAL BETA-CELLS  
 
The main function of the β-cell is to secrete insulin in response to a glucose stimulus. 
Response to an environmental stimulus is not only a metabolic one, the physiological long 
term adaptation of pancreatic β-cells is driven by stimuli such as glucose and incretin 
hormones acting via cAMP (e.g. Glp-1) and involves regulated gene expression. Several 
rapidly inducible immediate-early genes (IEGs) have been identified in β-cells. Many of these 
IEGs code for transcription factors and have the potential to control the transcription of 




Exposure of isolated islets and insulin-secreting cells to elevated levels of fatty acids in vitro 
impairs Insulin gene expression when glucose concentrations are concomitantly elevated
57
. 
Palmitate and oleate inhibit insulin secretion, but only palmitate impairs Insulin gene 
expression, with palmitate impairment of the Insulin gene appearing to be mediated by direct 
inhibition of Insulin promoter activity
279
. Palmitate inhibits Pdx1 and MafA binding activities 
through different mechanisms: culture of isolated islets in the presence of palmitate prevents 
the nuclear translocation of Pdx1 that normally occurs upon glucose stimulation, while it 
blocks glucose induction of MafA mRNA expression
280
. The combined over-expression of 
Pdx1 and MafA prevents palmitate inhibition of Insulin gene expression in isolated rat islets, 
highlighting the essential role for these two transcription factors in the mechanisms of lipo- 
toxicity
280
. Basal KATP channel activity was 40% lower in islets cultured at 4.5mM and 
palmitate, and 60% lower in islets cultured at 15mM glucose plus either palmitate or oleate
281
. 
Insulin content decreased by 75% in islets exposed to FFAs in the presence of high (15mM) 
but not low (4.5mM) glucose concentrations, but the number of secretory granules was 
unchanged
281




To induce β-cell dysfunction, I chose to treat cells with high glucose and palmitate. NIT-1 
cells were treated in triplicate with 20 or 25mM glucose and 0.3 or 0.4mM palmitate, and 
GSIS assays were performed. The cells were starved for 2 hours at 37°C before incubation 
with 1xKRH for 1 hour (basal secetion) before incubation with 1XKRH with 20mM glucose 
for 1 hour (stimulated secretion). Released insulin in the supernatent was quantified with 
ELISA in technical triplicates. As Figure 40 shows, compared to cells grown under normal 
conditions, there is the most reduction in GSIS (60%) under conditions of 20mM glucose and 
0.4mM palmitate. The increase in the GSIS response when the cells are treated with 20mM 
glucose compared to 15mM glucose has been observed before, and is probably due to the fact 











Figure 40. GSIS of NIT-1 cells treated with different concentrations of glucose and palmitate.  
NIT-1 cells were treated in triplicate with 20 or 25mM glucose (G) and 0.3 or 0.4mM palmitate (P), and 
GSIS assays were performed. The cells were starved for 2 hours at 37°C before incubation with 1xKRH 
for 1 hour (basal secetion) before incubation with 1XKRH with 20mM glucose for 1 hour (stimulated 
secretion). Released insulin in the supernatent was quantified with ELISA in technical triplicates and 
the values are means ± SE (n=3). ***p ≤ 0.01, **p ≤ 0.02. NIT-1 cells treated with 20mM glucose and 









































5.2.2.  GLOBAL LANDSCAPE OF ACTIVATING AND REPRESSIVE REGIONS OF 
CHROMATIN IN NORMAL AND DYSFUNCTIONAL BETA-CELLS  
 
To look at H3K4me3 and H3K27me3 marks in normal and dysfunctional β-cells, I performed 
ChIP in normal NIT-1 β-cells and dysfunctional β-cells (with two conditions: cells treated 
with 15mM glucose and 0.3mM palmitate, and 20mM glucose and 0.4mM palmitate) with the 
H3K4me3 and H3K27me3 antibodies. When I performed the experiments in early 2010, there 
was no prior knowledge of where active and repressive regions of chromatin in β-cells were 
located. I therefore hypothesized that the Ins1 gene would be active (i.e. H3K4me3-enriched), 
and that MyoD and Utf1 (identified to not be bound by Pdx1, NeuroD1 nor MafA, Chapter 3) 
would be more repressed (i.e. H3K27me3-enriched). The RIK2600 gene is bound by Pdx1 and 
NeuroD1 in normal NIT-1 cells, so I included that as a potential positive control for the 
H3K4me3 ChIP. Fold enrichment represents the abundance of enriched DNA fragments over 
a negative control region not bound by the antibody of interest, and I also reasoned that the 
regions highly enriched for H3K4me3 would probably not be marked by H3K27me3 and vice 
versa, so the regions highly enriched for H3K4me3 could serve as the negative control region 
for the H3K27me3 ChIP, and vice versa.  
  
H3K4me3 was enriched at the Ins1 gene in both normal and dysfunctional β-cells relative to 
MyoD, and the RIK2600 gene showed a decrease in the level of H3K4me3 enrichment as the 
concentration of glucose and palmitate increased (Figure 41A). The other negative control 
region for the H3K4me3 ChIP was Utf1, and it showed no enrichment for H3K4me3 relative 
to MyoD. The converse was seen for the H3K27me3 ChIP, with low levels of enrichment for 
Ins1 relative to RIK2600 (the other negative control region for the H3K27me3 ChIP), and 
high enrichments for MyoD and Utf1 (Figure 41B).  
 
I extended the search to a genome-wide level, and performed ChIP-Seq with H3K4me3 and 
H3K27me3 on normal NIT-1 β-cells and dysfunctional β-cells. I selected dysfunctional β-
cells treated with 20mM glucose and 0.4mM palmitate for subsequent genome-wide 
 
157 
experiments because the enrichments for H3K4me3 and H3K27me3 were higher in those 
conditions than in 15mM glucose and 0.3mM palmitate. There was also more of a decrease in 
the GSIS response in cells treated with 20mM glucose and 0.4mM palmitate (Figure 40). The 
ChIPs were performed in biological duplicates (i.e. chromatin was harvested on cells treated 
on two separate occasions with high glucose and fatty acids and ChIPs performed on separate 
days) and validated the quality of the ChIPs in the same fashion as in Figure 41 before 
preparing the sample for sequencing. Input DNA was sequenced as a control for background 
noise in both normal and dysfunctional β-cells, and subsequent reads mapped against that.   
 
I also performed FAIRE on normal and dysfunctional β-cells to identify regions of open and 
closed chromatin. DNA segments that actively regulate transcription in vivo are typically 
characterized by eviction of nucleosomes from chromatin and are experimentally identified by 
their hypersensitivity to nucleases. In FAIRE, chromatin is cross-linked with formaldehyde in 
vivo, sheared by sonication, and phenol-chloroform extracted. Cross-linking between histones 
and DNA (or between one histone and another) is likely to dominate the chromatin 
crosslinking profile
283,284
. Therefore, covalently linked protein–DNA complexes are 
sequestered to the organic phase, leaving only protein-free DNA fragments in the aqueous 
phase, which is then recovered and prepared for sequencing. For the background reference, 
the same procedure is performed on a portion of the cells that had not been fixed with 










Figure 41. ChIP of H3K4me3 and H3K27me3 in normal NIT-1 β-cells and β-cells treated with 
varying concentrations of glucose and palmitate. Chromatin from NIT-1 cells in different treatment 
conditions: normal media (blue bars), 15mM glucose and 0.25mM palmitate (red bars) and 20mM 
glucose and 0.4mM palmitate (red bars) was sheared and ChIP was performed with antibodies against 
(A) H3K4me3 and (B) H3K27me3. Fold enrichment represents the abundance of enriched DNA 
fragments over a control region. Each ChIP experiment was performed with three technical replicates 
for each RT-PCR, and the average of the normalized ratio to the target gene/control region was 
calculated and presented. This data is representative of ChIP experiments performed in three biological 
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In analysis of the H3K4me3 and H3K27me3 ChIP-Seq libraries, raw mapped reads were 
compiled for each biological duplicate and HOMER
189
 was used for peak calling. Control 
samples (genome sequencing without antibodies for H3K4me3 and H3K27me3) were used as 
the background input, with two-fold enrichment relative to the background and FDR 0.001 as 
the thresholds. For FAIRE analysis, F-Seq
190
 was used for peak identification using the raw 
mapped reads. The sequencing output of DNA without formaldehyde fixation was used for the 
control, and the identified peaks from the control sequencing were subtracted from those in 
FAIRE sequencing. The standard deviation of 6.0 was used for the threshold. The closest TSS 
from each peak was identified for gene annotation. 
 
There was a notably larger number of FAIRE peaks for dysfunctional β-cells than normal 
cells, 61962 in contrast to 46668 (Table 10). There was also an increase in the number of 
H3K4me3 ChIP-Seq peaks in dysfunctional β-cells when compared to normal β-cells, 15780 
peaks vs. 14204. There was a decrease in H3K27me3 peaks in dysfunctional β-cells, 10739 
compared to 12686 peaks in normal β-cells. At the promoter regions, there were also more 
FAIRE peaks (5720) and H3K4me3 (3117) peaks in dysfunctional β-cells than normal cells, 
which had 341 FAIRE peaks and 2892 H3K4me3 peaks. There was a decrease in the number 
of H3K27me3 peaks located at the promoter in dysfunctional β-cells (555) compared to 
normal β-cells (664). Taken together, it suggests that there is an increase in the global level of 
open chromatin at the promoters of dysfunctional β-cells when compared to normal β-cells.  
 
The average profile of H3K4me3 was plotted across the TSS and there was a binomial 
distribution of peaks at the TSS (Figure 42). The peak downstream of the TSS was higher, 
compared to the peak before the TSS, this is consistent with the profile of H3K4me3 normally 
seen at promoters
136
, and probably demarcates transcription factor binding. There was a dip in 
peaks at the end of the TSS, also consistent with previous reports
136
. The average profile of 







FAIRE H3K4me3 H3K27me3 FAIRE H3K4me3 H3K27me3 
# total peaks  46668 14204 12686 61962 15780 10739 
# promoter peaks  341 2892 664 5270 3117 555 
# TSS peaks 347 259 115 458 268 80 
# 5’UTR peaks 6 566 76 92 612 47 
# intergenic peaks  14306 1205 4972 7657 1820 4150 
  
Table 10. Summary of mapped reads and peak calling of FAIRE, H3K4me3 and H3K27me3 
ChIP-Seq libraries in normal and dysfunctional β-cells.  
Raw mapped reads (in BED format) were compiled for each biological duplicate and were used for 
peak calling by HOMER
189
. Control samples (genome sequencing without antibodies for H3K4me3 and 
H3K27me3) were used as the background input, with two-fold enrichment relative to the background 
and an FDR of 0.001 were used as the thresholds. For the FAIRE experiments, F-Seq
190
 was used for 
peak identification based on the raw mapped reads. The sequencing output of DNA without 
formaldehyde fixation was used for control. The identified peaks from the control sequencing were 







Figure 42. H3K4me3 methylation at TSS. The average profile of H3K4me3 was plotted across the 
TSS and there was a binomial distribution of peaks at the TSS. Y axis: modification level or DNA-








Figure 43. H3K27me3 methylation at TSS. The average profile of H3K27me3 was plotted across the 




It was interesting that there was more open chromatin in dysfunctional β-cells especially in 
the FAIRE libraries. I hypothesized there were differences in the cis-regulatory elements 
found at the open chromatin regions, so motif finding was performed with these libraries. The 
motif lengths of 8, 10, and 12bp were searched against the repeat-masked mm8 Mus musculus 
genome and position-specific weight matrices were calculated based on the HOMER 
database. Motif analysis of open chromatin in normal cells show top enrichments for the 
transcription factors FoxA1 (p value = 1.15E-42), FoxA2 (p value = 8.27E-42), POU class 5 
homeobox 1 (Oct)-4 (p value = 7.06E-32), POU class 3 homeobox (Oct)-2 (p value = 1.59E-
30), and Pdx1 (p value = 7.78E-29) (Table 11A). The transcription factor Upstream 
stimulating factor (Usf)-1 was also in the top 20 enriched motifs, with a p value of 2.24E-06. 
In contrast, open chromatin of dysfunctional β-cells show top enrichments for general 
regulators such as Sp transcription factor (Sp)-1 (p value = 1.09E-109), CTCF (p value = 
1.42E-54) and Nfy(CCAT)-binding factor (p value = 4.73E-53) (Table 11B). A full list of 
motifs are listed in Supplementary Table 7. 
 
All these indicate that in dysfunctional cells, open chromatin is biased to binding sites for 
general transcription factors, while in normal cells, tissue-specific TF binding sites tend to 


























Table 11. FAIRE peaks in (A) normal β-cells show tissue-specific transcription factor motifs, 
while (B) motifs in dysfunctional β-cells show enrichment for general transcription factors.  
The motif lengths of 8, 10, and 12bp were searched against the repeat-masked mm8 Mus musculus 
genome and position-specific weight matrices were calculated based on the HOMER’s database. (Dr 
Choi performed this analysis.) 
 
  








5.2.3.  GENES EPIGENETI CALLY ALTERED IN DYSFUNCTIONAL BETA-CELLS  
 
I next wanted to know if the genes associated with the respective epigenetic marks in normal 
and dysfunctional β-cells had similarities in their biological networks and/or molecular roles. 
To achieve this, I uploaded the RefSeq identity list of nearest associated genes of each 
chromatin mark in each cellular condition (H3K4me3, H3K27me3, FAIRE in normal and 
dysfunctional β-cells) into IPA187 and identified the top biological networks and cellular 
processes and functions associated with them. I then utilized the comparison function in IPA 
to compare the matching datasets in the two conditions (genes marked by FAIRE in normal β-
cells vs. genes marked by FAIRE in dysfunctional β-cells, and the same for H3K4me3 and 
H3K27me3). 
 
There was more of an over-representation of genes identified by FAIRE-Seq that are involved 
in nervous system development in normal β-cells compared to dysfunctional β-cells, and an 
over-representation of genes involved in connective tissue development and embryonic 
development in dysfunctional β-cells (Figure 44). In the FAIRE-Seq dataset there are also 
genes more enriched for infectious mechanisms and infectious diseases in dysfunctional β-
cells compared to normal β-cells. It is of interest that there was a higher enrichment for genes 
involved in cellular growth and proliferation, cell death, cell cycle, molecular transport, DNA 
replication, recombination and repair, protein synthesis and gene expression in dysfunctional 
β-cells when compared to normal β-cells. There were also genes involved in protein 
trafficking enriched only in the dysfunctional β-cells, while genes involved in endocrine 
system development and function were enriched only in the normal β-cells. This shows that 
genes identified to be in regions of open chromatin by FAIRE-Seq in dysfunctional β-cells are 
more enriched for in general cellular regulation and development of other developmental 
lineages, including embryonic development, when compared to normal β-cells, in agreement 
with the motifs identified in Section 5.2.2.  A full list of genes involved in those pathways is 
listed in Supplementary Table 8A. 
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There was an over-representation of genes involved in cellular development, cardiovascular 
development and function, embryonic development, nervous system and development, 
organismal development, skeletal and muscular system development and function, tissue 
development, and respiratory development and function, in the genes enriched for H3K4me3 
in dysfunctional β-cells when compared to normal β-cells (Figure 45). Similar to the FAIRE-
Seq dataset, there was also an over-representation of genes involved in cellular growth and 
proliferation, cellular movement, and lipid metabolism in dysfunctional β-cells. Disease-
related genes found to be more enriched in the dysfunctional β-cells were those involved in 
endocrine system disorders, gastrointestinal diseases, genetic disorders, metabolic disease, 
neurological disease, cardiovascular disease, and psychological disorders. In line with the 
comparison of genes identified by FAIRE-Seq, these results show that genes identified to be 
in regions of active chromatin by H3K4me3-Seq in dysfunctional β-cells are more involved in 
general cell regulatory activities and the development of other lineages, including embryonic 
development, when compared to normal β-cells. A full list of genes involved in those 
pathways is listed in Supplementary Table 8B. 
 
Genes implicated in genetic disease, skeletal and muscular disorders, neurological disorders, 
connective tissue disorders, inflammatory disease, cardiovascular and haematological disease 
were more enriched for H3K27me3 genes in normal β-cells than dysfunctional β-cells. Genes 
involved in carbohydrate metabolism were slightly more enriched in the H3K27me3 genes in 
dysfunctional β-cells when compared to normal β-cells (Figure 46). Similarly, genes 
implicated in nutritional disease were only identified to be significantly enriched for 
H3K27me3 genes in dysfunctional β-cells and not in normal β-cells. There are more genes 
enriched for H3K27me3 in normal β-cells involved in system development and function, 
namely the nervous system development and function, renal and urological, skeletal and 
muscular, cardiovascular, embryonic development. There was an over-representation of genes 
with H3K27me3 involved in cell morphology, cell-to-cell signalling and interaction and cell 
death, in normal β-cells when compared to dysfunctional β-cells. Interestingly, there are more 
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genes associated with H3K27me3 involved in organismal injury and abnormalities in 
dysfunctional β-cells than normal cells. This shows that genes identified to be in repressive 
regions of chromatin by H3K27me3-Seq in normal β-cells are enriched for the development 
and function of different lineages, various diseases, and cell regulation. A full list of 
genesinvolved in those pathways is listed in Supplementary Table 8C. 
 
Taken together, the comparison of the genes associated with the respective epigenetic marks 
in normal and dysfunctional β-cells demonstrates that there is a significant increase in genes 
involved in cellular regulatory activities and the specification of other developmental lineages 








Figure 44. Comparison of FAIRE-peaks in normal and dysfunctional β-cells with IPA shows more 
enrichment of genes involved in general cellular regulation and development of other developmental 




Figure 45. Comparison of H3K4me3-peaks in normal and dysfunctional β-cells with IPA shows 
more enrichment of genes involved in general cellular regulation and development of other 










Figure 46. Comparison of H3K27me3-peaks in normal and dysfunctional β-cells with IPA shows 
more enrichment of genes involved in the development and function of different lineages, various 




5.2.4.  DYSFUNCTIONAL BETA-CELLS ARE REPRESSIVE LY MARKED AT  IMPORTANT 
Β-CELL GENES  
 
I next wanted to see if specific genes important for normal β-cell function had differential 
chromatin profiles in dysfunctional β-cells, so ChIP-Seq peaks were visualized in the UCSC 
genome browser with the NCBI36/mm8 Mus musculus reference assembly. As shown in 
Figure 47, (A) Pdx1, (B) NeuroD1, (C) MafA are marked by less H3K4me3 in dysfunctional 
β-cells than in normal cells, as evidenced by the decrease in number of tags in the y axis. This 
was coupled with an increase in the number of H3K27me3 tags at the same locations. 
Surprisingly, Ins1 (Figure 47D) had a slight decrease in the number of H3K4me3 tags at the 
promoter. I next looked at some genes important for the response of β-cells to a glucose 
stimulus (highlighted in Chapter 3, Table 9). There was less H3K4me3 at Glut2, Snap25, 
Vamp2, Cacna1a, Chgb, Kirrel6.2, Sytl4, Stxbp1, and Syt7, coupled with an increase in 
H3K27me3 (Figure 47E-M). I also looked at genes involved in other β-cell functions, and 


















































































































Figure 47. In dysfunctional β-cells, genes important for β-cell function are marked by decreased 
H3K4me3 levels and increased H3K27me3 levels at their promoter.  H3K4me3 and H3K27me3 
ChIP-Seq was performed in normal and dysfunctional NIT-1 cells and the presence or absence of these 
marks in important β-cell genes was visualized with the UCSC genome browser. (A) Pdx1, (B) 
NeuroD1, (C) MafA, (D) Ins1, (E) Glut2, (F) Snap25, (G) Vamp2, (H) Cacna1a, (I) Chgb, (J) Kirrel6.2, 




Genes that are normally not expressed in β-cells include Gcg (an α-cell expressed gene) and 
Sst (secreted by δ-cells of the pancreas). There was increased H3K4me3 at those two loci in 
dysfunctional β-cells (Figure 48A, B). The T2D-associated genes Kcnq1 (Figure 48C) and 
Tcf7l2 (Figure 48D) showed an increase in K4me3 and a decrease in H3K27me3 in 
dysfunctional β-cells respectively.  Kcnq1-over-expression impairs GSIS285, and the over-
expression of Tcf7l2 exerted minor inhibitory effects on glucose-regulated changes in 




To see if a change in the chromatin state was associated with gene expression, I designed 
primers against these genes and looked at mRNA changes in normal and dysfunctional β-
cells. There was a decrease in the expression for most of the genes which had lower 
H3K4me3 in β-cells, e.g. Pdx1, NeuroD1, MafA, Ins1, Glut2, Snap25, Vamp2, Cacna1a,  
Chgb, Kirrel6.2, Sytl4, Stxbp1, Syt7 (Figure 49). There was a 3.5-fold increase in Ucp2 
mRNA levels too, consistent with the fact that hyperglycemia-induced mitochondrial 
superoxide production activates Ucp2, which decreases the ATP/ADP ratio and thus reduces 
the insulin-secretory response
262
. There was a 2-fold increase in the expression of Gcg and Sst 
(Figure 49) that were marked by increased H3K4me3 in dysfunctional β-cells. There was also 
a 2-fold increase in the T2DM-associated genes Kcnq1 and Tcf7l2 in dysfunctional β-cells 
(Figure 49).  
 
To summarize, in dysfunctional β-cells, there was a decrease in H3K4me3 at important β-cell 
genes that correlated with a decrease in gene expression, and increase in H3K4me3 and the 

























Figure 48. In dysfunctional β-cells, non- or lowly-expressed genes β-cell genes are marked by 
increased H3K4me3 levels and decreased H3K27me3 levels at their promoter.  H3K4me3 and 
H3K27me3 ChIP-Seq was performed in normal and dysfunctional NIT-1 cells and the presence or 
absence of these marks in important β-cell genes was visualized with the UCSC genome browser. (A) 





Figure 49. Genes important for normal β-cell function are expressed at lower levels in 
dysfunctional β-cells, while genes normally expressed at low levels in dysfunctional β-cells have 
increased gene expression. NIT-1 β-cells were treated with 20mM glucose and 0.4mM palmitate for 
48hr and RNA harvested from untreated and treated cells (n=4 each). Transcript levels of these genes 
were assayed by RT-PCR, mean values ± S.E. are plotted as fold change relative to the level of the 




































5.2.5.  DYNAMIC ASSOCIATION OF PDX1,  NEUROD1  AND MAFA  WITH CHROMATIN 
IN NORMAL AND DYSFUNCTIONAL BETA-CELLS  
 
There is a more open chromatin configuration in dysfunctional β-cells (Chapter 5.2.2.) and 
dysfunctional β-cells are more highly enriched in genes involved in general cellular regulatory 
activities and the specification of other developmental lineages (Chapter 5.2.3.). 
Dysfunctional β-cells also have reduced levels of H3K4me3 at transcription factors and other 
genes required for proper β-cell function, and increased H3K4me3 levels in some genes not 
normally expressed in β-cells (Chapter 5.2.4.), which mostly correlated with corresponding 
gene expression changes. In glucolipotoxic conditions, MafA expression is inhibited, whereas 
Pdx1 is affected at the post-translational level in its ability to translocate to the nucleus
280
. It is 
not known what effects high glucose and lipids have on the expression of NeuroD1, but 
Figure 51 shows that mRNA levels of NeuroD1 are reduced in the dysfunctional β-cells I 
generated, along with that of Pdx1 and MafA. I therefore hypothesized that chromatin 
remodelling in dysfunctional β-cells is in part brought about by the loss of key β-cell 
transcription factors, and that changes in that would affect chromatin states. 
 
To look at transcription factor association with H3K4me3 and H3K27me3 on a genome-wide 
scale, the surrounding regions (±5kb) of each TFBS were examined for the tag distribution of 
H3K4me3 and H3K27me3. For the co-occupancy of the transcription factors, the TFBSs that 
overlapped within 50bp were merged into a single peak. The numbers of H3K4me3 and 
H3K27me3 tags were counted according to the distance from the center of the TFBS and 
log10 transformed for modification level. The minimum modification level for H3K4me3 and 
H3K27me3 among the three TFBSs and co-occupied sites was taken and used as the basal 
level. Each modification level was normalized based on the basal level of H3K4me3 and 
H3K27me3 respectively. As Figure 50 shows, the Pdx1 (green), NeuroD1 (blue), MafA (red) 
are all highly marked by H3K4me3 in normal β-cells when compared to the low level of Pdx1 
(light green), NeuroD1 (light blue), MafA (yellow) TFBS marked with H3K27me3, 
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demonstrating that there is an open state of chromatin in normal β-cells when Pdx1, NeuroD1 
and MafA are bound.  
 
To explore this in greater detail, TFBS (±65bp from peak center) of either Pdx1, NeuroD1 and 
MafA were overlapped with promoters of genes (± 2kb from TSS) that are switched on or off 
in NIT-1 cells. This was to look at all the genes that are expressed in normal β-cells and 
seeing whether they would be switched on when either Pdx1, NeuroD1 or MafA are bound. 
There are a lot fewer genes that are switched off (15%) when any of these three transcription 
factors are bound, compared to the 45% genes that are switched off when none of them are 
bound (Figure 51). This indicates that transcription factor binding has an activating effect on 
gene expression.  
 
Interestingly, when the TFBS were overlapped with H3K4me3 and H3K27me3 in 
dysfunctional β-cells, there was a 2-fold increase in the levels of Pdx1 (light green), NeuroD1 
(light blue), MafA (yellow) and triply occupied (grey) TFBS associated with H3K27me3 
while levels of Pdx1 (green), NeuroD1 (blue), MafA (red) and triply occupied (black) TFBS 
associated with H3K4me3 remained at similar levels as those in normal β-cells, p values < 1e-
100 (Figure 52). To look at this from a different angle, Figure 52C shows that TFBS 
overlapped with H3K4me3 in normal and dysfunctional β-cells have similar levels of 
H3K4me3 modification, and Figure 52D shows that TFBS overlapped with H3K27me3 in 
normal and dysfunctional β-cells has a 2-fold higher level of H3K27me3 modification in 
dysfunctional β-cells.   
 
I hypothesized that the increase in the repressed chromatin state in dysfunctional β-cells that 
were associated with any of the three transcription factors would also have a decrease in gene 
expression, as H3K27me3 is an indicator of a repressive chromatin state. To this end, I ran a 
microarray on RNA extracted from normal and dysfunctional β-cells (n=4 each). Figure 53A 
shows that genes which had a TFBS and were marked by a increase in H3K27me3 in 
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dysfunctional β-cells also had a decrease in gene expression. This data is shown from another 
angle in Figure 53B, where dysfunctional β-cells show a higher H3K27me3 at the Pdx1 TFBS 
(p value = 3.7E-48), NeuroD1 TFBS (p value  = 5.8E-85) and MafA TFBS (p value = 3.4E-
85).  A full list of genes from the microarray is listed in Supplementary Table 9. 
 
This clearly indicates that the regions bound by these transcription factors in normal β-cells 
tend to have an increased level of H3K27me3 in dysfunctional β-cells, and this is associated 
with a decrease in gene expression. This is in contrast to the overall more open state of 
chromatin in dysfunctional β-cells, as shown by the increased levels of H3K4me3 and FAIRE 







Figure 50. Pdx1, NeuroD1 and MafA TFBS are enriched for H3K4me3 in normal β-cells. The 
surrounding regions (±5kb) of each TFBS were examined for the tag distribution of H3K4me3 and 
H3K27me3. The numbers of H3K4me3 and H3K27me3 tags were counted according to the distance 
from the center of the TFBS and then log10 transformed for modification level. The minimum 
modification level for H3K4me3 and H3K27me3 among the three TFBSs was used as the basal level. 
Each modification level was normalized based on the basal level of H3K4me3 and H3K27me3 






Figure 51. Transcription factor binding has an activating effect on gene expression in normal β-
cells. TFBS (±65bp from peak center) of either Pdx1, NeuroD1 and MafA were overlapped with 
promoters of genes (± 2kb from TSS) that are switched on or off in NIT-1 cells. (Gireesh Bogu 




(A)                                                                     (B) 
 
 
(C)                                                                           (D) 
 
 
Figure 52. Pdx1, NeuroD1 and MafA TFBS are enriched for H3K4me3 in normal β-cells and 
display increased levels of H3K27me3 in dysfunctional β-cells. TFBS were overlapped with 
H3K4me3 and H3K27me3 in dysfunctional β-cells and there was a 2-fold increase in the levels of Pdx1 
(light green), NeuroD1 (light blue), MafA (yellow) and triply occupied (grey) TFBS associated with 
H3K27me3 (B) while levels of Pdx1 (green), NeuroD1 (blue), MafA (red) and triply occupied (black) 
TFBS associated with H3K4me3 remained at similar levels as those in normal β-cells (A). To look at 
this from a different angle, (C) shows that TFBS overlapped with H3K4me3 in normal and 
dysfunctional β-cells have similar levels of H3K4me3 modification, and (D) shows that TFBS 
overlapped with H3K27me3 in normal and dysfunctional β-cells had a 2-fold higher level of 
H3K27me3 modification in dysfunctional β-cells (p values < 1E-100). N=normal β-cells, 











Figure 53. (A) Genes bound by either Pdx1, NeuroD1 or MafA that were marked by a increase in 
H3K27me3 in dysfunctional β-cells also had a decrease in gene expression. (B)  H3K27me3 levels 
at the TFBS in the dysfunctional (sick) and normal β-cells. Dysfunctional β-cells show a higher 
H3K27me3 at the Pdx1 TFBS (p value 3.7E-48), NeuroD1 TFBS (p value p = 5.8E-85) and MafA 





I wanted to look in greater detail at the network of genes bound by each transcription factor 
that was associated with H3K27me3 in dysfunctional β-cells. The transcription factor ChIP-
Seq peaks that overlapped with H3K27me3-ChIP-Seq in dysfunctional β-cells were imported 
into IPA. Networks associated with its biological, molecular and cellular function, 
physiological system development and function were generated. 
 
Genes bound by Pdx1 in normal β-cells and showing an increase in H3K27me3 in 
dysfunctional β-cells were enriched in amino acid and carbohydrate metabolism, cell cycle, 
digestive system development and cellular activities such as molecular transport, RNA 
trafficking, damage and repair (Table 12). Genes bound by NeuroD1 in normal β-cells and 
showed an increase in H3K27me3 in dysfunctional β-cells were enriched in general cellular 
activities, endocrine development and function, embryonic and hematological development, 
and amino acid metabolism (Table 13). Genes bound by MafA in normal β-cells and showed 
an increase in H3K27me3 in dysfunctional β-cells were enriched in molecular transport, DNA 
replication, RNA post-transcriptional modification, gastrointestinal disease, cellular and 
embryonic development, cell signaling, cell cycle and cell death (Table 14). A full list of 
genes involved in each of those networks, pathways and functions is listed in Supplementary 
Table 10. 
 
Taking into account there was reduced expression of Pdx1, NeuroD1 and MafA in 
dysfunctional β-cells, I have shown that the H3K27me3-marked genes (that have a TFBS) in 
dysfunctional β-cells are enriched for genes involved in metabolic and general cellular 




Associated Network Functions Network Score 
 Amino Acid Metabolism, Drug Metabolism, Molecular Transport 34 
 Carbohydrate Metabolism, Small Molecule Biochemistry, Cell Cycle 34 
 Cell Cycle, Organismal Functions, Cellular Assembly and Organization 31 
 Behavior, Digestive System Development and Function, Cell Signaling  31 
 Molecular Transport, RNA Trafficking, RNA Damage and Repair 31 
 
   Diseases and Disorders p-value # Molecules 
Endocrine System Disorders  1.88E-34 711 
Gastrointestinal Disease  1.88E-34 953 
Genetic Disorder  1.88E-34 1730 
Metabolic Disease  1.88E-34 801 
Neurological Disease  5.17E-23 1056 
   Molecular and Cellular Functions p-value # Molecules 
Gene Expression  1.07E-16 565 
Cell Cycle  1.20E-15 407 
Cell Death  2.28E-13 763 
Cellular Growth and Proliferation 1.30E-10 809 
Cellular Development  1.24E-08 671 
   Physiological System Development and Function p-value # Molecules 
Organismal Development  1.59E-12 340 
Organismal Survival  4.33E-12 332 
Embryonic Development 2.60E-10 249 
Nervous System Development and Function  1.12E-07 497 
Organ Development 8.47E-07 288 
  
Table 12 Top biological networks and pathways associated with Pdx1 binding sites that are 
marked by H3K27me3 in dysfunctional β-cells. 
Pdx1 ChIP-Seq peaks were identified with MACS and overlapped with H3K27me3-ChIP-Seq in 
dysfunctional β-cells, and IPA was used to generate this list of networks associated with its biological, 
molecular and cellular function, physiological system development and function. The score is a 
numerical value used to rank networks according to their degree of relevance to the network eligible 




Associated Network Functions  Network Score 
 Cell Morphology, Cellular Growth and Proliferation, Hematological 
System Development and Function 39 
 Endocrine System Development and Function, Cell Morphology, Small 
Molecule Biochemistry 36 
 Cellular Development, Embryonic Development, Tissue Development 34 
 Hematological System Development and Function, Hematopoiesis, 
Tissue Morphology 34 
 Amino Acid Metabolism, Small Molecule Biochemistry, DNA 
Replication, Recombination, and Repair 34 
 
   Diseases and Disorders p-value # Molecules 
Genetic Disorder 2.62E-54 1405 
Endocrine System Disorders  1.49E-48 609 
Gastrointestinal Disease  1.49E-48 850 
Metabolic Disease  1.49E-48 667 
Neurological Disease  6.50E-44 894 
   Molecular and Cellular Functions p-value # Molecules 
Cell Death 9.60E-12 578 
Cellular Development 2.36E-11 517 
Cellular Assembly and Organization  2.41E-10 264 
Cell Morphology 1.05E-09 293 
Cellular Growth and Proliferation 2.30E-09 595 
   Physiological System Development and Function p-value # Molecules 
Tissue Development  1.87E-10 341 
Organismal Survival  1.18E-09 209 
Nervous System Development and Function  1.84E-09 403 
Behavior 2.27E-08 168 
Organ Development  2.35E-08 211 
 
Table 13. Top biological networks and pathways associated with NeuroD1 binding sites that are 
marked by H3K27me3 in dysfunctional β-cells. 
NeuroD1 ChIP-Seq peaks were identified with MACS and overlapped with H3K27me3-ChIP-Seq in 
dysfunctional β-cells, and IPA was used to generate this list of networks associated with its biological, 
molecular and cellular function, physiological system development and function. The score is a 
numerical value used to rank networks according to their degree of relevance to the network eligible 




Associated Network Functions Network Score 
 Molecular Transport, Protein Trafficking, DNA Replication, 
Recombination, and Repair 34 
 RNA Post-Transcriptional Modification, Gastrointestinal Disease, 
Genetic Disorder 34 
 Cellular Development, Embryonic Development, Tissue Development 32 
 Cell Signaling, Auditory Disease, Dermatological Diseases and 
Conditions 32 
 Cell Cycle, DNA Replication, Recombination, and Repair, Cell Death 32 
 
   Diseases and Disorders p-value # Molecules 
Genetic Disorder  1.38E-59 1819 
Endocrine System Disorders  3.22E-50 759 
Gastrointestinal Disease 3.22E-50 1092 
Metabolic Disease  3.22E-50 846 
Neurological Disease 2.18E-46 1137 
   Molecular and Cellular Functions p-value # Molecules 
Cell Death  3.58E-13 760 
Gene Expression  6.65E-13 538 
Cellular Development 1.02E-10 660 
Cellular Assembly and Organization  5.24E-10 357 
Cellular Growth and Proliferation 8.78E-10 777 
   Physiological System Development and Function p-value # Molecules 
Cell-mediated Immune Response 5.02E-07 161 
Hematological System Development and Function 5.02E-07 248 
Hematopoiesis  6.02E-07 217 
Nervous System Development and Function  1.08E-06 485 
Behavior  1.25E-06 202 
 
Table 14. Top biological networks and pathways associated with MafA binding sites that are 
marked by H3K27me3 in dysfunctional β-cells. 
MafA ChIP-Seq peaks were identified with MACS and overlapped with H3K27me3-ChIP-Seq in 
dysfunctional β-cells, and IPA was used to generate this list of networks associated with its biological, 
molecular and cellular function, physiological system development and function. The score is a 
numerical value used to rank networks according to their degree of relevance to the network eligible 




5.2.6.  B IVALENCY I N THE NORMAL AND DYSFUNCTIONAL BETA-CELL  
 
Bivalent chromatin contains both activating and repressive marks in the same area. Activating 
chromatin modifications increase the accessibility of the chromatin to RNA polymerase, 
where repressing modifications decrease the accessibility to RNA polymerase. Usually, these 
do not both occur at the same location, as it seems they would have opposing effects; 
however, they are both present in bivalent chromatin. The repressing modifications usually 
take precedence, causing the gene to become inactivated. Once the repressing modifications 
are removed however, the activating modifications attract transcription machinery, and the 
gene becomes activated. Bivalent chromatin was first identified in embryonic stem cells and 
they were proposed to serve a role in genetic imprinting and in development
137
.  Bivalent 
domains are also found in other cell types, e.g. mouse embryonic fibroblasts, neural 
progenitors
138
 and human T cells
139
. A recent comparison of H3K4me3 and H3K27me3 in 
islets show that these bivalent domains are usually mutually exclusive or absent, but there are 
few genes that had high levels of both marks, e.g. the Hox gene clusters and neuronal 
transcription factors, perhaps indicating a retention of “memory” of earlier transcription or the 
re-activation of these genes under certain metabolic conditions
140
. Therefore I hypothesized 
that bivalent domains exist in β-cells and not only in islets that comprise of other endocrine 
cell types, and that some of these bivalent domains would change in dysfunctional β-cells, 
possibly affecting its impaired ability to secrete insulin in response to a glucose stimulus.  
 
There were 5288 bivalent genes in normal β-cells, and of those, 693 genes lost the H3K27me3 
mark in dysfunctional β-cells, while 38 genes lost the H3K4me3 mark in dysfunctional β-
cells. A full list of bivalent genes thus marked is available in Supplementary Tables 11A-C. 
This is consistent with the fact that there was an increase in the numbers of H3K4me3 and 
FAIRE peaks, and decrease in the global numbers of H3K27me3 peaks in dysfunctional β-
cells. As there was such a high number of bivalent genes in normal β-cells that lost the 
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H3K27me3 mark in dysfunctional β-cells compared to those that lost the H3K4me3 mark in 
dysfunctional β-cells, I wanted to know how similar or different these genes were in terms of 
their biological function, when compared to the bivalent genes identified in normal β-cells. 
The RefSeq identity list of nearest associated bivalent genes indentified in normal β-cells, 
together with the nearest associated bivalent genes in normal β-cells that had lost H3K27me3 
in dysfunctional β-cells, was uploaded into IPA187. The top biological networks and cellular 
processes and functions associated with them were identified, and I utilized the comparison 
function in IPA to compare these two datasets.  
 
Strikingly, there was a much higher over-enrichment for bivalent genes in normal β-cells that 
were involved in many aspects of developmental processes when compared to bivalent genes 
in normal cells that had lost the H3K27me3 in dysfunctional β-cells, e.g. organ, cellular, 
tissue, embryonic, nervous system, connective, skeletal development (Figure 54). There was 
also a higher enrichment for genes involved in disorders in the same list, e.g. genetic, 
neurological, skeletal and muscular, cardiovascular, connective tissue, developmental, 
inflammatory, gastrointestinal, immunological, physiological, and metabolic diseases. A full 
list of genes involved in these pathways is listed in Supplementary Table 12. I did not 
compare the 38 bivalent genes in normal β-cells that had lost the H3K4me3 mark in 
dysfunctional β-cells because there were too few genes in that list to yield a statistically 
significant result. 
 
Taken together, this suggests that genes that are bivalently marked in normal β-cells are more 
involved in developmental processes and cell regulatory processes, compared to genes that are 








Figure 54. Genes that are bivalently marked in normal β-cells are more involved in 
developmental processes and cell regulatory processes, compared to genes that are bivalently 
marked in normal β-cells and have lost the repressive H3K27me3 mark in dysfunctional β-cells. 
Normal=normal β-cells, S=dysfunctional β-cells.  
 
199 
For a more rigorous analysis of the H3K4me3 and H3K27me3 overlaps, the H3K4me3 and 
H3K27me3 peaks were overlapped and the genes containing those peaks were identified. This 
is in contrast to the above-mentioned overlaps of genes containing both H3K4me3 and 
H3K27me3, as that did not guarantee that the peaks were actually overlapping, just that the 
genes had to contain both H3K4me3 and H3K27me3 peaks. With the more stringent method 
of analysis, there were 113 bivalent genes in normal β-cells, with 16 genes losing the 
H3K4me3 mark (i.e. 16 genes with lower H3K4me3 mark in dysfunctional β-cells) and 98 
genes losing the H3K27me3 mark in dysfunctional β-cells. A full list of bivalent genes with 
peak overlaps is available in Supplementary Table 11D. This trend is similar to what is 
observed when the less stringent H3K4me3 and H3K27me3 overlaps were used.  
 
The developmental Hox gene cluster was bivalently marked (Figure 55), as identified by a 
group who profiled H3K4me3 and H3K27me3 in human pancreatic islets
140
. H3K4me3 levels 
in the Hox gene cluster were slightly increased and H3K27me3 levels slightly decreased in 
dysfunctional β-cells when compared to normal β-cells. Bivalent genes in normal β-cells that 
lost H3K27me3 in dysfunctional β-cells include those involved in pancreatic development 
and/or function, e.g MafB, Oxidation resistance (Oxr)-1, Calcium/calmodulin-dependent 
protein kinase (Camk)-2b, miR-9, SRY (sex determining region Y)-box (Sox)-17 (Figure 56A-
E); genes involved in neuronal development and function, e.g. Semaphorin (Sema)-3d and 
Cadherin EGF LAG seven-pass G-type receptor (Celsr)-1 (Figure 56F, G); and members of 
the Fox family transcription factors e.g. Foxq1 and Foxf2 (Figure 56H, I). The potassium 
channel Potassium voltage-gated channel Shaw-related subfamily member (Kcnc)-1 is also 
bivalently marked in β-cells (Figure 56J). Of great interest is the T2DM-identified potassium 
channel Kcnq1 (Figure 58A).   
 
There was an increase in the levels of H3K4me3 and decrease in H3K27me3 at the MafB gene 
in dysfunctional β-cells (Figure 56A), however this did not correlate with levels of gene 
expression, which remained the same as in normal β-cells (Figure 57). In embryos, MafB is 
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expressed before MafA, and the differentiation of β-cells proceeds through a MafB+ MafA- 








. Furthermore, the MafB to MafA transition 
follows induction of Pdx-1 expression in MafB
+
 Ins+ cells, suggesting that MafB may have a 
dual role in regulating embryonic differentiation of both α- and β-cells while MafA regulates 
replication/survival and function of β-cells after birth70. Within the adult pancreas, MafB is 
only expressed in islet α-cells and contributes to cell type–specific expression of the Gcg 
gene
287
. The fact that the chromatin environment around the MafB gene in normal β-cells was 
bivalently marked in normal β-cells, and that there was a shift towards a more permissive and 
open chromatin state in dysfunctional β-cells is extremely interesting. Perhaps this is the 
chromatin signature of a gene that was required for earlier embryonic development and not in 
the mature β-cell, but it still retained the epigenetic memory of its earlier expression, and is 
poised to “revert” back to its previous cellular state should an appropriate stimulus occur. 
However, it is important to note that this shift towards a more open chromatin state did not 
lead to an increase in MafB gene expression (despite there being a 2-fold increase in the 
glucagon gene expression in dysfunctional β-cells (Figure 49), suggesting that 
glucolipotoxicity is merely triggering a change in chromatin environment at the MafB gene, 
perhaps allowing for the possibility for transcriptional activators to bind and mediate changes 
in gene expression, should additional/ prolonged stimulus occur.  
 
There was an increase in H3K4me3 and decrease in H3K27me3 at the Oxr1 gene in 
dysfunctional β-cells (Figure 56B), and this was coupled with a 2.2-fold increase in gene 
expression (Figure 57). Oxr1 is the receptor for Orexin A (Oxa), and Oxa plays a critical role 
in the regulation of sleep/wake states, feeding behaviour, reward processes and the regulation 
of food intake in a dose-dependent fashion
288
. Oxa increases food intake in rodents, and 
fasting activates Oxa neurons in both the lateral hypothalamic area and gut
288
. Oxa is also 
present in the pancreas, and depolarizing stimuli evoke the release of Oxa from rat pancreatic 
islets in a calcium-dependent manner, causing an increase in glucagon secretion and reducing 
insulin secretion
289
. Oxr1 co-localizes with insulin β-cells and glucagon α-cells in normal rats, 
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and the incidence of Oxr1-expressing cells in diabetic rats treated with streptozotocin was 
significantly increased, along with an increased co-localization with glucagon-expressing 
cells
290
. In the context of Oxr1 being bivalently marked in normal β-cells and having a more 
open chromatin state in dysfunctional β-cells that correlated with an increase in Oxr1 mRNA 
levels, and taking into account Gcg gene expression increases 2-fold in dysfunctional β-cells 
while Ins1 expression decreases 40% (Figure 49), this suggests that the mechanism of 
chromatin opening at the Oxr1 gene could be in part responsible for the decrease in insulin 
secretion and the increase in Gcg expression in diabetic rats. 
  
There was an increase in H3K4me3 in dysfunctional β-cells and concomitant decrease in 
H3K27me3 at the Camk2b gene (Figure 56C), and there was also a 2-fold increase in mRNA 
levels of Camk2b (Figure 57). Camk2b activity is required to induce MafA expression under 
high glucose conditions
291
, and this is consistent with the fact that dysfunctional β-cells were 
exposed to a higher glucose concentration (20mM) than normal β-cells (7mM). MafA mRNA 
expression was reduced in dysfunctional β-cells (Figure 49), indicating that this modest 
increase in Camk2b expression was not sufficient to combat the overall effects that 
glucolipotoxicity had on MafA expression.  
 
miR-9 displays higher H3K4me3 in dysfunctional β-cells (Figure 56D). This is consistent with 
the fact that miR-9 reduces exocytosis in GSIS via diminishing the expression of Onecut-2, 
which in turn increases the level of Granuphilin
292
. Granuphilin is a Rab-GTPase effector 
associated with β-cell secretory granules and negatively affects insulin release. miR-9 also 
targets and reduces Sirtuin (Sirt)-1 expression in insulin-secreting cells
293
. Sirt1 positively 
regulates insulin secretion in pancreatic β-cells by repressing the Ucp2 gene294. Therefore it is 





Sox17 is also bivalently marked in normal β-cells (Figure 56E), with low levels of H3K4me3 
and higher levels of H3K27me3. There is a very slight decrease in levels of H3K27me3 in 
dysfunctional β-cells, but that did not correlate with changes in gene expression (Figure 57). 
Sox17 is a transcription factor required for the normal development of the definitive gut 
endoderm 
295
 and physically interacts with β-catenin (a component of the Wnt-signalling 
pathway) in order to potentiate its transcriptional activation of its target endodermal genes
296
. 
It is uncertain whether it is expressed in the adult mouse pancreas
297,298
, and is very lowly 
expressed in NIT-1 normal and dysfunctional β-cells.  Sox17 is bivalently marked in human 
ESCs and upon hESC differentiation, expression of Sox17 in definitive endoderm cells 
appears to be activated by demethylation of histone H3K27, while suppression of Sox17 in 
hepatocytes seems to be modulated by the methylation of H3K27
299
. Perhaps bivalency of 
Sox17 in β-cells is a remnant of its earlier bivalent state in ESCS, and though there was no 
noticeable change in the chromatin environment around Sox17 in dysfunctional β-cells, 
perhaps additional/ prolonged stimulus is needed for an appreciable change at the Sox17 gene 
locus.  
 
There is an increase in H3K4me3 at the Sema3d gene in dysfunctional β-cells and a decrease 
in H3K27me3 (Figure 56F), which was accompanied by a 2.4-fold increase in gene 
expression (Figure 57). Sema3d induces the collapse and paralysis of neuronal growth cones, 
and could potentially act as repulsive cues toward specific neuronal populations
300
. Another 
neural gene Celsr1 was also bivalently marked in normal β-cells and had an increase in 
H3K4me3 and decrease in H3K27me3 in dysfunctional β-cells (Figure 56G). However, this 
increase in open chromatin configuration resulted in a 40% decrease in Celsr1 gene 
expression in dysfunctional β-cells (Figure 57). Celsr1 is a neural gene involved in cell 
signalling during nervous system formation
301
.  Taken together, it appears that increase in 





There was also an increase in H3K4me3 in Foxq1 and a slight decrease in H3kK27me3 in 
dysfunctional β-cells (Figure 56H), this was accompanied by a 1.8-fold increase in Foxq1 
mRNA (Figure 57). Like other members of the Fox family that are involved in embryonic 
development, cell cycle regulation, tissue-specific gene expression, cell signaling, and 
tumorigenesis, Foxq1 is expressed in the visceral endoderm during development
302
 and  is 
over-expressed in colorectal cancers and enhances tumorigenicity and tumor growth 
presumably through its angiogenic and antiapoptotic effects
303
. Foxq1 is also over-expressed 
in pancreatic cancer
304
. Foxf2 was also bivalent marked in normal β-cells and had an increased 
H3K4me3 in dysfunctional β-cells (Figure 56I). However, there was an increase in the levels 
of H3K27me3 in dysfunctional β-cells too, with slight increases in gene expression (Figure 
57). Foxf2 is expressed during development in the mesodermal tissues involved in epithelio-
mesenchymal interactions, and in the central nervous system, eye, ear, and limb buds
305
. 
Taken together, it suggests that genes bivalent marked in normal β-cells that are involved in 
specifying other developmental lineages have a more open chromatin configuration in β-cell 
dysfunction.  
 
Kcnc1 is bivalently marked (Figure 56J) in normal β-cells, with a decrease in H3K4me3 and 
increase in H3K27me3 in dysfunctional β-cells, which correlates with a 55% decrease in gene 
expression (Figure 57). Kcnc1 mediates the voltage-dependent K
+
 permeability of excitable 
membranes
306
. This suggests β-cell dysfunction leads to a more repressive chromatin 
environment around the Kcnc1 gene, resulting in a decrease in gene expression. 
 
Kcnq1 is bivalently marked at its promoter (Figure 58A), and there is an increase in 
H3K4me3, which is accompanied by a 2-fold increase in Kcnq1 mRNA expression levels 
(Figure 57). Kcnq1 is a voltage-gated potassium channel and is involved in repolarizing 
cardiac tissue following an action potential, and transporting water and salts in tissues
307
. 
Variants in KCNQ1 are associated with susceptibility to T2DM in the Korean, Chinese and 
European population
308
 and variants in KCNQ1 predicts future T2DM in Scandinavian 
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populations, possibly by mediating impaired insulin secretion
309
. When Kcnq1 was over-
expressed in mouse insulinoma MIN-6 cells, both the density of the Kcnq1 current and the 
density of the total K
+
 current were significantly increased. In addition, insulin secretion by 
glucose, pyruvate, or tolbutamide was significantly impaired, suggesting that increased Kcnq1 
protein expression limits insulin secretion from pancreatic β-cells by regulating the potassium 
channel current
285
. Taken together, it appears Kcnq1 is bivalently marked in normal β-cells 
and changes in the chromatin environment around its promoter leads to an increase in gene 
expression, thereby contributing to reduce GSIS in dysfunctional β-cells.  
 
Very interestingly, KCNQ1 is located in an imprinted gene cluster at the telomeric end of 
mouse chromosome 7 which contains a differentially methylated CpG island, KvDMR. 
KvDMR is required for the imprinting of multiple genes, including the genes encoding the 
maternally expressed placental-specific transcription factor Ascl2, the cyclin-dependent kinase 
Cdk1n1c, and Kcnq1. KvDMR maps within the intron of Kcnq1 and contains the promoter for 
a paternally expressed 91kb non-coding (nc) antisense transcript Kcnq1ot, which plays a 
direct role in silencing the multiple mRNAs genes in the Kcnq1-imprinted gene cluster
310
. 
Kcnq1ot interacts with the Polycomb repressive complex 2 and with the H3K9-specific 
methyltransferase G9a, and its expression coincides with the assembly of repressive chromatin 




Kcnq1ot has a decreased H3K4me3 peak in dysfunctional β-cells when compared to normal β-
cells (Figure 58B). Perhaps one model by which Kcnq1 is being regulated in dysfunctional β-
cells is that the presence of a more repressive chromatin environment surrounding Kcnq1ot 
reduces transcription of the Kcnq1ot ncRNA, which in turn leads to a reduced repression of 
the Kcnq1 gene by creating a more open chromatin state, thereby resulting in an increase in 




In summary, bivalent marks in normal β-cells are present at genes regulating pancreatic and 
neuronal development and/or function, and potassium channels that mediate ion permeability. 
This bivalent state is modified in dysfunctional β-cells and results in gene expression changes 







Figure 55. The Hox gene cluster is bivalently marked by H3K4me3 and H3K27me3 levels in 










































































Figure 56. In dysfunctional β-cells, bivalent genes regulating pancreatic development and/or 
function, neuronal and other developmental lineages, and ion channels, are marked by changes in 
H3K4me3 and H3K27me3 at the promoter. Bivalent genes in normal β-cells that lost H3K27me3 in 
dysfunctional β-cells include those involved in pancreatic development and/or function, e.g (A) MafB, 
(B) Oxr1, (C) Camk2b, (D) miR-9, (E) Sox17; genes involved in neuronal development and function, 
e.g. (F) Sema3d and (G) Celsr1; members of the Fox family transcription factors (H) Foxf2 and (I) 





Figure 57. Expression of bivalent genes regulating pancreatic development and/or function, 
neuronal and other developmental lineages, and ion channels are changing in dysfunctional β-
cells. NIT-1 β-cells were treated with 20mM glucose and 0.4mM palmitate for 48hr and RNA harvested 
from untreated and treated cells (n=4 each). Transcript levels of these genes were assayed by RT-PCR, 
mean values ± S.E. are plotted as fold change relative to the level of the corresponding gene expression 











Figure 58. Kcnq1 (a) and Kcnq1ot (b) have opposing bivalent marks in normal β-cells that change 








5.3.  DISCUSSION  
 
5.3.1.  CHROMATIN REMODELLING IN RESPONSE TO BETA-CELL DYSFUNCTION  
 
Epigenetic changes are associated with physiological dysfunction due to environmental 
stimuli. Histone methylation is significantly increased in non-transcribed regulatory regions 
near or within human Type 1 Diabetes susceptibility regions, including loci containing the 
gene for CLTA4 and genes in inflammation-associated pathways
312
.  The activation of β-cell 
genes requires an appropriate euchromatin DNA template characterized by hyper-methylation 
of H3K4, maintained by the HMT Set7/9
162
.Therefore, I hypothesized that there would be 
chromatin remodelling in β-cells in response to a glucolipotoxic stimulus that impairs its 
ability to secrete insulin in response to glucose.  
 
There was a global increase of chromatin opening in dysfunctional β-cells, as indicated by the 
increase in numbers of FAIRE and H3K4me3 peaks at the promoters of genes, and a decrease 
in H3K27me3 at the promoters of genes in dysfunctional β-cells (Table 10). Motif analysis of 
FAIRE peaks in normal and dysfunctional β-cells showed that there was a bias for binding 
sites for general transcription factors like SP-1, CTCF, NF-Y (Table 11). SP-1 belongs to a 
family of ubiquitously expressed, C2H2-type zinc finger-containing DNA binding proteins that 
activate or repress transcription of many genes in response to physiological and pathological 
stimuli
313
. There is emerging evidence to indicate that in addition to functioning as a 
'housekeeping' transcription factor, Sp1 may mediate nuclear signaling in response to 
hormones such as insulin
314
. CTCF plays many roles in transcriptional repression, insulator 
function, and imprinting genetic information
315
. NF-Y is a ubiquitous transcription factor 
involved in the activation of most promoters
316
. Motifs for FAIRE peaks in normal β-cells 
showed enrichments for tissue-specific transcription factors like FoxA1 and FoxA2, Oct2 and 
Oct4, and Pdx1 (Table 11). FoxA1 and FoxA2 are important for pancreatic function, with 
FoxA1
-/-
 islets exhibiting decreased GSIS and reduced pancreatic insulin and glucagon 
content
317
. FoxA2 is important in pancreatic development and function, and regulates many 
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genes involved in maintaining the mature β-cell phenotype62. FoxA1 and FoxA2 co-occupy 
multiple regulatory domains in the Pdx1 gene, and ablation of both Foxa1 and Foxa2 in the 
pancreatic primordium results in complete loss of Pdx1 expression and severe pancreatic 
hypoplasia
318
. Oct2 was originally described in cells of the immune system, and plays a 
regulatory role in the neuro-endocrine brain
319
. Oct4 is a key regulator of pluripotency in 
embryonic stem cells
320
, and high expression of Oct4 and Nanog homeobox (Nanog) in 
metaplastic pancreatic ducts (with Oct4 expression preceding Ras mutation) suggests that 
these homeobox transcription factors are associated with the early stage of pancreatic cancer 
carcinogenesis and may play an important role in that process
321
. The Usf1 motif was one of 
the top 20 motifs identified in the normal β-cell FAIRE datasets. Usf1 and NeuroD1 
contribute to islet-specific glucose-6-phosphatase catalytic-subunit-related protein (IRGP) 
gene expression in islets
110
. Taken together, this data shows that in dysfunctional β-cells, open 
chromatin is biased to binding sites for general transcription factors; in normal cells, tissue-
specific TFBS tend to show a more open chromatin configuration. Comparison of the genes 
associated with the respective epigenetic marks in normal and dysfunctional β-cells 
demonstrated that there is a significant increase in genes involved in cellular regulatory 
activities and the specification of other developmental lineages in dysfunctional β-cells 
(Figures 44-6). 
 
To summarize, I have shown that important genes in normal β-cells are marked by active 
chromatin marks, and there is global chromatin remodelling when β-cells become 
dysfunctional, which results in an opening in the chromatin at genes involved in cellular 




5.3.2.  CHROMATIN AND TRANS CRIPTIONAL DYNAMICS IN DYSFUNCTIONAL BETA-
CELLS   
 
Genes important for β-cell function are marked by H3K4me3 in their promoters in normal β-
cells, e.g. Pdx1, NeuroD1, MafA, Ins1, Glut2, Snap25, Vamp2, Cacna1a, Chgb, Kirrel6.2, 
Sytl4, Stxbp1, and Syt7 (Figure 47). This is in stark contrast to two prior studies of H3K4me3 
ChIP-Seq in human pancreatic islets, where the authors did not find the H3K4me3 mark in 
highly expressed genes in islets, including those encoding islet-specific hormones Ins, Gcg, 
Sst, Iapp, Ppy and Ttr
140,179
.  This prompted the authors to speculate that some genes critical 
for islet function have an unconventional promoter chromatin signature, indicative of a unique 
transcriptional control mechanism
176
. However, the fact that there were positive enrichments 
for H3K4me3 at so many important β-cell genes in my study does not support their 
conclusion. Perhaps this is due to species differences - they used pancreatic human islets 
while I used mouse insulinoma cell lines. The fact they used whole pancreatic islets from 
cadaveric donors (islets are extremely fragile and sensitive to external manipulation, and islet 
harvesting is a laborious process that triggers a cascade of stressful events involving activation 
of apoptosis and necrosis and the production of pro-inflammatory molecules that negatively 
influence islet yield and function)
322
 might have also compounded the results. β-cell paucity of 
their samples might have also contributed to their conflicting results, and there is 
heterogeneity when using whole islets that contain α, β, δ, ε, and PP cells.  
 
Under glucolipotoxic conditions in DIO models
168
 and cell culture conditions mimicking 
diabetes
169
, MafA expression is inhibited, whereas Pdx1 is affected at the post 
posttranslational level in its ability to translocate to the nucleus
280
, resulting in decreased 
Insulin gene expression. It is not known what effect glucolipotoxic conditions have on 
NeuroD1, but I have shown there is a decrease in mRNA levels of all three transcription 
factors in dysfunctional β-cells (Figure 49). Glucotoxicity and lipotoxicity leads to the 
production of ROS, which activate Mitogen-activated protein kinase 8 (Jnk), resulting in a 
decrease in Insulin receptor substrate (Irs) signalling, which may directly be involved in 
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decreased Pdx1 activity by translocation from the nucleus to the cytoplasm
323
. Glucose and 
FFA also induce ER stress, while chronic glucose elevation inhibits FFA oxidation and favors 
the generation of ceramide and lipid partitioning, which also results in β-cell dysfunction324.  
 
Genes bound by Pdx1, NeuroD1 and MafA in normal β-cells are associated with H3K4me3, 
not H3K27me3 (Figure 50). There is an increase in the association of these transcription 
factors with H3K27me3 in dysfunctional β-cells and a corresponding decrease in gene 
expression (Figure 52). Taking into account there was reduced expression of Pdx1, NeuroD1 
and MafA in dysfunctional β-cells (Figure 49), the H3K27me3-marked genes (that have a 
TFBS) in dysfunctional β-cells are enriched for genes involved in metabolic and general 
cellular regulatory processes (e.g. cell cycle, cell signalling) (Tables 12-14). In the case of 
Pdx1, where there also is (in theory) reduced Pdx1 translocation to the nucleus, the increase in 
H3K27me3 of its target genes could also be due to the presence of less Pdx1 in the nucleus.  
 
Taken together, two things are happening: Transcriptional activity of Pdx1, NeuroD1 and 
MafA are reduced, and so are those of their target genes. The former is due to the high glucose 
and fatty acid conditions leading to epigenetic changes in their promoters (as evidenced by 
reduced H3K4me3 levels at the Pdx1, NeuroD1 and MafA promoters in dysfunctional β-cells, 
Figure 47). The latter has two possible explanations: As a consequence of treatment with high 
glucose and fatty acids, there is a decrease in the level of the active H3K4me3 mark at the 
promoters of Pdx1, NeuroD1 and MafA, leading to their decrease in gene activity. This then 
directly leads to epigenetic changes in the promoters of their target genes, resulting in changes 
in gene expression. The second possibility is that conditions of high glucose and fatty acids 
lead to epigenetic changes at the promoters of Pdx1, NeuroD1 and MafA target genes, on top 
of epigenetic changes at the promoters of those three transcription factors, resulting in changes 
in gene expression. The experiments I have performed cannot distinguish between these two 
possible scenarios. However, since chomratin modifiers are usually not sequence-specific, and 
that Pdx1, NeuroD1 and MafA interact with HATs, HMTs and HDACs in order to maintain 
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the expression of Insulin and other genes, it is unlikely that chromatin modifiers would target 
specific gene sets. Hence, the first scenario is more likely.  
 
I therefore propose a model in which glucolipotoxic conditions lead to increase in ROS and 
other metabolic changes that result in a reduced H3K4me3 mark at the Pdx1, NeuroD1 and 
MafA genes and correspondingly lower mRNA levels in dysfunctional β-cells. This in turn 
leads to chromatin remodelling at the promoters of their target genes, resulting in changes in 
gene expression that ultimately affect β-cell function. This is similar to the model that is 
proposed to occur in IUGR rodents, where a cascade of epigenetic events is triggered by 





ChIPs for these transcription factors can be performed in dysfunctional β-cells, and if reduced 
levels of binding are seen when compared to normal cells, it would lend support to the model I 
have proposed. There are several other important transcription factors involved in maintaining 
the mature β-cell phenotype, e.g. FoxA2, Hnf4α; these also interact with chromatin modifiers 
to modulate gene expression
325
. Therefore, ChIPs for those transcription factors could be 
performed in normal and dysfunctional β-cells, to see if a similar form of regulation is 
occurring. ChIPs of other epigenetic marks and/or HATs/ HMTs/ HDACs can also be 
performed under varying conditions of glucolipotoxicity, in order to tease apart the 
mechanistic effects underlying β-cell dysfunction. DNA methylation at the promoters of 
important β-cell genes can analyzed to shed light on how DNA methylation and histone 
modification co-operate to modulate changes in gene expression. These experiments can also 
be performed in DIO animals or human pancreatic islets from normal and diabetic patients, to 
see if similar changes are observed in vivo. 
 
5.3.3.  B IVALENT STATES IN NORMAL AND DYSFUNCTIONAL BETA-CELLS   
 
Bivalent opposing marks are associated with low levels of expression in pluripotent cells, but 
these resolve into monovalent methylation marks during ESC differentiation. Bivalent genes 
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in ESCs are mostly transcription factors, hence the notion that bivalent marks silence genes in 
ESCs, priming them for activation upon differentiation
137
. Bivalent domains are also found in 
other cell types, e.g. mouse embryonic fibroblasts, neural progenitors
138
 and human T cells
139
. 
A recent comparison of H3K4me3 and H3K27me3 in human pancreatic islets show that these 
bivalent domains are usually mutually exclusive or absent, but there are a few genes that had 
high levels of both marks, e.g. the Hox gene clusters and neuronal transcription factors, 
perhaps indicating a retention of “memory” of earlier transcription or the re-activation of these 
genes under certain metabolic conditions
140
. Bivalent marks have also been described to co-
exist with methylated DNA in the promoter regions of human cancer cells, suggesting that 
aberrant de novo DNA methylation that commonly accompanies cancer-related genes could 




When H3K4me3 and H3K27me3 overlapping peaks in normal and dysfunctional β-cells were 
analyzed, there were 113 bivalent genes in normal β-cells. There were 16 genes with lower 
H3K4me3 mark in dysfunctional β-cells and 98 genes with a lower H3K27me3 mark in 
dysfunctional β-cells. This is consistent with the fact that there was an increase in the numbers 
of H3K4me3 and FAIRE peaks, and decrease in the global numbers of H3K27me3 peaks in 
dysfunctional β-cells. Genes that are bivalently marked in normal β-cells are more enriched 
for in developmental processes and cell regulatory processes, compared to genes that are 
bivalently marked in normal β-cells and have lost the repressive H3K27me3 mark in 
dysfunctional β-cells (Figure 54).  
 
Some examples of bivalent genes in normal β-cells that have reduced levels of H3K4me3 
and/or increased levels of H3K27me3 in dysfunctional β-cells include genes involved in 
pancreatic development and/or function, e.g. MafB, Oxr1, Camk2b, miR-9, Sox17 (Figure 56). 
Genes involved in neuronal development and function, e.g. Sema3d and Celsr1, and members 
of the Fox family transcription factors Foxf2 and Foxq1 are also bivalently marked (Figure 
56). The potassium channel Kcnc1 has both active and repressive chromatin marks, along with 
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the T2DM-identified potassium channel Kcnq1 (Figure 58). Bivalent chromatin states are 
modified to different extents in dysfunctional β-cells and lead to gene expression changes that 
could ultimately contribute to its inability to properly respond to glucose.  
 
5.4.  SUMMARY  
 
My hypothesis was that when β-cell dysfunction occurs, remodelling of the chromatin 
environment adversely affects the expression and activity of Pdx1, MafA and NeuroD1 and 
other important β-cell transcriptional regulators. I have addressed this by looking at regions of 
active and repressive chromatin in normal and dysfunctional β-cells, and found that 
dysfunctional β-cells have a more open chromatin configuration marking genes involved in 
cellular regulatory activities and the specification of other developmental lineages. I have also 
found an increase in the number of transcription factor-associated genes that bear an increased 
H3K27me3 mark in dysfunctional β-cells. Bivalent genes are present in normal β-cells, and a 
change in the bivalent state is observed at genes involved in development and/or function. 
This chromatin remodelling leads to changes in gene expression that could ultimately 
























6.1.  INTRODUCTION  
 
ESCs are derived from the pluripotent inncer cell mass of early embryos and possess a nearly 
unlimited capacity for self-renewal and the potential to differentiate into the many cell types 
of mammalian organisms. These properties qualify ESCs as an excellent system to analyze in 
vitro lineage commitment and cellular differentiation. Though mouse ESCs (mESCs) and 
human ESCs (hESCs) are not developmentally identical, clues obtained from experimental 
work performed in mESCs might shed light towards the application of mouse differentiation 
systems to hESCs, and might therefore lead to the establishment of strategies for future 
regenerative cell therapies. One strategy to generate β-cells in vitro is to closely mimic 
embryonic development by exposing ESCs to factors (e.g. transcription factors, growth 
factors, signaling molecules, the appropriate extra-cellular matrix (ECM) environment) that 




In vitro recapitulation of β-cell development has been attempted by: (1) directed 
differentiation using lineage selection with genetically modified ES cells that express 
pancreas-specific promoter and reporter system
328,329
, (2) application of specific growth and 
ECM factors during differentiation
330,331
 and (3) constitutive expression of genes crucial for 
pancreatic development
328,332
. However, currently strategies require optimization with respect 
to maturation of insulin-producing cells and the ability of these differentiated cells to respond 
to glucose when transplanted in diabetic animal models. Therefore, promising future strategies 
include the conditional expression of transgenes, histotypic differentiation supported by 
vascular endothelial cells and ECM-based three-dimensional culture systems, and application 
of physiological-like differentiation conditions. 
 
Pdx1 has been shown to be essential in the development of the pancreas, with deficits in 
expression levels resulting in reduced insulin secretion, accelerated β-cell apoptosis, and 
insulin-deficient diabetes in mice
81
. I have also shown in Sections 3-5 that Pdx1 is 
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comparatively more important than other key regulators like NeuroD1 and MafA. Thus, I 
hypothesized that over-expression of Pdx1, in combination with culture conditions that 
mimic endoderm and pancreas development, will aid in the differentiation of mouse 




6.2.  RESULTS  
 
6.2.1.  GENERATION OF MOUS E CLONAL ESC  L INES THAT OVER-EXPRESS PDX1 
 
An inducible mouse ESC line over-expressing Pdx1 was generated using the E14 engineered 
cell line AINV18
333
. The objective was to expose it to several differentiation conditions and to 
examine gene expression levels as a first step in determining efficiency of differentiation. In 
this system, the parental AINV18 ESC line contains an expression cassette for the reverse tet 
transactivator (rtTA) inserted into the constitutively expressed ROSA26 locus (Figure 59A). 
The cDNA of interest, in this case Pdx1, is targeted by Cre-mediated homologous 
recombination downstream of the tetracycline (tet) operator. This results in Pdx1 being under 
the control of the tet operator, which can be switched on upon addition of doxycycline (a tet 
analog). This recombination event also places a previously inactive neomycin resistance gene 
under the control of a PGK-ATG promoter, allowing selection of Pdx1 recombination with 
neomycin. 
 
With this method, I generated two ESC clones over-expressing Pdx1 that were able to switch 
on Pdx1 expression at the mRNA and protein level within 3 hours, maintain robust expression 
over a period of 12 days, and switch off Pdx1 expression upon withdrawal of doxycycline 





Figure 59. Co-transfection of pLox containing Pdx1 with Cre causes Cre-mediated recombination 
of Pdx1, now under the control of the tetOP, and G418 resistance is established. (B) Quantitative 
RT-PCR analysis of Pdx1 mRNA expression (upper panel) and protein levels (lower panel) before and 
after addition of doxycycline, with NIT-1, a β-cell line serving as a positive control. Similar results 




6.2.2.  D IRECTED D IFFERENTIATION OF MESCS  TO THE BETA-CELL L INEAGE  
 
Using a differentiation protocol that was used to over-express Ngn3 in a similarly inducible 
manner
334
, I differentiated the parental AINV18 cell line and looked at gene expression 
changes of several key genes involved in maintaining pluripotency, formation of definitive 
endoderm, pre-pancreatic endoderm, endocrine  precursors and β-cells (Figure 60A-F).  
 
In stage 1, ESC differentiation was initiated by generating embryoid bodies, to allow cells to 
form a three-dimensional structure that allows intra-cellular signaling. Leukemia inhibitory 
factor (LIF) was withdrawn to promote differentiation, as seen by the decrease in the 
pluripotency marker Oct4 and Sox2 (Figure 60A). In Stage 2, serum was withdrawn and 
Nodal signaling by adding Activin A and Fibroblast growth factor (FGF)-4 to potentiate 
endoderm formation and anterior gut fate. This resulted in up-regulation of FoxA2, Sox17, 
Gata4 and Gata6 (Figure 60B), markers of primitive endoderm. In stage 3, Activin A and 
FGF4 were maintained in the culture medium and bone morphogenic protein (BMP)-4 and 
FGF10 were added to expand the population of putative pancreatic progenitors. This effect 
was confirmed by maintenance of FoxA2, Sox17, Gata4 and Gata6 levels (Figure 60B). 
Pancreas specification depends on addition of RA and suppression of Shh by cyclopamine, 
which represses the mesodermal markers Gsc and induces expression of Pdx1 (Figure 60C), 
Ngn3 (Figure 60D) and Ptf1a, as detected by Stage 5. Low glucose was used in stages 4 and 5 
because glucose restriction may initiate generation of insulin producing cells
335
. Nicotinamide, 
a SIRT-specific inhibitor, is commonly used as part of the differentiation cocktail to drive 
ESCs towards the β-cell lineage330. This protocol was modified with the addition of β-cellulin, 
a glycoprotein highly expressed in the pancreas, to promote the differentiation, regeneration 
and proliferation of pancreatic β-cells in vitro conditions186. Addition of β-cellulin also 
enhances the expression of Pdx1, Ngn3, Nkx6.1, Insulin (Figure 60C-F) and other genes 
specifying pancreatic progenitors. Therefore, with this protocol, a population of cells 
expressing markers representing β-cells e.g. Nkx6.1 (Fiugure 60E) and Insulin (Figure 60F) 




 Figure 60. Expression of marker genes at each stage of ESC differentiation towards the β-cell 
lineage. β-actin was used as an internal control for normalization. Three technical replicates were 
performed for each RT-PCR, and the average of the normalized ratio of gene/β-actin was calculated. 
Similar results were obtained with the second Pdx1 ESC clone.  
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2.3.  D IRECTED D IFFERENTIATION OF MESCS  TOWARDS THE BETA-CELL 
L INEAGE ,  IN COMBINATION WITH PDX1  OVER-EXPRESSION  
 
As Pdx1 expression was detected at stage 5 of the differentiation protocol (Figure 60C), I 
asked whether over-expressing Pdx1 before, during, or after stage 5 would enhance the 
differentiation process. I induced Pdx1 expression by addition of doxycycline to the 
differentiation medium at stages 4, at stage 5, and midway through stage 5 (Figure 61A). 
Marker gene expression was assessed at each stage of differentiation by RT-PCR (Figure 
61B-F). The experiment was performed with both Pdx1 ESC clones, and results shown in 
Figure 63 are representative of one clone, with the trend in the expression results also seen in 
the other clone. I assayed a panel of markers for each differentiation stage, i.e., pluripotency, 
formation of definitive endoderm, pre-pancreatic endoderm, endocrine precursors and β-cells, 
at each stage in the protocol. The controls for the experiment are the parental AINV18 cell 
line without any genetic modification and the Pdx1 clone without doxycycline treatment.  
 
Levels of Oct4 transcripts decreased below that of control cells at the end of the 
differentiation experiment, with some remnants of Oct4 present in the Pdx1 over-expressing 
clone (Figure 61B), indicative of cells still remaining undifferentiated. Pdx1 transcription was 
massively up-regulated upon addition of doxycycline (Figure 61C), showing that the cells 
were responsive to induction of doxycycline in the context of the differentiation medium. 
Levels of Ngn3 transcripts were not increased upon Pdx1 over-expression (Figure 61D), nor 
was Nkx6.1 (Figure 61E) and Insulin (Figure 61F). In fact, the levels of Ngn3, Nkx6.1 and 
Insulin (and other markers representing pancreatic progenitors, data not shown) were higher in 
the AINV18 parental cell line and in the Pdx1 clonal ESCs without the addition of 
doxycycline. The data suggests that over-expression of Pdx1 did not aid differentiation 
towards the β-cell lineage, but seems to impede it. This almost seems counter-intuitive, as one 
would expect, with Pdx1 being upstream of these transcription factors and being crucial for β-
cell development, over-expressing Pdx1 would lead to an increase in the levels of pancreatic 








Figure 61. Pdx1 over-expression does not enhance differentiation of ESCs towards the endocrine 
lineage. (A) Differentiation of ESCs towards endocrine pancreas-like progenitors. A schematic diagram 
of the differentiation protocol and Pdx1 induction. (B) to (E) shows expression of markers from each 
stage of differentiation. Data shown are analyses performed at the end of stage 5 on embryoid bodies 
that had doxycycline added at stage 4, stage 5, or midway through stage 5. The parental AINV18 cell 
line and the Pdx1 cell line (without dox) served as controls, and for each RT-PCR three replicates were 




6.3.  DISCUSSION  
 
Embryonic stem cells hold great promise for therapy as they can differentiate into any cell 
type in the body. As such, much effort has been invested in enhancing the derivation of 
different cell types, such as the pancreatic β-cell. I have shown that over-expressing Pdx1 
does not enhance the differentiation towards the β-cell lineage (Figure 61). This was 
somewhat surprising, as Pdx1 lies upstream of transcription factors involved in specifying the 
endoderm and endocrine lineage, my hypothesis was that over-expressing Pdx1 would lead to 
an increase in the levels of pancreatic progenitor transcripts, not decrease (Figure 61). It is 
possible that there was over-saturation of translational machinery when Pdx1 was over-
expressed, as there was a massive increase in the levels of Pdx1 mRNA transcripts (500-fold) 
upon addition of doxycycline and, therefore, other mRNA transcripts could not be translated 
efficiently (Figure 61). This huge increase in Pdx1 levels could have also led to non-specific 
and non-physiological binding and spurious activation of its target genes. One strategy to 
overcome non-physiological levels of Pdx1 is to switch on Pdx1 in biphasic pulses (e.g. for 
several hours in Stage 4, and midway through Stage 5 for a couple of hours, to mimic the 
biphasic expression levels of Pdx1 levels in the developing embryo).  
 
Immuno-staining for C-peptide, Insulin, and the other β-cell markers should also be 
performed on differentiated cells, to determine the protein levels and co-localization of factors 
characteristic of β-cells, as I’ve only looked at mRNA transcripts so far. Fluorescence-
activated cell sorting (FACS) will be carried out as a quantitative assay to assess the 
percentage of cells expressing the relevant markers, for example the endodermal markers 
Sox17 or FoxA2, to evaluate the efficiency of the differentiation process. Enrichment of 
differentiated cells expressing endodermal surface markers can also be performed, (e.g. Cxcr4 






6.3.1.  MODIFICATION OF THE ECM 
 
Mature β-cells do not produce any basement membrane or ECM, using instead VEGF-A to 
attract endothelial cells which form capillaries with a vascular basement membrane next to the 
β-cells337. Laminins and the β1 integrin subunit are crucial for the stimulatory effect of 
endothelial ECM proteins on insulin mRNA expression. Therefore, β-cells must interact with 
endothelial cells in order to function properly. In dissociated E13.5 precursor pancreatic cell 
cultures, the addition of soluble laminin-1 increased the number of β-cells produced338. Also, 





, an ECM commonly used in culturing human ESCs, contains 
growth factors like bFGF, EGF, IGF-1, PDGF, NGF, laminin, collagen IV. It is known that 
long term culture of fetal porcine islet-like cell clusters with Matrigel enhances insulin 
secretion
341
. As the differentiation protocol can be easily modified, and because the ECM is 
crucial in providing a proper ECM context, efforts could be made to focus on plating 
embryoid bodies onto the various ECMs mentioned above (after stage 1 of the differentiation 
protocol, or midway in the differentiation protocol when cells are more mature) onto various 
ECMs (laminin 1, collagen IV, matrigel, 804G matrix, and specialized matrices which contain 
different combinations of ECM proteins). A similar approach would be to co-culture 
differentiating cells onto mouse islet endothelial cells (e.g. MS-1 cells), which promote β-cell 
proliferation through the secretion of HGF, suggesting the existence
 
of an endothelial-
endocrine axis within adult pancreatic islets important for adult β-cell proliferation342.  
 




In order to modify exogenous components of the differentiation cocktail, other growth factors 
and signaling molecules shown to be important in β-cell development can be added, such as 
FGF7 and Noggin
27
. Exendin-4 (a Glp-1 analog that increases GSIS from β-cells)343, can also 
be supplemented to the culture medium. Under appropriate conditions, the HDAC inhibitor 
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Trichostatin A (TSA) can differentiate bone marrow stem cells into islet-like clusters capable 
of secreting insulin
344
. TSA and sodium butyrate (both class I and II HDAC inhibitors) 
treatment increased the development of Ngn3-positive endocrine progenitors and modified the 
endocrine sub-type lineage choices
345
. Therefore, there is much to be optimized with respect 
to differentiation culture conditions. 
 
6.4.  SUMMARY  
 
The desire to generate clinically relevant populations of cells from ESCs remains the driving 
force of ESC research. I have shown that over-expression of Pdx1 alone does not improve 
differentiation towards the pancreatic β-cell lineage. Future work includes a combinatorial 
approach, consisting of timely over-expression of a key pancreatic transcription factor with 



























7.1.  TRANSCRIPTIONAL REGULATION OF PDX1,  NEUROD1  AND MAFA  IN 
PANCREATIC BETA-CELLS  
 
Pancreatic β-cells are important in maintaining glucose homeostasis in the adult, secreting 
insulin in a timely and appropriate fashion in response to a metabolic stimulus. The inability 
of the β-cell to keep up with increasing insulin demand, coupled with insulin resistance in 
other parts of the body, leads to Type 2 Diabetes. It is therefore of scientific interest to 
understand how these highly specialized cells perform their function, and to also understand 
the molecular mechanisms in which β-cell dysfunction occurs. The transcriptional and 
epigenetic networks governing the unique properties of β-cells has not been extensively 
studied as yet, with only a handful of publications describing genome-wide profiling of 
transcription factors and the epigenetic profile of β-cells86,177,179,325. The transcription factors 
Pdx1, NeuroD1 and MafA are required for the maintenance of the mature β-cell phenotype, 
with deficiencies in any of them leading to diabetic phenotypes
1,195,346
. I have thus first 
focussed on further elucidating the transcriptional networks regulated by them.    
 
Pdx1 and NeuroD1 co-occupy hundreds of genomic loci
86
, implying that a significant fraction 
of Pdx-1 and NeuroD1 binding sites exist within regulatory modules, where they may control 
gene expression in a synergistic manner. However, it was unknown whether MafA interacts at 
similar loci to co-regulate genes important for β-cell function, as no genome-wide ChIP 
binding studies have been performed for MafA. I have shown in Chapter 3 that Pdx1, 
NeuroD1 and MafA bind to one another’s promoters, along with the Insulin promoter. The 
Pdx1, NeuroD1 and MafA peaks are also enriched around all three peak centers, suggesting 
they associated strongly with one another. There was a large number of Pdx1-only peaks and a 
big overlap of NeuroD1 and MafA binding sites, and this similarity was also reflected in the 
motifs identified for MafA and NeuroD1. This suggests that Pdx1 is acting more 
independently, with NeuroD1 and MafA having very similar and possibly redundant roles. A 
more independent role of Pdx1 would also concur with the fact that 17% of Pdx1 peaks are 
found in promoter regions, compared to NeuroD1 and MafA. Depletion of NeuroD1 has more 
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effect on the target genes it binds to, 834 genes are regulated by NeuroD1 only, in comparison 
to the 175 and 151 regulated by Pdx1 and MafA respectively. This suggests that NeuroD1 is 
acting in an indirect manner. In all three cases, there are a greater number of genes being up-
regulated upon knock-down, indicating that these transcription factors have a generally more 
repressive role on their target genes, rather than activating. Gene ontology analysis on the 
target genes revealed over-representation in categories such as metabolic processes, 
developmental processes and cellular processes.  
 
As the binding sites of Pdx1, NeuroD1 and MafA and the genes they regulated categorized 
into similar regulatory networks, and these three transcription factors synergistically bind to 
and regulate the Insulin promoter
124
, I hypothesized that these three transcriptional factors 
would combinatorially regulate other genes in the genome. To explore how combinatorial 
transcription factor binding correlated with changes in gene expression upon combinatorial 
transcription factor knockdown, the number of regulated genes that had any combination of a 
transcription factor was overlapped with the genes identified to be changing upon each 
combination of transcription factor knockdown. Genes containing Pdx1 binding sites in their 
promoters display maximal differential expression in the single, double or triple knockdown 
experiments (Figure 28). The highest percentage of genes regulated are those in the double 
knockdown, irrespective of whether the gene is bound by single, double or all three 
transcription factors (Figure 29). Of the single transcription factor regulated genes, NeuroD1-
regulated genes have a higher percentage of bound genes (6-8%) compared to Pdx1 and MafA 
(<4%). This could be due to the fact that 12.5% of NeuroD1-regulated genes are transcription 
factors (Table 6), as compared to 8.5% of Pdx1- and MafA- regulated genes. This higher 
proportion of transcription factors in NeuroD1 regulated genes again suggests that NeuroD1 
mediates downstream gene expression changes via other transcription factors. Taken together, 
I have shown that while Pdx1 on its own had the most effect on gene regulation, triply and 




7.2.  PDX1,  NEUROD1  AND MAFA  TARGET GENES HAVE FUNCTIONAL 
EFFECTS ON THE BETA-CELL PHENOTYPE  
 
Transcription factors play an important role in pancreatic β-cell development and function. 
This is manifested clinically by MODY syndromes, in which heterozygous mutations in 
HNF4α, HNF1α, PDX1, HNF1β and NEUROD1 cause progressive impairments in insulin 
secretion and the eventual development of diabetes mellitus
90
. The main function of the 
mature β-cell is to respond appropriately to the fluctuating levels of blood glucose with the 
secretion of insulin. This is mediated and controlled by many transcription factors, of which 
Pdx1, NeuroD1 and MafA are a few. As Pdx1, NeuroD1 and MafA have been shown to co-
regulate many genes of similar biological functions (Chapter 3), I hypothesized that these 
Pdx1 NeuroD1 and MafA target genes were important in maintaining the insulin secretory 
response, and that depletion of their expression in β-cells would result in impaired ability to 
respond to glucose, as determined by a GSIS assay. In Chapter 4, I have shown that Pdx1, 
NeuroD1 and MafA repress Itgb1bp2 and Cplx2 in order to achieve an enhanced GSIS 
response. Pdx1, NeuroD1 and MafA activate Tspyl1, F13a1 and Septin7 to reduce GSIS 
(Figure 39). This additional knowledge emphasizes the exquisite level of regulation required 
for the appropriate response of β-cells to a glucose stimulus.   
 
Future work involves extending the study to more genes regulated by these three transcription 
factors, in order to identify new regulators important in GSIS. The β-cell is also responsive to 
other nutrients and numerous neural and hormonal factors, and specific amino acids may 
acutely and/or chronically regulate insulin secretion
347
. Therefore it is also of biological 
interest to study the role of these commonly regulated target genes in response to different 





7.3.  CHROMATIN REMODELLING IN RESPONSE TO BETA-CELL 
DYSFUNCTION  
 
The discovery of defects in epigenetic modification in T1DM in susceptibility loci makes it 
one of the strongest candidates for that elusive “missing link” of auto-immune disease 
research, providing a mechanism common to and potentially linking both environment 
stimulation and genetic susceptibility in immunopathogenesis. The activation of β-cell genes 
in the pancreas requires an appropriate euchromatin DNA template characterized by hyper-
methylation of H3K4 that is maintained by the HMT Set7/9
162
.Therefore, I hypothesized that 
there would be chromatin remodelling in β-cells in response to a glucolipotoxic stimulus that 
impairs its ability to secrete insulin in response to glucose. In Chapter 5, I profiled marks of 
active and repressive chromatin in normal and dysfunctional β-cells, and found that there was 
a global increase of chromatin opening in dysfunctional β-cells, as indicated by the increase in 
numbers of FAIRE and H3K4me3 peaks at the promoters of genes, and a decrease in 
H3K27me3 at the promoters of genes in dysfunctional β-cells. Motif analysis of FAIRE peaks 
in dysfunctional β-cells showed that there was a bias for binding sites for general transcription 
factors e.g. SP-1, CTCF, NF-Y, while motifs for FAIRE peaks in normal β-cells showed 
enrichments for tissue-specific transcription factors like FoxA1 and FoxA2, Oct2 and Oct4, 
and Pdx1. Comparison of the genes associated with the respective epigenetic marks in normal 
and dysfunctional β-cells demonstrated that there is a significant increase in genes involved in 
cellular regulatory activities and the specification of other developmental lineages in 
dysfunctional β-cells.  
 
Genes important for β-cell function are marked by H3K4me3 in their promoters in normal β-
cells, e.g. Pdx1, NeuroD1, MafA, Ins1, Glut2, Snap25, Vamp2, Cacna1a, Chgb, Kirrel6.2, 
Sytl4, Stxbp1, and Syt7. On a global scale, genes bound by Pdx1, NeuroD1 and MafA in 
normal β-cells are associated with H3K4me3, not H3K27me3 (Figure 50). There is an 
increase in the association of these transcription factors in dysfunctional β-cells with the 
repressive H3K27me3 mark, and a corresponding decrease in gene expression (Figure 52). 
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Taking into account there was reduced expression of Pdx1, NeuroD1 and MafA in 
dysfunctional β-cells, the H3K27me3-marked genes (that have a TFBS) in dysfunctional β-
cells are enriched for genes involved in metabolic processes, developmental processes and 
general cellular regulatory processes (e.g. cell cycle, cell signalling). I therefore propose a 
model in which glucolipotoxic conditions lead to increase in ROS and other metabolic 
changes that result in a reduced H3K4me3 mark of Pdx1, NeuroD1 and MafA and 
correspondingly lower mRNA levels in dysfunctional β-cells. This in turn leads to chromatin 
remodelling at the promoters of their target genes, resulting in changes in gene expression that 
ultimately affect β-cell function. More work is needed (highlighted in Chapter 5.3.2.) to truly 
understand the molecular mechanisms behind chromatin remodelling in β-cell dysfunction. 
 
Bivalent genes marked by both active and repressive chromatin marks, though first identified 
in ESCs, are not ESC-specific
179,326
. In this thesis, I show that these apparently conflicting 
domains exist in normal β-cells and majority of them lose their H3K27me3 marks in 
dysfunctional β-cells, consistent with the global increase in the numbers of H3K4me3 and 
FAIRE peaks and decrease in the global numbers of H3K27me3 peaks in dysfunctional β-
cells. Genes that are bivalently marked in normal β-cells are more enriched for in 
developmental processes and cell regulatory processes, compared to genes that are bivalently 
marked in normal β-cells and have lost the repressive H3K27me3 mark in dysfunctional β-
cells. Some examples of bivalent genes in normal β-cells that have reduced levels of 
H3K4me3 and/or increased levels of H3K27me3 in dysfunctional β-cells include genes 
involved in pancreatic development and/or function, e.g. MafB, Oxr1, Camk2b, miR-9, Sox17; 
genes involved in neuronal development and function, e.g. Sema3d and Celsr1; members of 
the Fox family transcription factors e.g. Foxf2 and Foxq1; and the potassium channels Kcnc1 
and Kcnq1 (Figure 56). Therefore, I have shown that bivalent chromatin states are modified to 
different extents in dysfunctional β-cells and result in gene expression changes that could 




The interplay between epigenetic and transcriptional regulation is a complex process that 
depends on numerous factors. Transitions between different chromatin states are dynamic and 
depend on a balance between factors that promote a repressive state and those than promote a 
transcriptionally active one. Therefore, drugs that target different components of the 
epigenetic machinery can co-operate in restoring normal gene activity. For example, 5-aza-2’-
deoxycytidine interferes with the activity of Dnmt1, leading to genome hypo-methylation, 
reactivating tumor suppressor genes that were silenced
348
. However, it is toxic, and cannot be 
used for therapeutic purposes on its own
349
. When combined with the HDAC inhibitor TSA, it 
reactivates silenced tumor suppressor genes in cancer cells
350
. This suggests the combination 
of chromatin modifiers can be used to treat diseases. 
 
Clinical trials with HDAC inhibitors have repeatedly demonstrated low toxicity despite the 
expectation that they may cause global gene dysregulation, and preliminary studies indicate 
that they may prove useful in treating diabetes
185
. The HDAC Sirt1 stimulates several 
important signaling pathways involved in regulating energy utilization, including the synthesis 
of new mitochondria
351
. Mitochondrial activity in metabolically active tissues (such as 
muscle) will increase metabolic rate, drive glucose metabolism and fatty acid oxidation and 
thereby improve insulin sensitivity and enhance energy expenditure in multiple tissues
352,353
. 
Sirt1 activation also plays a significant role on other key cellular regulators involved in 
metabolic and oxidative stress. In a DIO mouse model, new chemical entities (NCEs) at Sirtris 
Pharmaceuticals
354
 significantly improved insulin sensitivity and glucose levels in a similar 
manner observed in DIO mice genetically altered to have increased Sirt1 levels
355
. DIO mice 
treated with these same NCE SIRT1 activators also had reduced weight gain, increased energy 
expenditure and had global profiles of metabolites in tissues and plasma that were consistent 






It is desirable that the balance of genes whose regulation would be altered with by epigenetic 
modifiers would tip the balance from unfavorable diabetogenes to those with enhanced 
benefits. Results I have presented in my thesis have identified areas of chromatin remodeling 
in β-cell dysfunction. With the insights gained from that and future experiments that look at 
epigenomic changes in animal models of diabetes or diabetic patient islets, coupled with 
screening for drugs that can modulate the chromatin environment to reverse the dysfunctional 
β-cell phenotype, it is hoped that eventually, genome-wide transcriptional and epigenetic 
characterization will lead to patient-specific therapies that also allow monitoring of genome-
wide epigenetic consequences of these therapies.  
 
7.4.  CONCLUDING REMARKS  
 
This thesis emphasizes a role of transcriptional regulation in the maintenance of pancreatic β-
cell function, and presents unique evidence for chromatin remodelling in β-cell dysfunction. 
The genetic information of an organism is differentially regulated in a spatial and temporal 
manner through complex mechanisms that we are only just beginning to comprehend. 
Epigenetic modifications control gene expression by changing specific regions of the genome 
to maintain silencing or activating activity, often in response to an environmental stimulus. 
The trigger for the differential marking of the genome remains largely uncharacterized, but 
remarkable progress is being made on this front. In order to fully harness the potential of 
chromatin-modifying drugs in complex diseases like Type 2 Diabetes, it is imperative to better 
understand the molecular mechanisms by which transcription factors interact with the 
chromatin, and the impact of the environment on these interactions. To this end, my work 
presents novel insights into Pdx1-, NeuroD1- and MafA-regulated pathways that influence β-









ATP Adenosine triphosphate 
bHLH basic helix-loop-helix  
bLZ Basic leucine-leucine zipper 
ChIP Chromatin immunoprecipitation 
ChIP-chip Chomatin immunoprecipitation-chip 
ChIP-Seq ChIP coupled with high-throughput sequencing 
CHO Chinese hamster ovary 
COREs Clusters of open regulatory elements 
DMEM Dulbecco modified Eagle’s medium 
DIO Diet-induced obese 
ECM Extra-cellular matrix 
ER Endoplasmic reticulum  
ESC Embryonic stem cells  
FACS Fluorescence-activated cell sorting  
FBS Fetal bovine serum 
FFA Free fatty acids 
GSIS Glucose stimulated insulin secretion 
GWAS Genome-wide association studies 
HD Homeodomain 
HDL-C High-density lipoprotein cholesterol  
IDDM Insulin dependent diabetes mellitus 
IEGs Immediate-early genes 
IPA Ingenuity Pathway Analysis  
IUGR Intrauterine growth retardation  
IVG Integrated Genomics Viewer 
KRH Krebs-Ringers-Hepes  
LDL-C Low-density lipoprotein cholesterol 
LIF Leukemia inhibitory factor 
MEFs Mouse embryonic fibroblasts  
miRNA MicroRNA 
MODY Maturity Onset Diabetes of the Young 
NADH Nicotinamide dinucleotide  
nc Non-coding 
NTC Non-targeting control  
PBS Phosphate buffered saline 
RA Retinoic acid 
RGS Regulators of G protein signaling 
RNAi RNA interference 
ROS Reactive oxygen species 
SACO Serial analysis of chromatin occupancy 
SNPs Single nucleotide polymorphisms  
T1DM Type 1 Diabetes Mellitus 
T2DM Type 2 Diabetes Mellitus 
TFBS Transcription factor binding site  
TSA Trichostatin A 
TSS Transcription start site  
UCSC University of California, Santa Cruz 





GENE ABBREVIATIONS  
 
Gene symbol Gene name 
Acac Acetyl-CoA carboxylase 
Aldob Aldolase B fructose-bisphosphate  
Ampk Protein kinase AMP-activated β1 non-catalytic subunit 
Arnt2 Aryl-hydrocarbon receptor nuclear translocator 2 
Arx Aristaless related homeobox  
Atp1b1 ATPase Na+/K+ transporting β1 polypeptide  
Bend BEN domain containing  
BMP Bone morphogenic protein 
Cacna Calcium channel voltage-dependent P/Q type 
Camk Calcium/calmodulin-dependent protein kinase  
cAMP Cyclic adenosine monophosphate 
Celsr Cadherin EGF LAG seven-pass G-type receptor  
Chgb Chromogranin B 
Clic Chloride intracellular channel  
Cplx Complexin 
Cre cAMP-response element  
CTCF CCCTC-binding factor  
DNMT DNA methyltransferase  
Elfn Extracellular leucine-rich repeat and fibronectin type III domain containing 
Exoc Exocyst complex component  
F13a1 Coagulation factor XIII A1 polypeptide  
FGF Fibroblast growth factor 
Fox Forkhead box  
Gad Glutamate decarboxylase  
Gcg Glucagon  
Gcnt Glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group)  
Gk Glucokinase 
Glp Glucagon-like peptide 
Glut Glucose transporter 
GPDH Glycerol phosphate dehydrogenase 
HAT Histone acetyl transferase  
HDAC Histone deacetylase 
Hist1 Histone cluster 1  
HMT Histone  methyltransferase 
Hnf Hepatocyte nuclear factor 
Hox Homeobox  
IA1 Insulinoma-associated 1 
Iapp  Islet amyloid polypeptide 
IGF Insulin-like growth factor 
IL Interleukin 
IRS Insulin receptor substrate 
Itg1bp Integrin β 1 binding protein (melusin)  
JNK Mitogen-activated protein kinase 8 
Kcnc1 Potassium voltage-gated channel Shaw-related subfamily member 1 
Kcnq1 Potassium voltage-gated channel, KQT-like subfamily, member 1 
Kirrel 2 Kin of IRRE like 2 
Kirrel6.2 Potassium inwardly-rectifying channel subfamily J member 11  
M3R M3 muscarinic receptors 
MafA v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
MeCP Methyl-CpG-binding protein 
Nanog Nanog homeobox 
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Gene symbol Gene name 
Ndrg NDRG family member  
NeuroD1 Neurogenic differentiation 1 
NFκB Nuclear factor kappa-light-chain-enhancer of activated B cells 
Ngn3 Neurogenin 3 
Nkx NK homeobox  
Nna Neuronatin 
Oct2 POU class 3 homeobox 2 
Oct4 POU class 5 homeobox 1 
Oxa Orexin A  
Oxr Oxidation resistance 
Pax Paired-box 
Pcsk1 Proprotein convertase subtilisin/kexin type 1 
Pdx1 Pancreatic duodenal homeobox 1 
PEPCK Phosphoenolpyruvate carboxykinase  
Ppp1r Protein phosphatase 1, regulatory (inhibitor) subunit  
PPY Pancreatic polypeptide 




 transporting cardiac muscle fast twitch 1  
Shc Src homology 2 domain containing transforming protein 
Shh Sonic hedgehog 
SHP Small heterodimer partner 
Sik  Salt-inducible kinase 
Sirt Sirtuin 
Slc1a2 Solute carrier family 1 (glial high affinity glutamate transporter) member 2  
Snap Synaptosomal-associated protein  
SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
Sox SRY (sex determining region Y)-box 
Sp1 Sp transcription factor 1 
Srebp Sterol regulatory element binding protein  
Sst Somatostatin 
Stx Syntaxin  
Sur Sulfonylurea receptor 
Syt Synaptogamin  
Tcf7l2 Transcription factor 7–like 2  
TGF-β Transforming growth factor β 
Tmem27 Transmembrane 27 
TNF-α Tumor necrosis factor α 
Tspyl TSPY-like  
TTR Transthyretin  
Ucp2 Uncoupling protein 2  
Vamp Vesicle-associated membrane protein 
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